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Introduction & Aim

Since the first successful application of In Vitro Fertilization (IVF) in 19781 
and Intracytoplasmic Sperm Injections (ICSI) in 1992,2 there has been a steady 
increase in the utilization of these assisted reproduction techniques (ART) to 
achieve pregnancy in subfertile couples. Initially, the natural menstrual cycle 
was allowed to recruit the ovarian follicle for IVF. The ovarian follicle is the 
microenvironment in which the oocyte matures. However, the lack of control 
of ovulation and the low propensity for a viable embryo and pregnancy after 
single oocyte fertilization led to the development of Controlled Ovarian 
Hyperstimulation treatment (COH) to yield more oocytes. The advantage is 
that COH overcomes the inefficiency of monofollicular ovulation in women 
and it extends the range of indications for IVF/ICSI treatment. 
The principal aim of COH is to stimulate growth and maturation of multiple 
ovarian follicles, which is achieved through the use of Follicle Stimulating 
Hormone (FSH) analogues. The administration of a Gonadotropin Releasing 
Hormone (GnRH) agonist or -antagonist is compulsory to prevent premature 
ovulation/luteinization of the ovarian follicle, which precludes oocyte 
retrieval. When sufficient ovarian follicles are mature, a single dose of human 
Chorionic Gonadotropin (hCG) or recombinant Luteinizing Hormone 
(rLH) is administered to induce final oocyte maturation, much similar to 
the surge of LH during the menstrual cycle. Thirty-six hours after hCG/
rLH administration, oocytes are retrieved by transvaginal ultrasound guided 
puncture of the ovarian follicle. The retrieved oocytes are fertilized, and the 
embryo deemed most viable is transferred to the uterus for implantation.
Currently, the combination of COH and IVF/ICSI is a moderately 
successful technique to achieve pregnancy in subfertile couples. After six 
treatment cycles, the cumulative life birth rate is slightly over 50%, which does 
leave room for improvement.3 Epidemiologic and experimental studies provide 
ample suggestions to improve IVF/ICSI treatment success, which range from 
improving embryo culture conditions and embryo selection to improving patient 
characteristics (i.e. promoting weight loss, quitting smoking and acquiring 
healthy nutritional habits). However, also the ovarian response to COH, i.e. 
the number of growing follicles and amount of steroid hormones produced, 
affect the chance of IVF/ICSI treatment success and risk of complications.4, 5
The ovarian response is a reflection of extrinsic- and intrinsic-ovarian factors 
that are (non-)permissive for (multiple) follicle growth. Epidemiologic and 
experimental studies show that such factors can be the result of prevalent genetic-, 
metabolic- or nutritional and lifestyle factors.6-8 Indeed, the ovarian response can be 
predicted with the use of demographic, ultrasound and endocrine markers, which 
are currently used to decide on an optimal COH strategy. Unfortunately, most of 
such factors are non-modifiable, with little variability between treatment cycles 
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and are therefore not suitable to modify or optimize the ovarian response to COH. 
Additionally, these factors are not always successful in adequately predicting the 
ovarian response. Indeed, this will also result from unknown genetic, metabolic 
and environmental (i.e. lifestyle) factors.9
Parallel with the increased demand for assisted reproductive techniques, 
the prevalence of unhealthy diet consumption is increasing.10 Given the 
nature of multiple follicle growth, the relation between oocyte and follicle 
growth and the modifiable nature of nutrition, nutrition could have a role 
in the ovarian response to COH and IVF/ICSI treatment outcomes. On a 
micronutrient level, studies increasingly show the relation between the folate 
mediated one-carbon pathway and nutrition in the periconception period and 
reproductive outcomes and offspring health.11 Unfortunately little attention 
is given to the preconception period whilst it constitutes an opportunity to 
improve outcomes of spontaneous as well as ART pregnancies. 
The studies in this thesis aim to further outline the role of preconception 
nutrition, in particular of the folate mediated one-carbon pathway, in the 
ovarian response to COH and IVF/ICSI treatment outcomes. 
The main objectives of this thesis are to investigate the following:
1: What is the role of folate in human reproduction? 
2:  How is the preconception microenvironment of the human oocyte 
influenced by folate? 
3:  What is the influence of preconception nutrition and folate on COH and 
IVF/ICSI treatment outcomes?
These findings might further promote and support the importance of an 
optimal preconception nutritional status of couples undergoing COH and 
IVF/ICSI treatment. 
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Folate in human reproductive 
performance
J.M. Twigt, J.S.E. Laven and R.P.M. Steegers-Theunissen
Vitamins in the prevention of human diseases. W. Hermann and R. Obeid, eds. 
2011 Berlin, Walter de Gruyter

INTRODUCTION
The natural B-vitamin folate is mandatory for cellular metabolism, fulfilling 
a multitude of roles in various processes ranging from cell-cycle regulation, 
amino acid biosynthesis, DNA nucleotide synthesis and protein processing.12 
Therefore, it is not surprising that folate deficiency potentially results in 
many derangements in growth and development with implications also for 
reproduction.13 Folic acid is a synthetic derivative of folate, which is more 
resilient against oxidation than naturally occurring folates. By means of the 
intertwined folate- and methionine-cycle (Fig. 1), folates are predominantly 
utilized in one-carbon metabolism for the synthesis of three out of four 
DNA-nucleotides (adenine, guanine and thymine) and metabolism of the 
amino acids, methionine, serine, glycine and cysteine. 
Many enzymes involved in folate metabolism require cofactors for normal 
functioning. Methionine synthase (MTR) is a zinc protein and requires vitamin 
B12 (cobalamin) as a cofactor and vitamin B6 (pyridoxine) is a cofactor for the 
transsulphuration pathway. Furthermore, vitamin B2 is needed for adequate 
synthesis of 5,10-methylenetetrahydrofolate reductase (MTHFR) and zinc is 
also necessary for adequate uptake of folate from the jejunum.14, 15
Humans do not have the ability to synthesize folate. The demand for folate 
therefore has to be met entirely by dietary intake. Green leafy vegetables, 
beans or liver are natural sources of folate. Alternatively, in several countries 
grain, cereal and bread products are increasingly often fortified with folic 
acid, making these products a rich source of folic acid. Folate is present in 
food as 5-methyltetrahydrofolate (5-mTHF) with a polyglutamate tail. In the 
jejunum, 5-mTHF-polyglutamate is hydrolyzed to 5-mTHF-monoglutamate 
by glutamate carboxypeptidase-II. Because of its low pH optimum, the proton-
coupled folate transporter favours folate transport into the enterocytes of the 
jejunum. Within the enterocytes, 5-mTHF-monoglutamate is converted into 
5-mTHF and thereafter released into the circulation.16 In peripheral tissue, 
several mechanisms for 5-mTHF uptake exist. Folate receptors (FR) exist 
in three isoforms, α, β and γ that bind circulating 5-mTHF. The FR-folate 
complex is internalized by endocytosis and subsequent acidification of the 
compartment leads to dissociation of 5-mTHF from the receptor. The 
mechanism of export from the endosome is likely to be facilitated by the 
proton-coupled folate transporter. FRα is required for the placental transport 
of 5-mTHF. In peripheral tissue, however, the reduced folate carrier is the 
most predominant mechanism for 5-mTHF uptake.16-18
Intracellular the methyl moiety of 5-mTHF is used by MTR to remethylate 
homocysteine (Hcy) to methionine and forming tetrahydrofolate (THF). 
Methionine is further metabolized into S-Adenosylmethionine (SAM) by 
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methionine adenosyltransferase (MAT). SAM is the ultimate methyl donor 
for virtually all methylation reactions. After transmethylation of SAM, 
S-Adenosylhomocysteine (SAH) is formed. By means of a reversible reaction, 
S-Adenosylhomocysteine Hydrolase (AHCY) hydrolyzes SAH to Hcy and 
adenosine. A folate independent remethylation pathway for Hcy is present 
by means of betaine-homocysteine methyltransferase (BHMT) that utilizes 
a methyl group from betaine to form dimethylglycine and methionine. 
Approximately 50% of Hcy is metabolized via the remethylation pathway. 
The remainder is metabolized via the transsulphuration pathway. In this 
pathway the non-essential amino acid cysteine is required for the synthesis 
of the endogenous anti-oxidant glutathione. This pathway, however, is tissue 
specific, with all necessary enzymes only being expressed in the liver, small 
intestine, kidney and pancreas.19 
After partition of the methyl group, THF is further metabolized via the 
folate cycle in several ways (Fig.1). (1) THF reacts with formate to form 
10-formyl-THF, which either dehydrates to 5,10-methenyl-THF, which is 
then metabolized to 5,10-methylene-THF (5,10-mTHF), or is allocated to 
the formation of purines. (2) THF reacts with serine, catalyzed by serine 
hydroxymethyltransferase (SHMT) to form glycine and 5,10-mTHF. In a 
reaction catalyzed by MTHFR, 5,10mTHF is reduced to 5-mTHF that can 
be further conveded into the methionine cycle. MTHFR forms the junction 
between the methionine and folate cycle, here it is determined whether 
5,10-mTHF is utilized for 5-mTHF production or de novo synthesis of 
thymidylate (dTMP) from deoxyuridylate (dUMP). 
A multitude of genes coding for enzymes are required for adequate folate 
metabolism. Several single nucleotide polymorphisms have been identified 
which affect the efficiency of one-carbon metabolism. However, only 
polymorphisms in the MTHFR and methionine synthase reductase (MTRR) 
enzyme have shown to be of clinical significance in folate metabolism and later 
pathology. In the gene coding for the MTHFR enzyme a C->T substitution at 
position 677 results in a thermolabile variant of the enzyme.20 The frequency of 
this polymorphism is dependent on geographical location and varies between 
0.1-0.5.21 Homozygotes for this mutation have a 70% reduced MTHFR 
activity, resulting in hyperhomocysteinemia and DNA hypomethylation.22, 23 
A 66A->G polymorphism in the MTRR gene has an estimated allele frequency 
of 0.39-0.59 and results in reduced activity of the MTRR enzyme.21, 24 The 
product of the MTRR gene maintains MTR in its active state. It should be 
noted, however, that enzymatic deficiencies due to these polymorphisms are 
only clinically relevant when nutritional deficiency of cobalamin (MTRR) or 
folate (MTHFR) are co-existent. 
17
C
ha
pt
er
 II
M
et
hi
on
in
e
S-
Ad
en
os
yl
m
et
hi
on
in
e
S-
Ad
en
os
yl
ho
m
oc
ys
te
in
e
Se
rin
e
Pr
od
uc
t
C
H
3-P
ro
du
ct
H
om
oc
ys
te
in
e
G
ly
ci
ne
Sa
rc
os
in
e
5-
m
T
H
F
T
H
F
dU
M
P
dT
M
P
10
-fo
rm
yl
 T
H
F
5,
10
-m
et
he
ny
l T
H
F
Fo
rm
at
e
5,
10
-m
et
hy
le
ne
 T
H
F
Pu
rin
es
Se
rin
e
G
ly
ci
ne
M
T
H
FR
SH
M
T
T
YM
S
M
T
R
 / 
M
T
R
R
C
BS
AH
C
Y
M
AT
G
N
M
T
D
H
FRC
ob
al
am
in
m
C
ob
al
am
in
Be
ta
in
e
D
im
et
hy
lg
ly
ci
ne BH
M
T
Fo
lic
 a
ci
d
D
H
F
C
ho
lin
e
C
ys
ta
th
io
ni
ne
H
om
os
er
in
e
C
ys
te
in
e
C
T
H
Fo
la
te
 c
yc
le
M
et
hi
on
in
e 
cy
cl
e
Tr
an
ss
ul
ph
ur
at
io
n 
pa
th
w
ay
a-
ke
to
bu
ty
ra
te
N
H
3
Ad
en
os
in
e
H
20
G
lu
ta
th
io
ne
Ta
ur
in
e
SO
4
Fi
g 
1.
 Th
e 
m
et
hi
on
in
e 
an
d 
fo
la
te
 c
yc
le
. A
bb
re
vi
at
io
ns
: A
H
C
Y:
 S
-A
de
no
sy
lh
om
oc
ys
te
in
e H
yd
ro
la
se
. B
H
M
T:
 B
et
ai
ne
-H
om
oc
ys
te
in
e M
et
hy
ltr
an
sf
er
as
e.
 C
BS
: C
ys
th
at
io
ne
-
β-
Sy
nt
ha
se
. 
C
T
H
: 
C
ys
th
at
io
ne
-y
-L
ya
se
. 
D
H
F:
 D
ih
yd
ro
fo
la
te
. 
dT
M
P:
 d
eo
xy
th
ym
id
in
e 
m
on
op
ho
sp
ha
te
. 
dU
M
P:
 d
eo
xy
ur
id
in
e 
m
on
op
ho
sp
ha
te
. 
G
N
M
T:
 G
ly
ci
ne
-N
-
M
et
hy
ltr
an
sf
er
as
e.
 M
AT
: M
et
hi
on
in
e 
Ad
en
os
yl
tr
an
sf
er
as
e,
 M
T
R
: M
et
hi
on
in
e 
sy
nt
ha
se
. M
T
R
R
: M
et
hi
on
in
e 
sy
nt
ha
se
 re
du
ct
as
e.
 S
H
M
T:
 S
er
in
e 
hy
dr
ox
ym
et
hy
ltr
an
sf
er
as
e.
 
T
H
F:
 T
et
ra
hy
dr
of
ol
at
e.
 T
YM
S:
 Th
ym
id
yl
at
e 
sy
nt
ha
se
.
18
C
ha
pt
er
 II
The pathogenicity of folate deficiency can in theory be elicited in various 
ways. Due to its nature, especially vulnerable are highly proliferating tissues 
with a high rate of genomic and epigenomic replication and RNA- and protein 
synthesis. These processes all depend on the availability of one-carbon groups 
provided by the folate dependent one-carbon pathway. DNA methylation is an 
epigenetic mechanism. Methylation of cytosine residues in CG repeats, named 
CpG-island, exert regulatory properties on gene transcription by interfering 
with binding of factors necessary for gene transcription. A sufficient folate 
supply is necessary for adequate DNA methylation, with hypomethylation 
giving rise to altered gene expression.25 Folate also influences factors required 
for the maintenance of DNA integrity. Efficacy of nucleotide excision repair 
mechanisms and de novo DNA synthesis is modulated by the availability 
of thymidine triphosphate. Due to folate deficiency increasing amounts of 
deoxyuridine triphosphate is misincorporated into DNA.26, 27 Furthermore, 
folate deficiency alters the gene expression profile and cytosine hypomethylation 
promotes the deamination of cytosine to uracil, thereafter further stressing 
uracil specific repair mechanisms and reducing DNA stability.28
As portrayed earlier, folate substrate or cofactor deficiency (vitamin B2, 
-B6 and –B12 and zinc) results in the accumulation of Hcy. Therefore, Hcy 
levels in blood serum are regarded as a sensitive marker for the functioning 
of folate metabolism. Despite its necessity, excess Hcy can exert harmful 
effects in several ways. Reactive Hcy metabolites can form adducts with lysine 
residues in proteins or can be misincorporated into proteins as a substitute for 
methionine, thereby potentially affecting protein function.29 Secondly, it has 
long been acknowledged that Hcy may disturb the redox balance of the cell by 
the generation of reactive oxygen species (ROS).30 An adequate redox balance 
is required for normal physiology, also in many reproductive processes.31 
An excess of ROS results in oxidative stress, which indiscriminately can 
affect the functionality of all cellular constituents. Finally, the equilibrium 
between Hcy and adenosine and SAH is favoured towards SAH and SAH 
is a potent inhibitor of most SAM-dependent methyltransferases.32 DNA 
hypomethylation, therefore, not only occurs in the situation of reduced 
availability of SAM due to reduced Hcy remethylation but also due to the 
inhibitory effect of SAH on methyltransferases.33
The interdependency of all factors involved in folate metabolism make 
that it is difficult to discern which is an intermediate and which is an actual 
effector driving pathologic processes. However, the downstream effects of 
these pathological processes have in common that they independently affect 
genomic, epigenomic and proteomic integrity that are essential for normal 
cellular functioning. 
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PRECONCEPTION FOlATE IN WOMEN
At birth, women have a resting pool of immature oocytes that have arrested 
in the diplotene stage of the meiotic prophase I. A single layer of pre-
granulosa cells surrounds the oocyte; together this complex is called the 
primordial follicle. During the process of follicular growth and maturation 
an antrum is formed which is filled with follicle fluid. The follicle fluid is 
the microenvironment in which the developing oocyte resides. It is a plasma 
exudate that reflects follicular cell metabolism. As a result the magnitude 
of folate or folic acid ingestion affects 5-mTHF and Hcy levels in follicle 
fluid.34, 35 Continuously a cohort of follicles initiate the process of maturation, 
at the end of the monthly menstrual cycle one follicle and its oocyte have 
reached the maturity suitable for ovulation and consequent fertilization. 
An adequate folate balance can potentially reduce the risk or overcome 
subfertility in women.36-39 Follicular sensitivity to gonadotropins is in part 
modulated by proper functioning of the methionine cycle. Low MTHFR 
activity has been associated with low follicular activity.40-42 Consequently 
high Hcy levels are associated with an inadequate high ovarian response to 
gonadotropins in ewes.43 Furthermore, raised levels of Hcy in follicle fluid 
have a detrimental effect on oocyte and embryo quality.44-46 An adequate 
redox balance is of influence on follicular development and ovulation, and 
a disruption of this balance has been shown to induce follicular atresia and 
decrease sensitivity of the follicle to gonadotropins.31, 42, 47-49
PRECONCEPTION FOlATE IN MEN
In men preconception folate status potentially influences semen quality. During the 
mitotic phase of spermatogenesis methylation marks have to be maintained.50 Also, 
the genome and cellular machinery is replicated, adding to the increased demand 
for one-carbon groups from the folate- and methionine cycle. During mitosis 
and meiosis new methylation marks are acquired. The pattern of methylation is 
specific for the differentiation state of the spermatocyte and the entire epigenome 
is completely established at the pachytene stage of meiosis.51
Observational studies indicate that men with low dietary folate intake have 
a higher frequency of sperm aneuploidy, increased levels of sperm DNA damage 
and a low sperm density and count, which is associated with a higher rate of 
subfertility.52-54 Furthermore, high thiol levels, including Hcy, in the ejaculate 
have been associated with male subfertility.46 On the other hand, combined 
supplementation of folate and zinc sulphate increases total normal sperm count 
by 76%.55 Despite its influence on folate metabolism, the MTHFR 677C->T 
polymorphism is only a risk factor in the setting of insufficient folate intake.56, 57
20
C
ha
pt
er
 II
Similar to follicular maturation, ROS are important second messengers 
during spermatogenesis.58 Spermatocytes have a high content of polyunsaturated 
fatty acids, lack DNA repair mechanisms and have no anti-oxidant defence.59 
Therefore, the developing spermatocyte is exceptionally prone to disturbances 
in the redox balance resulting in excessive oxidative stress, which can arise 
due to hyperhomocysteinemia. In general, subfertile men have higher levels 
of ROS in semen, which is associated with lower sperm motility, fertilizing 
capacity and sperm DNA integrity.60
POST CONCEPTION FOlATE IN WOMEN
During embryogenesis, folate dependent processes are required for normal 
development. As has just been covered, at the point of fertilization the entire 
epigenome has been attained by both gametes. This pattern is specific for 
the oocyte and spermatocyte and, excluding imprinted genes, needs to be 
synchronized. Almost the entire DNA methylation pattern is erased after 
fertilization. With the exception of imprinted genes the genome is demethylated 
at the blastocyst stage.61 During subsequent cleavages from the blastocyst 
stage onward the DNA is remethylated in a lineage specific manner.61 The 
importance of an adequate supply of methyl groups during the periconception 
period is demonstrated by a phenotype of hypertension, obesity and diabetes 
in predominantly male offspring exposed to a low methionine diet during 
early pregnancy.62, 63 Approximately 8 days post-fertilization placentation 
begins. Crucial for normal placentation is the invasion of trophoblasts into the 
endometrial epithelium.64 Excess levels of Hcy induces trophoblast apoptosis 
and inhibits trophoblast invasion into endometrial epithelium.65 As a possible 
result of excess Hcy, oxidative stress occurs that inhibits normal placentation 
and alters placental gene expression.66, 67 In experimental settings folate 
deficiencies inhibit normal placentation and results in a higher foetal morbidity 
and mortality.68, 69 Before circulation is established the embryo resides in a 
hypoxic environment, during which it is most susceptible to oxidative stress.70 
During embryogenesis, ROS are important second messenger in the regulation 
of transcription factors.71 Derangement hereof affects successful embryonic 
development and can result in miscarriages.31 This is also reflected by the lower 
embryo quality after in vitro embryo cultures, were embryos endure higher 
than normal levels of oxidative stress.72
FOlATE AND THE FOETUS
Maternal deficiency of folate during the periconception period is associated 
with several congenital malformations of the foetus. Generally, congenital 
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malformations are considered to be of multifactorial origin, being subject to 
both genetic and environmental influences. Neural crest cells are progenitors 
of structures most commonly affected by folate deficiencies. Relative to other 
embryonic progenitor cells, neuroepithelium cells have a high expression 
of FR, indicating their dependency on a sufficient folate supply.73 In vitro 
studies have indicated that neural crest cells are sensitive to fluctuations in 
folate and Hcy concentrations.74
Nutrients necessary for early foetal development are acquired from 
uterine secretions or, after proper placenta development, from the maternal 
circulation. Syncytiotrophoblasts form the endothelium of the placental 
vasculature.75 On the apical membrane of the syncytiotrophoblast FRα 
is expressed, which binds circulating 5-mTHF with high affinity. At the 
basolateral membrane 5-mTHF is transported from the syncytiotrophoblast 
into the foetal circulation facilitated by the reduced folate carrier. Theoretically 
this mechanism allows for the build-up of a high concentration gradient, 
securing foetal 5-mTHF supply, even in a folate deficient environment.17, 18
Historically, neural tube defects (NTD) pose the greatest example of 
congenital malformations due to folate deficiency. A five-time reduction 
in NTD birth prevalence can be achieved by periconception folic acid 
supplement use of the mother.76 Additionally, food folic acid fortification 
programs have shown a population wide reduction in NTD birth prevalence 
ranging from 26-50%.77 Hyperhomocysteinemia in the mother has most 
widely been drawn on as risk indicator for NTD, with elevated levels being 
elicited by reduced availability of 5-mTHF due to polymorphisms in genes 
involved in folate metabolism and uptake or nutritional folate deficiency. 
Many functional polymorphisms, in genes essential for folate uptake and 
metabolism have been investigated, nevertheless only the polymorphisms 
MTRR66A>G and MTHFR677C->T have been shown to increase the 
birth prevalence of NTD.76, 78 In vitro studies have indicated that direct 
interference with the efficiency of methylation reactions increases the birth 
prevalence of NTD.79-81 In addition, oxidative stress alters expression of genes 
necessary for neural tube closure and increase the birth prevalence of NTD.82, 
83 Interestingly, a 70% reduction in NTD birth prevalence can be achieved by 
strong adherence to a Mediterranean diet alone.84
As the most frequently occurring congenital malformation, congenital 
heart defects (CHD) have been associated with a maternal deficiency of folate 
intake and/or metabolism. A 6% drop in the birth prevalence of CHD has 
been noted after the mandatory fortification of food with folic acid.85 The 
underlying mechanism of this association is however still lacking. MTHFR 
deficiency due to the 677C->T polymorphism and oxidative stress has 
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been associated with CHD in an experimental setting and an excess of Hcy 
inhibits proper septation of the developing heart.68, 69, 86, 87 Nevertheless, in the 
patient population only hyperhomocysteinemia in the mother posed a 4.4 
times higher risk of CHD birth prevalence where MTHFR deficiency alone 
seems not to be a risk factor for CHD in offspring.88, 89 The common effect 
of reduced DNA methylation hereof has not been established as an etiologic 
factor in CHD birth prevalence.
Orofacial clefts (OFC) pose a heterogeneous group of malformations ranging 
from the relatively mild cleft lip to the more severe cleft palate with or without cleft 
lip. The birth prevalence of OFC has been related to folate deficiency in a multitude 
of studies.90 However folate supplementation or MTHFR polymorphisms now 
seem not to be associated with the incidence of OFC.88, 90
DNA hypomethylation can induce meiotic segregation errors which can 
give rise to trisomy 21 in offspring, causing Down syndrome (DS).91 This 
association has led to the investigation of folate deficiency in DS occurrence. 
Despite a plausible biological mechanism, many contradicting observations 
have been made and no significant connection between maternal MTHFR 
deficiency or elevated Hcy levels and DS exists.92-94
FOlATE AND PREGNANCY COMPlICATIONS
Between 50-60% of all conceptions fail to survive until the end of the first 
trimester of pregnancy.95 The placenta is a highly vascularised organ, therefore 
hyperhomocysteinemia and its underlying causes have been proposed as risk 
factors for placenta linked pregnancy complications. Predominant among 
these are foetal growth restriction, pre-eclampsia, placental abruption and 
habitual abortion. In experimental studies there have been associations between 
MTHFR polymorphisms, folate deficiency and pregnancy complications.68, 69 
Nevertheless, experimental findings are not unanimously reflected in clinical 
findings, where foetal growth restriction, pre-eclampsia and habitual abortion 
are not associated with the MTHFR 677C->T polymorphism.96-98 Maternal 
Hcy status does, however, associate with the occurrence of placenta related 
pregnancy complications and folic acid use during pregnancy reduced the risk 
of low birth weight and small for gestational age foetuses.99-104 In the case of 
pre-eclampsia though it is not clear whether the hyperhomocysteinemic state is 
the cause or effect of the pathological process.105 Only hyperhomocysteinemia 
and not MTHFR polymorphisms as a risk factor can be explained by the fact 
that the methylation pathway is restored by folic acid use, which is widely 
recommend to all pregnant women in the western world.
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CONClUSION
Evidence is accumulating on the significance of an adequate folate pathway 
during human reproduction. Because various essential pathways are affected 
by a shortage of folate, research into the aetiology, pathophysiology and 
prevention of adverse reproductive outcome is complicated. This is further 
complicated by the fact that intervention studies during human pregnancies 
are nearly impossible, which necessitates inference from in vitro and animal 
models or observational studies. 
Research into single nutrients and gene polymorphisms is a necessity 
to identify new risk factors and helps to explain underlying biological 
mechanisms. This type of research, however, is best suited for highly controlled 
animal- and in vitro studies. In epidemiological studies the rational is to 
focus on associations between adverse reproductive outcome and biomarkers 
of the folate- and methylation cycle, i.e., Hcy, SAM, SAH, vitamin B12, 
and DNA and histone methylation patterns.106 Besides folate, many cofactors 
and proper functioning genes are needed for the provision of methylgroups. 
Because intrinsically biomarkers and methylation patterns of the genome are 
adjusted for factors influencing these determinants, both measurements are 
useful to assess the long- and short-term folate status. 
Despite growing knowledge on epigenetic mechanisms and intriguing 
evidence in animals, at present little is known about the relation between 
adverse reproductive outcome and epigenetics in human. The epigenome 
is at the crossroad of environmental exposure and gene expression profiles. 
Therefore, epigenetics pose an interesting field of future research, which can aid 
in the identification of both genetic and environmental exposures underlying 
adverse reproductive outcomes associated with methylation cycle deficiencies.
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AbSTRACT
We utilized a setup based on extensive pre-fractionation of proteolytic peptides 
and nanoflow reversed-phase liquid chromatography mass spectrometry 
(LC-MS/MS) to identify the (sub)proteome of human follicle fluid. In this 
in-depth screen, 268 specific proteins were identified, the majority of which are 
involved in coagulation- and immune response pathways. Our aim is to define 
a set of follicle fluid protein markers, which could predict oocyte quality.
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INTRODUCTION
In Vitro Fertilization (IVF) is an assisted reproduction technology to achieve 
pregnancy in subfertile couples and animals. The acquired oocytes are fertilized 
in vitro, yielding embryos that are scored for viability using morphologic 
criteria. In human, ongoing pregnancy rates per treatment cycle vary between 
16-33%.4 In part, this is due to the inability to select the most viable oocytes 
and embryos. Therefore, more accurate selection will likely improve success 
rates after IVF treatment.
Oocytes provide RNA, proteins and cellular machinery for the early zygote, 
therefore, oocyte quality predicts embryo quality and implantation rates.107 
During ovarian follicle development, a cavity filled with fluid is formed. 
Follicle fluid comprises the preconception microenvironment in which the 
oocyte develops. Follicle fluid is a secretory product of granulosa cells and a 
selective exudate of blood serum.108 Hence, follicle fluid is a complex mixture of 
proteins, metabolites and ionic compounds reflecting follicle metabolism and 
comparable to blood serum.109-111 Oocyte and embryo quality are associated 
with the presence and concentration of single biomarkers in follicle fluid, for 
example folate, cobalamin and homocysteine.44, 112-114 Finally, the composition 
of follicle fluid is indicative of the follicular developmental stage.115, 116
To select the best oocyte and embryo, it will be helpful if we can objectively 
assess oocyte quality. Given the complexity of the numerous independent 
processes involved in oocyte maturation, it is unlikely that a single biomarker 
can predict oocyte quality.117 By characterization of the follicle fluid (sub)
proteome, a profile of biomarkers associated with oocyte quality could 
be discovered. This may offer prognostic information aiding the selection 
of the most viable oocytes and embryo. In the current study, we present a 
novel approach to analyze the follicle fluid (sub)proteome. We compare two 
methods based on nanoflow LC-MS/MS combined with peptide and protein 
fractionation using IEF and SDS-PAGE to uncover a detailed map of the 
human follicle fluid (sub)proteome.
MATERIAlS AND METHODS
Study design
The FOod, Lifestyle and Fertility Outcome study studies the influence of 
preconception nutrition and lifestyle on fertility and pregnancy outcome 
and is described in detail before.44 During oocyte retrieval, we separately 
collected follicle fluid from the largest follicle in each ovary. The follicle 
fluid samples were centrifuged for 10 min at 1,700 rpm to remove cells. The 
samples were frozen without preservatives and stored at -20˚C until assayed. 
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To improve protein coverage, we selected two follicle fluid samples from two 
follicles of comparable maturity (follicle diameter, 17.3 mm) from two folic 
acid supplemented women from couples with male factor infertility, which 
underwent mild GnRH-antagonist supported ovarian stimulation treatment 
and for who the oocyte from the respective follicle fluid was transferred after 
fertilization, from which no ongoing pregnancy occurred.
Proteomic analysis
The preparation of the follicle fluid samples and the proteomic analysis 
according to the two approaches was done as follows:
Removal of abundant proteins: IgGs were removed from the follicle 
fluid samples by depletion on a protein G Sepharose column. Subsequently, 
albumin was removed by adding ice cold 95% ethanol to the column eluate 
and incubated at 4˚C for 1 hour. Proteins were collected by centrifugation at 
16,000 g for 45 min at 4˚C (based on protocols in Fu et al. 2005).118
Approach 1, SDS-PAGE: Proteins were separated on a standard SDS-PAGE 
gel, fixed and stained with Coomassie Blue. The gel lane was divided into 22 
slices and further treated according to a standard in-gel digestion protocol.119
Approach 2, In-tube gel digestion and prefractionation of proteolytic 
peptides: A ‘tube gel’ was prepared by mixing 17 μl acrylamide (40%, 29:1) 
solution, 2.3 ul 10% ammonium persulfate and 1 μl of TEMED with 50 
μL of the follicle fluid sample and allowed to polymerize for 1 hr at RT. 
The gel piece was cut into pieces and further treated according to a standard 
in-gel digestion protocol.119 Proteolytic peptides were extracted from the gel 
material with 50 μL 30% acetonitrile and dried in a speedvac. 200 μl of 
Bromophenol Blue containing water and 2 μl of a 10% IPG buffer pH 4-7 
(Amersham) were added to the peptide sample and then deposited onto an 
11 cm IPG dry strip pH 4-7(Amersham). The strip rehydrated overnight at 
4˚C. An IPGPhor (Amersham) was used with the following settings: 30 min 
at 300V, 30 min gradient to 1000V and 5 hrs at 4000V. After the peptide 
separation, the IPG strip was cut into 0.5 cm slices and peptides from each 
slice were extracted with 50 μl 2% acetonitrile / 0.1% formic acid.
Mass spectrometry: Nano-flow LC-MS/MS was performed on an 
1100 series capillary LC system (Agilent Technologies) coupled to either 
an LTQ-Orbitrap or an LTQ linear ion trap mass spectrometer (both 
Thermo) operating in positive mode and equipped with a nanospray source, 
essentially as described in Bezstarosti et al.120 Peptide mixtures were trapped 
on a ReproSil C18 reversed phase column (Dr Maisch GmbH; column 
dimensions 1.5 cm × 100 μm, packed in-house) at a flow rate of 8 μl/min. 
Peptide separation was performed on ReproSil C18 reversed phase column 
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(Dr Maisch GmbH; column dimensions 15 cm × 50 μm, packed in-house) 
using a linear gradient from 0 to 80% B (A = 0.1% formic acid; B = 80% (v/v) 
acetonitrile, 0.1% formic acid) in 70 min and at a constant flow rate of 200 
nl/min using a splitter. The column eluate was directly sprayed into the ESI 
source of the mass spectrometer. Mass spectra were acquired in continuum 
mode; fragmentation of the peptides was performed in data-dependent mode. 
Database searching: Tandem mass spectra were extracted, charge state 
deconvoluted and deisotoped by Mascot Distiller version 2.3. All MS/MS samples 
were analyzed using Mascot (Matrix Science, London, UK; version 2.2). Mascot 
was set up to search the Uniprot database (taxonomy Homo sapiens, version 
2010_12, 97701 entries) assuming the digestion enzyme trypsin. Mascot was 
searched with a fragment ion mass tolerance of 0.80 Da and a parent ion tolerance 
of 15 ppm for Orbitrap spectra and 2.0 Da for ion trap spectra. Iodoacetamide 
derivative of cysteine was specified in Mascot as a fixed modification. Oxidation of 
methionine was specified in Mascot as variable modifications.
Criteria for protein identification: Scaffold (version Scaffold_2_06_02, 
Proteome Software Inc., Portland, OR) was used to validate MS/MS based 
peptide and protein identifications. Peptide identifications were accepted if 
they could be established at greater than 95.0% probability as specified by 
the Peptide Prophet algorithm.121 Protein identifications were accepted if 
they could be established at greater than 99.0% probability and contained 
at least one identified peptides (resulting in a 0.1% protein false discovery 
rate). Protein probabilities were assigned by the Protein Prophet algorithm.122 
Proteins that contained similar peptides and could not be differentiated based 
on MS/MS analysis alone were grouped to satisfy the principles of parsimony. 
We used Ingenuity Pathways Analysis (Ingenuity Systems Inc., Redwood 
City, CA) to uncover the functionalities of the identified proteins. The data 
is available in the PRIDE database.123 The data was converted using PRIDE 
Converter (http://pride-converter.googlecode.com).124
RESUlTS AND DISCUSSION
The IEF approach identified 241 proteins; the SDS-PAGE based method 139 
proteins (Table I). The number of proteins identified in the current study 
is higher than reported previously and confirms those identified in previous 
studies (Fig. 1), possibly because of the more extensive prefractionation 
protocol and more sensitive mass spectrometry.109-111
The most abundant proteins, e.g. proteins involved in coagulation and 
immune response pathways, overlap in the different data sets (Fig. 1). These 
same proteins were identified in both human and animal studies, aimed at 
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identifying proteins with differential abundances in serum and follicle fluid 
related to treatment outcomes or follicular developmental stage.113, 115, 116, 125-127
Here, coagulation and immune response pathways represent abundant 
pathways in follicle fluid. The coagulation pathway in follicle fluid is cited 
to be mainly involved in extracellular matrix remodelling, facilitating follicle 
growth, ovulation and corpus luteum formation.128 As part of immune 
response pathways, the function of the complement system in general is quite 
well established; its putative role in follicle fluid is nevertheless unclear. Some 
studies suggest a role during embryo implantation.113, 129
The complexity of follicle fluid in terms of the number of proteins and their 
abundance poses challenges in identifying putative biomarkers. In developing 
strategies, in which the follicle fluid proteome profile is indicative of oocyte 
quality, it could be helpful to take into account an exposure for which its effect 
on oocyte quality is established, such as preconception folic acid use. Folate 
metabolism is reflected in follicle fluid and folate availability affects oocyte 
and embryo quality after IVF.44 Studies in cultured lymphoblasts show that 
folate affects gene expression and protein profiles in proliferating tissues.130 
We therefore propose that we can use differentially expressed proteins due to 
folate availability to generate proteome profiles associated with oocyte quality.
In conclusion, we identified a higher number of proteins using the IEF 
approach compared to the SDS-PAGE approach. This may generally be true 
for complex protein mixtures in which a small number of highly abundant 
proteins constitute the majority of the (sub)proteome, as is the case for 
Fig. 1: The five most significant pathways in our follicle fluid screen compared to identifications of 
these pathways in previous screens, for which these were also among the most abundant pathways. 
The y-axis displays the –log (p-value) for the respective pathway. The threshold line denotes the cut-off for 
significance (p-value of 0.05). The ratio on top of the bar reflects the number of identified proteins in the 
screen relative to the number of proteins in the pathway. 
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follicle fluid. This study confirms previous proteomics screens of follicle fluid 
(Fig. 1) and to our knowledge presents the most detailed proteomic analysis of 
human monofollicular fluid thus far.109-111 High resolution, high throughput 
technologies like mass spectrometry based proteomics enable us to define 
profiles composed of multiple proteins with various biological functions, 
which may offer prognostic information that can aid in the selection of the 
best oocytes and most viable embryo. 
A next step in developing a prognostic follicle fluid proteome will have 
to involve a quantitative approach in which we assess differences in protein 
abundance levels with regard to oocyte and embryo quality. Focusing 
on exposures that are known to influence these outcomes can help select 
differential proteome profiles.32
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Table I. Identified proteins in follicle fluid using SDS-PAGE and IEF.
Name
Uniprot 
Accession 
ID
SDS-PAGE 
(no. 
peptides)
IEF  
(no. 
peptides)
MW 
(kDa)
Serum albumin P02768 38 85 69
Complement C3 P01024 91 114 187
Alpha-1-antitrypsin P01009 30 37 47
Serotransferrin P02787 29 70 77
C4B1 Q6U2E9 53 70 193
Basement membrane-specific 
heparansulfate proteoglycan  
core protein
P98160 34 117 469
Alpha-2-macroglobulin P01023 38 60 163
Fibrinogen beta chain P02675 22 39 56
Ig alpha1-1 chain C region P01876 10 22 38
Apolipoprotein A-I P02647 22 35 31
Ig kappa chain C region P01834 6 14 12
Fibronectin P02751 28 69 263
Antithrombin-III P01008 21 28 53
Ig gamma-1 chain C region P01857 8 20 36
Fibrinogen gamma chain P02679 19 27 52
Hemopexin P02790 13 26 52
Fibrinogen alpha chain P02671 21 27 95
Inter-alpha-trypsin  
inhibitor heavy chain H4 Q14624 25 34 103
Complement factor H P08603 15 50 139
Ceruloplasmin P00450 12 46 122
Inter-alpha-trypsin  
inhibitor heavy chain H2 P19823 14 20 106
Prothrombin P00734 11 30 70
Plasminogen P00747 13 43 91
Haptoglobin P00738 19 23 45
Protein highly similar to 
complement factor B B4E1Z4 28 31 141
Ig gamma-2 chain C region P01859 2 12 36
Inter-alpha-trypsin inhibitor 
heavy chain H1 P19827 10 28 101
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Alpha-1-antichymotrypsin P01011 16 20 48
Complement C5 P01031 16 38 188
Gelsolin P06396 17 21 86
Plasma protease C1 Inhibitor P05155 14 16 55
Angiotensinogen P01019 9 14 53
Apolipoprotein A-IV P06727 27 22 45
Kininogen-1 P01042 9 20 72
Heparin cofactor 2 P05546 8 15 57
Clusterin P10909 11 15 52
Beta-2-glycoprotein 1 P02749 2 15 38
Complement component C6 P13671 6 25 105
Vitamin D-binding protein P02774 6 22 53
Alpha-2-antiplasmin P08697 4 14 55
Histidine-richglycoprotein P04196 8 13 60
Alpha-1B-glycoprotein P04217 5 14 54
Vitronectin P04004 8 14 54
Complement component C7 P10643 3 18 94
Immunoglobulin  
lambda-like polypeptide 5 B9A064 6 6 23
Transthyretin P02766 6 10 16
Kallistatin P29622 3 13 49
Complement component C9 P02748 5 16 63
Ig mu chain C region P01871 8 11 49
Plasma kallikrein P03952 3 16 71
Insulin-like growth factor-
binding protein complex  
acid labile subunit
P35858 2 16 66
Alpha-2-HS-glycoprotein C9JV77 2 8 39
Ig heavy chain V-III  
region BRO P01766 1 2 13
Coagulation factor XII P00748 4 10 68
Protein AMBP P02760 2 12 39
Table I. Continued from previous page.
Name
Uniprot 
Accession 
ID
SDS-PAGE 
(no. 
peptides)
IEF  
(no. 
peptides)
MW 
(kDa)
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Glia-derived nexin P07093 10 10 44
Complement component  
C8 beta chain P07358 1 16 67
Pigment epithelium-derived 
factor P36955 10 13 46
Serum paraoxonase/arylesterase 1 P27169 7 11 40
Ig kappa chain V-III region SIE P01620 4 4 12
Complement component C8 
alpha chain P07357 3 11 65
Ig lambda-2 chain C regions P0CG05 1 2 11
Complement factor I P05156 5 14 66
Corticosteroid-binding 
globulin P08185 3 7 45
Complement component C8 
gamma chain P07360 7 5 22
Tetranectin P05452 8 9 23
Lipopolysaccharide-binding 
protein P18428 0 5 53
Ig heavy chain V-III region BUT P01767 1 5 12
Ig delta chain C region P01880 1 10 42
Thyroxine-binding globulin P05543 3 9 46
Serum amyloid A-4 protein P35542 4 2 15
Apolipoprotein E P02649 9 8 36
Ig lambda chain V-III region LOI P80748 2 2 12
Plasma serine protease inhibitor P05154 3 8 46
C4b-binding protein alpha chain P04003 0 13 67
N-acetylmuramoyl-L-alanine 
amidase Q96PD5 0 7 62
Complement factor H-related 
protein 1 Q03591 2 4 38
Versican core protein P13611 0 11 373
Ig heavy chain V-III region JON P01780 0 2 13
Ig heavy chain V-III region TUR P01779 1 3 12
Table I. Continued from previous page.
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Uniprot 
Accession 
ID
SDS-PAGE 
(no. 
peptides)
IEF  
(no. 
peptides)
MW 
(kDa)
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Complement C2 P06681 4 5 83
Ig alpha-2 chain C region P01877 1 4 37
Vitamin K-dependent protein S P07225 0 9 75
Carboxypeptidase N catalytic 
chain P15169 3 5 52
Ig kappa chain V-II region 
TEW P01617 1 5 12
Inter-alpha-trypsin inhibitor 
heavy chain H3 Q06033 0 12 100
Carboxypeptidase N subunit 2 P22792 1 7 61
Ig gamma-4 chain C region P01861 0 4 36
Pregnancy zone protein P20742 1 11 164
Monocyte differentiation 
antigen CD14 P08571 0 5 40
Ig heavy chain V-III region GAL P01781 1 6 13
Hepatocyte growth factor-like 
protein P26927 0 7 80
Apolipoprotein L1 O14791 5 4 44
Glyceraldehyde-3-phosphate 
dehydrogenase  P04406 5 5 36
Biotinidase P43251 0 3 61
Apolipoprotein C-I P02654 4 2 9
Coagulation factor XIII B chain P05160 0 10 76
Ig kappa chain V-I region WEA P01610 1 3 12
Leucine-richalpha-2-
glycoprotein P02750 5 5 38
Ig kappa chain V-IV region Len P01625 3 2 13
Sex hormone-binding globulin P04278 4 3 44
Prostatic acid phosphatise P15309 1 6 45
Afamin P43652 1 8 69
Ig heavy chain V-III region 
VH26 P01764 1 2 13
Fibulin-1 P23142 0 9 77
Table I. Continued from previous page.
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ID
SDS-PAGE 
(no. 
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(no. 
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MW 
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Protein Z-dependent protease 
inhibitor Q9UK55 0 5 51
Serum amyloid P-component P02743 6 4 25
Coagulation factor IX P00740 1 7 52
Haptoglobin-related protein P00739 1 5 39
Ig heavy chain V-III region CAM P01768 1 6 14
Ig gamma-3 chain C region P01860 0 4 41
Coagulation factor V P12259 0 4 252
Lysozyme C P61626 2 2 17
Coagulation factor X P00742 1 7 55
Hyaluronan-binding protein 2 Q14520 1 5 63
Alpha-1-acid glycoprotein 1 P02763 5 5 24
Hemoglobin subunit beta P68871 3 4 16
Ig kappa chain V-I region EU P01598 2 3 12
Extracellular matrix protein 1 Q16610 0 9 61
Inhibin alpha chain P05111 0 4 40
Actin, cytoplasmic 1 P60709 3 5 42
Sulfhydryl oxidase 1 O00391 0 7 83
Vitamin K-dependent protein Z P22891 0 4 45
Glutathione peroxidase 3 P22352 6 4 26
Insulin-like growth factor-
binding protein 3 P17936 1 3 32
Attractin O75882 0 9 159
Galectin-3-binding protein Q08380 0 6 65
Immunoglobulin J chain P01591 3 2 18
Vitamin K-dependent protein C P04070 1 3 52
Signal peptide, CUB and 
EGF-like domain-containing 
protein 1
Q8IWY4 0 7 108
Beta-Ala-His dipeptidase Q96KN2 0 6 57
Neuronal pentraxin-2 P47972 0 3 47
Carboxypeptidase B2 Q96IY4 0 3 48
Table I. Continued from previous page.
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Collagen alpha-3(VI) chain 12111 0 6 344
Ig kappa chain V-III region B6 P01619 0 3 12
Cadherin-5 P33151 0 2 88
Ig heavy chain V-III region GA P01769 0 2 13
Apolipoprotein C-III P02656 2 4 11
Lipoprotein lipase P06858 2 3 53
Complement factor D P00746 1 5 27
Tumor necrosis factor-
inducible gene 6 protein P98066 1 4 31
Tubulin alpha-1B chain P68363 0 6 50
Coagulation factor XIII A chain P00488 0 4 83
Laminin subunit alpha-1 P25391 0 4 337
Ig heavy chain V-III region TRO P01762 0 2 13
Complement factor H F8WDX4 0 2 51
Collagen alpha-1(IV) chain P02462 0 1 161
Uncharacterizedprotein F8VWA4 1 3 11
Ig heavy chain V-III region HIL P01771 0 5 14
Dopamine beta-hydroxylase P09172 0 4 69
Ig heavy chain V-III region BUR P01773 0 2 13
Mannosyl-oligosaccharide 
1,2-alpha-mannosidase IA P33908 0 1 73
Apolipoprotein D P05090 2 1 21
Zinc-alpha-2-glycoprotein P25311 1 5 34
Heat shockprotein HSP 90-beta P08238 0 6 83
Tubulin beta chain P07437 0 4 50
Fetuin-B Q9UGM5 0 3 42
Plakophilin-2 Q99959 0 2 97
Apolipoprotein A-II P02652 2 5 11
Metalloproteinase inhibitor 1 P01033 1 5 23
Collagen alpha-1(XV) chain P39059 1 2 142
Titin Q8WZ42 0 1 3816
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Transforming growth factor-
beta-induced protein ig-h3 Q15582 0 4 75
Lumican P51884 0 2 38
Dystonin Q03001 0 1 861
Peptidyl-prolylcis–trans 
isomerase B P23284 1 6 24
Complement C1r 
subcomponent P00736 1 3 80
Ig kappa chain V-III region 
VG(fragment) P04433 1 2 13
Ig kappa chain V-I region DEE P01597 1 1 12
Hornerin Q86YZ3 3 0 282
Thrombospondin-4 P35443 0 5 106
Complement C1r 
subcomponent-like protein Q9NZP8 0 5 53
Aggrecan E7EMK9 0 4 246
Tenascin-X P22105 0 4 464
Transferrin receptor protein 1 P02786 0 3 85
EGF-containing fibulin-like 
extracellular matrix protein 1 Q12805 0 3 55
Heat shock cognate 71 kDa 
protein P11142 0 2 71
E3 ubiquitin-protein ligase 
HUWE1 Q7Z6Z7 0 2 482
Plasminogen activator inhibitor 1 P05121 1 3 45
Hemoglobin subunit alpha P69905 3 1 15
14-3-3 protein theta P27348 2 1 28
Ig kappa chain V-I region Lay P01605 1 2 12
Retinol-binding protein 4 P02753 4 0 23
Phosphatidylinositol-glycan-
specific phospholipase D P80108 0 4 92
Coagulation factor XI P03951 0 3 70
Cholinesterase P06276 0 2 68
Phospholipid transfer protein P55058 0 2 55
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Ig lambda chain V-II region TRO P01707 0 1 12
Retinoic acid receptor 
responder protein 2 Q99969 1 2 19
Complement C1q 
subcomponent subunit B P02746 1 2 27
Ig kappa chain V-I region 
HK102 (fragment) P01602 1 1 13
Alpha-1-acid glycoprotein 2 P19652 0 2 24
Glutathione S-transferase A1 P08263 4 0 26
Peptidyl-prolylcis–trans 
isomerase A P62937 0 4 18
C-reactive protein P02741 2 0 25
78 kDa glucose-regulated protein P11021 0 3 72
Laminin subunit beta-2 P55268 0 3 196
Apolipoprotein B-100 P04114 0 2 516
Multiple inositol 
polyphosphate phosphatise Q9UNW1 0 2 55
Collagen alpha-2(IV) chain P08572 0 1 168
Endoplasmin P14625 0 1 92
Angiogenin P03950 3 1 17
Complement C1q 
subcomponent subunit C P02747 2 1 26
Serum amyloid A protein P02735 1 1 14
Ig lambda chain V-I region HA P01700 1 2 12
Alpha-enolase P06733 0 3 47
Complement C1s 
subcomponent P09871 0 3 77
Cartilage oligomeric matrix 
protein P49747 0 3 83
Ig kappa chain V-I region OU P01606 0 2 12
Coagulation factor VII P08709 0 2 52
Ig kappa chain V-III region 
NG9 (fragment) P01621 0 2 11
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Ig kappa chain V-II region 
RPMI 6410 P06310 0 2 15
Peptidyl-glycine alpha-
amidating monooxygenase P19021 0 2 108
Ectonucleotide pyrophosphatase/
phosphodiesterase family 
member 2
Q13822 0 1 99
Acyl-CoA synthetase family 
member 4 Q4L235 0 2 123
Peroxiredoxin-1 Q06830 2 1 22
Protein S100-A8 P05109 1 1 11
Phosphoglycerate kinase 1 P00558 1 2 45
Phosphatidylcholine-sterol 
acyltransferase P04180 0 3 50
Complement factor H-related 
protein 5 Q9BXR6 0 3 64
Hepatocyte growth factor 
activator Q04756 0 2 71
von Willebrand factor P04275 0 2 309
Ig kappa chain V-I region Mev P01612 0 2 12
Ezrin P15311 0 2 69
Fattyacid synthase P49327 0 2 273
Triosephosphate isomerise P60174 0 2 27
Heat shockprotein HSP 90-alpha P07900 0 1 85
Sushi repeat-containing  
protein SRPX P78539 0 1 52
Plastin-2 P13796 0 1 70
Insulin-like growth factor II P01344 2 0 20
Ig epsilon chain C region P01854 0 2 47
Thrombospondin-1 P07996 0 2 129
Retinol-binding protein 1 P09455 0 2 16
L-selectin P14151 0 2 42
RabGDP dissociation  
inhibitor beta P50395 0 2 51
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Protein kinase C-binding 
protein NELL2 Q99435 0 2 91
Histone H2A type 1-B/E P04908 0 2 14
Peroxidasin homolog Q92626 0 2 165
Protein KIAA0317 O15033 0 1 94
Amyloid beta A4 protein P05067 0 1 87
Dihydropyrimidinase-related 
protein 3 Q14195 0 1 62
Desmoglein-2 Q14126 0 1 122
Extracellular sulfatase Sulf-2 Q8IWU5 0 1 100
Ig kappa chain V-I region AU P01594 0 1 12
Fibrillin-1 P35555 0 1 312
Vasorin Q6EMK4 0 1 72
Table I. Continued from previous page.
Name
Uniprot 
Accession 
ID
SDS-PAGE 
(no. 
peptides)
IEF  
(no.  
peptides)
MW 
(kDa)
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AbSTRACT
Background
IVF/ICSI treatment is a moderately successful technique to achieve pregnancy 
in subfertile couples. Follicle fluid folate, as a substrate of the one-carbon 
pathway, affects follicle metabolism and oocyte and embryo quality. If we are 
able to identify new markers for the underlying mechanisms, we might be 
able to predict oocyte quality and improve IVF/ICSI treatment success rates.
Materials and Methods
In an observational study, we performed qualitative and quantitative 
proteomic analyses using nanoflow LC-MS/MS and TMT-labelling on 15 
monofollicular fluid samples of folic acid supplement users and on 15 samples 
from nonusers, retrieved from women undergoing IVF/ICSI treatment. The 
protein data is analyzed using Scaffold proteome software and differential 
abundances are expressed as Log2 fold change. Blood samples were obtained 
before and after treatment for determination of biomarkers of the one-
carbon pathway and estradiol. Ovarian follicles were visualised, counted and 
diameters recorded using transvaginal ultrasound.
Results
We identified 227 unique expressed proteins in follicle fluid. First, C-reactive 
protein was less abundant in folic acid supplement users (-2.03; p=<0.01). 
Additionally, apolipoproteins from HDL, most notably A-I (+1.28; p=<0.01) 
and C-I (+1.11; p=0.016) were more abundant in folic acid supplement users. 
Conclusion
Preconception folic acid supplement use seems to suppress the inflammatory 
pathways in follicle fluid and stimulates the HDL pathway, the preferential 
source of cholesterol for steroid hormone synthesis, with possible beneficial 
effects on embryo quality after IVF/ICSI treatment. In vitro studies are 
needed to further identify the tissue specificity of these pathways through 
which folate establishes these effects.
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INTRODUCTION
In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) is a 
moderately successful technique to achieve pregnancy in subfertile couples. 
The cumulative life birth rate after six IVF/ICSI cycles is approximately 51%.3 
Epidemiologic studies indicate that many factors affect IVF/ICSI treatment 
success.131 Therefore, if we can identify biomarkers of underlying pathways 
that affect oocyte quality, IVF/ICSI treatment may be improved by screening 
for such markers prior to fertilization and subsequent embryo transfer.
The ovarian follicle is the pre-ovulation microenvironment in which 
the oocyte matures. Oocyte maturation is a complex process involving 
many pathways and interactions with the follicular granulosa and theca 
cells.132 During follicle development and oocyte maturation, an avascular 
compartment forms. This compartment is filled with follicle fluid, which 
is in part an exudate of serum and partially composed of locally produced 
substances. Follicle fluid contents associate with oocyte quality and provides 
an overview of metabolic activity of follicular cells and systemic influences 
on the oocyte microenvironment.133 Indeed, directly investigating follicular 
cells could provide a more accurate view of follicle metabolism, but disregards 
possible harmful systemic influences on the oocyte microenvironment. 
Follicle fluid is readily available after IVF/ICSI treatment. Therefore, follicle 
fluid offers the unique potential for the identification of biomarkers for non-
invasive screening of oocyte quality.
Many epidemiologic and experimental studies show the influence of the 
B-vitamin folate on reproductive performance.11 Apart from associations 
between maternal folate status and pregnancy outcomes, folate seems to affect 
several ovarian pathways thereby affecting the number of oocytes retrieved 
after ovarian stimulation treatment and embryo quality.44, 46, 134 Folate is a 
one-carbon donor and affects many biological processes through various 
pathways of which one-carbon metabolism is of main interest.130, 135 Through 
one-carbon metabolism, folate facilitates the synthesis of amino acids, lipids, 
DNA nucleotides and methylation of various substrates, contributing to 
genomic integrity and cellular replication.11 Therefore, especially proliferating 
tissues, such as the growing ovarian follicle are sensitive to disturbances in 
one-carbon metabolism.
In this study we use proteomic techniques based on proteolytic peptide 
fractionation by isoelectric focusing (IEF) and sensitive nanoflow LC-MS/
MS in order to further specify the effect of the known influence of folate on 
oocyte quality and follicle metabolism on a protein level in follicle fluid. This 
is a first step in identifying biomarkers that affect human oocyte quality after 
IVF/ICSI treatment.
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MATERIAlS & METHODS
Study population
The FOod, Lifestyle and Fertility Outcomestudy (FOLFOstudy), designed 
to study the influence of periconception nutrition and lifestyles on fertility 
and pregnancy outcome, is described in detail before.136 In summary, between 
September 2004 and October 2006, 292 subfertile couples undergoing an 
IVF/ICSI treatment procedure at the tertiary referral fertility clinic of the 
Erasmus MC, University Medical Centre in Rotterdam, the Netherlands, were 
invited to participate. Women diagnosed with endometriosis or hydrosalpinx 
could not participate, since these conditions detrimentally influence IVF/
ICSI treatment outcome. Additionally, couples undergoing oocyte donation 
could not participate. After the inclusion period, 251 couples participated.
At the start of treatment all couples completed a questionnaire regarding 
nutrition, lifestyle, medication and disease history. We collected blood 
samples from all couples on cycle day (CD) 2, before treatment commenced. 
On the day of hCG administration serum was collected from women only.
From this observational cohort we selected n=30 monofollicular samples on 
outcome (not pregnant) and folate concentrations in follicle fluid. Therefore, 
the evaluation of folic acid supplement use was observational, not assigned. 
Based on Brouwer et al., we selected 15 samples with a follicle fluid folate 
concentration below 22.5 nmol/L (no folic acid supplement use, nonusers) and 
15 samples of women with a folate concentration equal to or above 22.5 nmol/L 
(folic acid supplement use, users).137 All monofollicular samples are from the 
oocyte that yielded the transferred embryo, but did not result in pregnancy.
The Dutch Central Committee for Human Research (CCMO) and 
the Medical Ethical and Institutional Review Board of the Erasmus MC, 
University Medical Centre in Rotterdam, the Netherlands, approved the study 
protocol. Participants provided written informed consent before participation 
and obtained materials and questionnaires were processed anonymously.
IVF procedure
All women started ovarian stimulation treatment with daily injections of 150 
IU recombinant follicle stimulating hormone (rFSH) s.c. on CD2 (Puregon®, 
MSD Oss, Oss, the Netherlands, or Gonal-F®, Merck-Serono, Schiphol-Rijk, 
the Netherlands). Administration of daily s.c. GnRH-antagonist (Orgalutran®, 
MSD Oss, Oss, the Netherlands, or Cetrotide®, Merck-Serono, Schiphol-Rijk, 
the Netherlands) was started when at least one follicle was 14 mm. To induce 
final oocyte maturation, a single dose of 5000 or 10 000 IU hCG s.c. (Pregnyl®, 
MSD Oss, Oss, the Netherlands) was administered as soon as the largest follicle 
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reached a diameter of 18 mm and at least one additional follicle of 15 mm was 
observed. Oocyte retrieval was carried out 35 h after hCG injection by transvaginal 
ultrasound-guided aspiration of follicles. Luteal phase supplementation of 600 mg/
day micronized progesterone intravaginally was started on the evening following 
oocyte pick-up and continued for 12 days thereafter. On day 3 after oocyte 
pick-up, a maximum of two embryos were transferred.
Sample collection and analysis
During oocyte retrieval, monofollicular fluid from the leading follicle of each 
ovary was aspirated and collected separately. These were then centrifuged for 10 
min at 1,700 rpm to separate red blood cells (RBC), leucocytes and follicular 
cells. The samples were frozen without preservatives and stored at -20˚C. 
Venous blood samples were drawn from each woman on CD2 before the first 
injection of rFSH and at the day of hCG administration. For determination of 
folate, cobalamin and hormones, venous blood samples were drawn into dry 
vacutainer tubes and allowed to clot. After centrifugation at 2,000 x g, serum was 
collected before being assayed. Serum and monofollicular fluid samples from 
each patient were analyzed using an immunoelectrochemoluminescence assay 
(Roche Modular E170, Roche Diagnostics GmbH, Mannheim, Germany). 
Total protein concentrations in monofollicular fluid were determined 
photometrically on a Hitachi 917 (Roche Diagnostics GmbH). Serum 
concentrations of FSH were measured by luminescence-based immunometric 
assay (Immulite 2000, Diagnostic Products Corporation (DPC), Los Angeles, 
CA, USA), and estradiol was determined using coated tube radioimmunoassay 
from the same supplier. For the determination of plasma total homocysteine 
(tHcy) and pyridoxine in whole blood, venous blood samples were drawn into 
EDTA containing vacutainer tubes. The EDTA-blood samples were placed 
on ice and within 1 hour, plasma was separated by centrifugation. Total 
homocysteine in EDTA plasma and monofollicular fluid and pyridoxine as 
pyridoxal-5-phosphate in whole blood was determined using HPLC with 
reversed phase separation and fluorescence detection. For the determination 
of RBC folate, 100 ml blood from one EDTA tube was hemolyzed with 2 
ml freshly prepared ascorbic acid (0.05 g ascorbic acid in 25 ml AD) directly 
after blood sampling. Subsequently, the hematocrit of the EDTA blood 
was determined on a Sysmex XE-2100 (Groffin Meyvis, Etten-Leur, The 
Netherlands). The hemolysate was centrifuged for 10 min at 2000g shortly 
before the folate measurement. The folate concentration in the hemolysate 
was calculated in RBC folate using the following formula: (nmol hemolysate 
folate X 21) – (nmol/l serum folate X (1 – hematocrit))/hematocrit = nmol/l 
RBC folate. Inter-assay coefficients of variation for folate were 4.5% at 13 
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nmol/L and 5.7% at 23 nmol/L; for cobalamin 3.6% at 258 pmol/L and 2.2% 
at 832 pmol/L; for tHcy 4.8% at 14.6 mmol/L and 3.3% at 34.2 mmol/L; 
for total protein 1.5% at 55 g/l and 1.3% at 84 g/l; for FSH < 5.8%; and 
for estradiol, <8.8%. The detection limit for folate was 1.36 nmol/L, for 
cobalamin 22 pmol/L, for pyridoxine 5 nmol/L; for tHcy 4 mmol/L, for total 
protein 0.1 g/l, for FSH 0.1 U/L and for estradiol 10 pmol/L. 
Statistical analysis
Given the skewed distribution of the variables, measures of location and 
spread are depicted as Median and Interquartile Range (IQR), respectively.
Monofollicular fluid total protein concentrations vary with follicle 
maturity.115, 116 Therefore, concentrations of tHcy and B-vitamins in 
monofollicular fluid are expressed in concentration per gram of protein.
Comparison of the two groups was done using the Mann-Whitney-U test. 
Proportions were compared using a chi-square test.
A p-value <0.05 was considered statistically significant. All statistical analyses 
were done using SPSS 17.0 for Windows software (SPSS Inc., Chicago, IL, USA).
Sample preparation and mass spectrometric analysis
IgGs were removed by depletion on a protein G Sepharose column. Albumin 
was removed by adding ice cold 95% ethanol to the column eluate, the resulting 
mixture was incubated at 4°C for 1 hr. Proteins were collected by centrifugation 
at 16,000 x g for 45 min at 4°C. A ‘tube gel’ was prepared by mixing 17 μL 
acrylamide (40%, 29:1) solution, 2.3 ul 10% ammonium persulfate and 1 μL of 
TEMED with 50 μL of the follicle fluid sample and allowed to polymerize for 1 
hr at RT. The ‘in-tube’ gel block was cut into pieces and further treated according 
to a standard in-gel digestion protocol.138 Extracted proteolytic peptides were 
labelled with TMT 6-plex labelling reagents (Thermo Scientific) allowing 
for peptide quantitation. Peptides were mixed at the 6-plex level and further 
fractionated by either reversed phase chromatography combined with elution 
at high pH, by isoelectric focusing on a 3100 Offgel fractionator (Agilent) or by 
HILIC chromatography. Each time, 18-22 fractions were collected and further 
analyzed by nanoflow LC-MS/MS. Nanoflow LC-MS/MS was performed 
on an 1100 series capillary LC system (Agilent Technologies) coupled to an 
LTQ-Orbitrap mass spectrometer (Thermo) operating in positive mode and 
equipped with a nanospray source. Peptide mixtures were trapped on a ReproSil 
C18 reversed phase column (Dr Maisch GmbH; column dimensions 1.5 cm × 
100 μm, packed in-house) at a flow rate of 8 μL/min. Peptide separation was 
performed on ReproSil C18 reversed phase column (Dr Maisch GmbH; column 
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dimensions 15 cm × 50 μm, packed in-house) using a linear gradient from 0 to 
80% B (A = 0.1 % formic acid; B = 80% (v/v) acetonitrile, 0.1 % formic acid) in 
70 min and at a constant flow rate of 200 nL/min using a splitter. The column 
eluent was directly sprayed into the ESI source of the mass spectrometer. Mass 
spectra were acquired in continuum mode; fragmentation of the peptides was 
performed in data-dependent mode. Peak lists were automatically created from 
raw data files using the Mascot Distiller software (version 2.3; MatrixScience). 
The Mascot search algorithm (version 2.2, MatrixScience) was used for 
searching against the IPI database (IPI_human_20100507.fasta). The peptide 
tolerance was set to 10 ppm and the fragment ion tolerance was set to 0.8 
Da. A maximum number of 2 missed cleavages by trypsin were allowed and 
carbamidomethylated cysteine and oxidized methionine were set as fixed and 
variable modifications, respectively. The Mascot score cut-off value for a positive 
protein hit was set to 60. Individual peptide MS/MS spectra with Mascot scores 
below 40 were checked manually and either interpreted as valid identifications 
or discarded. Typical contaminants, also present in immunopurifications using 
beads coated with pre-immune serum or antibodies directed against irrelevant 
proteins were omitted from the table. Each follicle fluid sample was analyzed at 
least two-times to reduce measurement error.
Scaffold (version Scaffold_2_06_02, Proteome Software Inc., Portland, 
OR) was used to validate MS/MS based peptide and protein identifications. 
Peptide identifications were accepted if they could be established at greater 
than 95.0% probability as specified by the Peptide Prophet algorithm.121 
Protein identifications were accepted if they could be established at greater 
than 99.0% probability and contained at least one identified peptides. Protein 
probabilities were assigned by the Protein Prophet algorithm.122 Proteins that 
contained similar peptides and could not be differentiated based on MS/MS 
analysis alone were grouped to satisfy the principles of parsimony.
RESUlTS
Study population
Except for Body Mass Index (BMI), baseline characteristics were comparable 
between folic acid supplement users and nonusers. The BMI in users is slightly 
lower (Table I)
Biochemical parameters
As a result of our selection criteria, there were differences in biomarker 
concentration in serum between users and nonusers prior to treatment 
(Table II). Users had higher levels of serum folate, RBC folate, cobalamin and 
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pyridoxine. Additionally, tHcy levels were lower in these women (Table II). 
Biomarker concentrations after treatment are similar to those before treatment 
and show a comparable profile, with vitamin levels higher and tHcy levels 
lower in users (Table II).
We observed comparable differences in follicle fluid biomarker levels 
(Table II). Users had higher follicle fluid levels of folate, cobalamin 
and pyridoxine; tHcy levels were lower in users. Total protein levels were 
comparable between users and nonusers.
Table I. Baseline characteristics of women undergoing ovarian stimulation treatment 
according to follicle fluid folate concentration (n=30).
Folic acid use  
(≥22.5 nmol/l) 
(n=15)
Non folic acid use 
(<22.5 nmol/l) 
(n=15) p
Age (years), median (IQR) 36.0 (35.0-40.0) 35.0 (32.0-38.0) ns
Body Mass Index (kg/m2),
median (IQR) 22.0 (20.0-24.0) 23.0 (23.0-25.0) 0.048
Ethnicity, % (n) 0.06
Dutch 57.1 (8) 93.3 (14)
Non-Dutch European 14.3 (2) 0 (0)
Non-European 28.6 (4) 6.7 (1)
Education, % (n)   ns
Low 6.7 (1) 20.0 (3)
Intermediate 33.3 (5) 26.7 (4)
High 60.0 (9) 53.3 (8)
Fertilization procedure, % (n) ns
IVF 73.3 (11) 86.7 (13)
ICSI 26.7 (4) 13.3 (2)
Cause of subfertility, % (n) ns
Male factor 46.7 (7) 20.0 (3)
Female factor 13.3 (2) 40.0 (6)
Combined 0 (0) 6.7 (1)
Unknown 40.0 (6) 33.3 (5)
Smoking (yes), % (n) 0 (0) 1 (6.7) ns
Duration of subfertility (months), 
median (IQR) 33.0 (14.0-56.0) 28.0 (12.0-50.0) ns
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Table II. Biochemical markers in blood serum and follicle fluid of women undergoing 
ovarian stimulation treatment according to follicle fluid folate concentrations (n=30).
Folic acid use  
(≥22.5 nmol/l) 
(n=15)
Non folic acid use  
(<22.5 nmol/l) 
(n=15) p
Follicles (n) 6 (2-7) 7 (5-8) ns
Follicle diameter (mm) 20.5 (18.6-22.6) 20.0 (17.3-21.0) ns
baseline serum
FSH (U/L) 8.3 (7.3-11.1) 8.5 (7.1-9.8) ns
Estradiol (pmol/L) 149.5 (131.8-208.3) 133.0 (111.0-180.0) ns
Cobalamin (pmol/L) 376.0 (288.0-447.0) 256.0 (210.0-325.0) 0.015
Pyridoxine (nmol/L) 97.0 (77.5-121.5) 66.0 (51.0-75.0) <0.01
Folate (nmol/L) 36.8 (31.6-40.6) 15.4 (12.7-17.7) <0.001
RBC folate (nmol/L) 1,618 (1,250-1,831) 937 (718-1,245) 0.02
Homocysteine (μmol/L) 7.6 (6.9-8.1) 11.2 (9.0-14.4) <0.001
hCG-day serum  
Estradiol (pmol/L) 1871 (1022-2981) 1868 (1381-3697) ns
Cobalamin (pmol/L) 389.5 (285.8-419.8) 244.0 (185.0-337.0) <.0.01
Pyridoxine (nmol/L) 102.5 (66.5-129.5) 63.0 (50.0-87.0) 0.012
Folate (nmol/L) 39.9 (33.5-44.0) 15.4 (12.3-21.7) <0.001
RBC folate (nmol/L) 1,899 (1,290-2,133) 911 (781-1,189) <0.001
Homocysteine (μmol/L) 7.2 (6.8-8.5) 10.8 (8.8-14.4) <0.001
Follicle fluid  
Cobalamin / total  
protein (pmol/g) 4.18 (3.54-5.33) 2.86 (2.34-3.96) 0.02
Pyridoxine / total  
protein (nmol/g) 2.12 (1.37-3.04) 1.14 (0.69-1.56) 0.02
Folate / total  
protein (nmol/g) 36.1 (31.8-40.4) 17.0 (11.1-19.6) <0.001
Homocysteine / total 
protein (μmol/g) 0.10 (0.085-0.11) 0.15 (0.12-0.21) <0.001
Total protein (g/L) 55.0 (53.0-61.0) 58.0 (55.0-60.0) ns
Variables are depicted Median (Interquartile Range)
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Follicle diameter and the number of visualized follicles at oocyte pickup 
were comparable between users and nonusers (Table II).
The follicle fluid proteome
The proteomics screen identified 227 unique expressed proteins 
(Supplementary Table). Proteins with at least a log2 fold change of 0.5 in 
users relative to nonusers are shown in Table III. The inflammatory marker 
C-reactive protein (CRP) is less abundant in users. Several proteins are more 
abundant in users such as the apolipoproteins (Apo). The increase in Apo CII, 
Apo AI, Apo CI and Apo CIII abundance are most profound. Apo-E, however, 
is less abundant in users (Supplementary Table)
Table III. Differentially abundant proteins in follicle fluid of folic acid supplement 
users relative to non folic acid users (n=30).
Protein
MW 
(kDa)
IPI  
identifier
Median log2 
fold change IQR p
Up regulated
Apolipoprotein C-II 11 IPI00021856 1.28 (1.11-1.45) ns
Apolipoprotein A-I 31 IPI00021841 1.28 (0.92-1.64) <0.01
Apolipoprotein C-I 9 IPI00021855 1.11 (0.73-1.49) 0.016
Apolipoprotein C-III 11 IPI00021857 0.73 (0.65-0.81) ns
Plasma Kallikrein 71 IPI00654888 0.67 (0.52-0.82) 0.085
Interleukin-1 receptor 
accessory protein 65 IPI00031789 0.65 (0.47-0.82) ns 
Apolipoprotein M 21 IPI00030739 0.62 (0.53-0.70) ns
Farnesyl pyrophosphate 
synthetase like-4 40 IPI00382869 0.56 (0.56-0.57) ns
C4b-binding protein 
alpha chain 67 IPI00021727 0.53 (0.37-0.68) ns
Histidine-rich 
glycoprotein 60 IPI00022371 0.51 (0.36-0.65) ns
Down regulated
Low affinity IgG Fc 
region receptor III-A 29 IPI00218834 -0.50 (-0.93-0.057) ns
Small proline-rich 
protein 3 18 IPI00082931 -0.93 (-1.22- -0.65) ns
C-reactive protein 25 IPI00022389 -2.03 (-2.26- -1.80) <0.01
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DISCUSSION
In this study, we show significant changes in monofollicular fluid protein 
abundance associated with follicle fluid folate concentrations of women who 
underwent IVF/ICSI treatment. Women who were folic acid supplement 
users had lower CRP levels in follicle fluid, an acute phase response protein 
that serves as a marker of inflammation. Additionally, users have higher 
Apo levels. Apo’s are constituents of cholesterol transport complexes, and 
cholesterol is the substrate for steroid hormone production.
These results should be considered within the context of the strengths and 
limitations of this study. The FOLFO study is a prospective periconception 
observational study specifically designed to address the influence of food and 
lifestyle factors on IVF/ICSI treatment outcomes. From this cohort we randomly 
selected follicle fluid samples with knowledge only on folate status and treatment 
outcome, with only BMI marginally different between the two groups. Oocyte 
quality between the women can be considered comparable, because all oocytes 
yielded embryos suitable for transfer. Given the observational nature of the study, 
we cannot exclude that folic acid supplement use is a proxy for other factors, such as 
adequate nutrition, high education and a healthy lifestyle. Nevertheless, the major 
difference between users and nonusers are folate and associated B-vitamin levels, 
suggesting that the observed effects in the follicle fluid proteome are indeed due 
to changes in one-carbon metabolism. The follicle fluid proteome is conditional 
on follicle maturity (i.e. size).115, 116 We have investigated the association between 
folate and the follicle fluid proteome in monofollicular fluids from only mature 
follicles comparable in size using a validated and reproducible technique.139 This 
excludes the possibility that differential protein abundances are due to differences 
in follicle size or the number of (im)mature follicles in a punctuate, but also allows 
to associate identifications in the follicle fluid to a specific oocyte.115, 116
A higher CRP abundance in nonusers suggests a more pronounced inflammatory 
process. Indeed, other studies are contradicting on the relation between folate and 
CRP levels.140, 141 In this study it is unclear whether the elevated CRP levels in 
follicle fluid of nonusers is due to local or peripheral changes in expression, and 
what mechanism resulted in CRP elevation. Indeed, BMI is slightly higher in 
nonusers, which also associates with CRP levels.142 Elevated estradiol levels, due to 
ovarian stimulation treatment or oral contraceptive use, also increase CRP levels.142, 
143 Despite that estradiol levels after stimulation treatment were comparable in our 
sample, given previous evidence for the effect of folate on the ovarian response, the 
higher CRP abundance in nonusers may also reflect a higher oestrogen exposure 
during the treatment cycle in these women.134, 144 Nevertheless, regardless the 
source of CRP, the elevated concentration is reflected in follicle fluid of nonusers 
and can therefore exert influence on oocyte and follicle development.
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A number of Apo’s, most notably AI and CI, are more abundant in 
follicle fluid of users. Apo’s are proteins that associate with triglycerides and 
cholesterol(-esters) to form lipoproteins, such as High Density Lipoprotein 
(HDL) and Low Density Lipoprotein (LDL). While Apo-AI is the principal 
Apo of HDL, all here identified differentially abundant Apo’s can associate with 
HDL.145 Although other lipoproteins can be detected, studies show that HDL 
is the principal lipoprotein in follicle fluid and HDL is the preferential source 
of cholesterol(-esters) for steroid hormone synthesis in the ovary.146-148 Uptake 
of cholesterol from HDL in the ovary does not involve internalization and 
degradation of the lipoprotein particle.148 Therefore, the source of increased 
Apo levels in follicle fluid remains elusive. Indeed, granulosa cells synthesize 
some Apo’s.149 Nevertheless, knockout models for cystathione β-synthase 
and methylenetetrahydrofolatereductase, crucial enzymes in one-carbon 
metabolism; show decreased liver Apo-AI production and circulating HDL 
levels.150, 151 In human, biomarkers of compromised folate metabolism associate 
with lower circulating HDL levels.150, 152 Regardless, animal and human 
clinical studies highlight the importance of HDL cholesterol metabolism in 
reproduction. Both hypercholesterolemia and decreasing HDL levels were 
negatively associated with oocyte and embryo quality.153, 154 Finally, knockout 
models for HDL metabolizing enzymes result in a subfertile phenotype.153
Two cytokeratins (Supplementary Table) appear markedly less abundant 
in samples from folic acid supplement users. In human, granulosa cells loose 
cytokeratin expression during maturation, not expressing cytokeratins once 
they near luteinisation.155 Thus, lower cytokeratin abundance in follicle fluid 
from folic acid supplement users would suggest the presence of more mature 
granulosa cells. This statement is supported by previous research on the 
effects of folate metabolism on ovarian follicle growth.134, 144 Nevertheless, 
given the issues with keratin identification in proteomic studies, i.e. the 
sequence homology between the different keratins and the high risk of keratin 
contamination during sample processing, we cannot draw strong conclusions 
on the differential abundance of cytokeratins between users and nonusers.156
Several mechanisms can underlie changes in the proteome of follicle fluid. 
First, not only folate concentrations are higher in serum and follicle fluid of 
users, but also the concentrations of two cofactors of one-carbon metabolism, 
cobalamin and pyridoxine. Also, tHcy is lower in both serum and follicle 
fluid of users. Resulting inhibition of one-carbon metabolism through 
one-carbon donor or cofactor shortage or elevated tHcy levels affects many 
processes.29 Inhibition of one-carbon metabolism can result in diminished 
DNA nucleotide, amino acid, phospholipid synthesis and oxidative stress.11 
Accordingly, also epigenetic mechanism, such as DNA methylation, necessary 
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for normal growth and development are affected, resulting in altered gene 
expression profiles.157 Finally, pyridoxine is involved in over 180 enzymatic 
reactions.158 Therefore, in vitro experiments are needed to pinpoint the 
possible independent effects of these cofactors and derivatives of one-carbon 
metabolism on the follicle fluid proteome. 
High resolution, high throughput technologies like mass spectrometry 
based proteomics of follicle fluid is a useful tool and medium to identify 
mechanisms through which one-carbon metabolism affects follicle metabolism. 
One-carbon metabolism is involved in and likely establishes its effects through 
numerous different pathways. Findings by Bliek et al. support this statement, 
were folate supplementation of culture media affected both mRNA and protein 
expression in lymphoblasts.130, 135 Given this complexity, -omics technologies, 
such as proteomics, can identify different independent and related processes 
and provide a view of the net effect of folate on ovarian follicle metabolism. 
Although we detect different protein abundances in follicle fluid of users and 
nonusers, we can only speculate on the origin of these differences. Most likely, 
both changes in follicle metabolism and peripheral tissues, resulting in different 
serum concentrations underlie our observations. Optimizing techniques to 
specifically isolate the different subtypes of follicular cells from monofollicular 
fluid, without culturing, could prove helpful in identifying the origin of the 
identified changes. Also, even though the oocyte is transcriptionally active, 
little is known about the contribution of the oocyte to the follicle fluid 
composition.159 Regardless, changes in protein abundance conditional on folate 
levels can provide information on possible mechanisms through which folate 
affects follicle metabolism and thereby reproductive capacity and outcome. 
CONClUSION
In this study, we identified 227 unique expressed proteins in follicle fluid, some 
of which are differentially abundant conditional on folic acid supplement 
use. Most likely, folate establishes its effect on the follicle microenvironment 
through changes in intra-ovarian pathways and peripheral tissues. Of 
special interest is the suggestion that follicle fluid folate influences follicle 
maturation, as suggested by cytokeratin abundance, a hypothesis that requires 
further testing. Additionally, folate possibly affects follicle metabolism and 
oocyte maturation through extra-ovarian mechanisms by exerting effects on 
Apo synthesis in the liver. 
In vitro studies using granulosa cells can help further elucidate the 
mechanism through which one-carbon metabolism affects intra-ovarian 
metabolism and can address the role of the availability of several cofactors and 
derivatives as biomarkers of this pathway
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Supplementary Table. Relative abundance of proteins in follicle fluid, conditional 
on folic acid supplement use.
Name Accession No
MW  
(kDa)
Folic acid 
supplement use 
(log2 fold 
change) p
Hemopexin IPI00022488 52 -0.2 0.51
Vitamin D-binding protein 
precursor IPI00555812 53 -0.1 0.93
Complement component 4B 
preproprotein IPI00418163 193 -0.1 0.97
Alpha-2-HS-glycoprotein IPI00022431 47 0 0.91
Ceruloplasmin IPI00017601 122 0 0.91
Complement factor B IPI00019591 141 -0.3 0.87
Isoform 1 of Complement 
factor H IPI00029739 139 0 0.97
Antithrombin-III IPI00032179 53 0.1 0.77
Isoform HMW of Kininogen-1 IPI00032328 72 0.2 0.94
Basement membrane-specific 
heparan sulfate proteoglycan 
core protein
IPI00024284 469 -0.3 0.36
Plasminogen IPI00019580 91 0.2 0.6
Inter-alpha (Globulin) inhibitor 
H2, isoform CRA-a IPI00305461 107 0.2 0.53
Beta-2-glycoprotein 1 IPI00298828 38 -0.1 0.82
Complement C5 IPI00032291 188 0 0.99
Prothrombin (Fragment) IPI00019568 70 0 0.85
Isoform 1 of Inter-alpha-trypsin 
inhibitor heavy chain H4 IPI00896419 103 -0.1 0.87
Alpha-1-Antichymotrypsin IPI00550991 51 -0.3 0.42
Isoform 1 of Fibronectin IPI00022418 263 0.1 0.76
Apolipoprotein A-IV IPI00304273 45 0 1
Alpha-1B-glycoprotein IPI00022895 54 0 0.94
Isoform 1 of Gelsolin IPI00026314 86 0.1 0.89
Afamin IPI00019943 69 0.1 0.82
Complement  
component 6 precursor IPI00879709 106 0 0.92
Inter-alpha-trypsin  
inhibitor heavy chain H1 IPI00292530 101 0.2 0.67
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Angiotensinogen IPI00032220 53 0 0.95
Apolipoprotein A-I IPI00021841 31 1.3 0.0011*
Complement C3 (Fragment) IPI00783987 187 -0.3 0.34
Isoform 1 of Clusterin IPI00291262 52 -0.1 0.82
Complement component C7 IPI00296608 94 0.3 0.7
Histidine-rich glycoprotein IPI00022371 60 0.5 0.54
Vitronectin IPI00298971 54 0 0.96
Complement component C9 IPI00022395 63 -0.3 0.51
Serpin peptidase inhibitor, clade 
D (Heparin cofactor), member 1 IPI00292950 60 -0.2 0.77
Protein AMBP IPI00022426 39 0.1 0.83
Complement component  
C8 alpha chain IPI00011252 65 -0.1 0.9
55 kDa protein IPI00029863 55 0.1 0.88
Complement factor I IPI00291867 66 -0.2 0.78
Isoform 2 of Attractin IPI00162735 141 0 0.93
Lumican IPI00020986 38 -0.1 0.89
Apolipoprotein A-II IPI00021854 11 0.3 0.63
Complement component  
C8 beta chain IPI00294395 67 0 0.95
Coagulation factor XII IPI00019581 68 0 0.91
Isoform 1 of Inter-alpha-trypsin 
inhibitor heavy chain H3 IPI00028413 100 0.2 0.7
Plasma kallikrein IPI00654888 71 0.7 0.085
Pigment epithelium-derived factor IPI00006114 46 -0.1 0.77
Retinol-binding protein 4 IPI00022420 23 0 1
Kallistatin IPI00328609 49 0 0.99
Isoform 1 of Coagulation  
factor XI IPI00008556 70 0.1 0.76
Coagulation factor IX IPI00296176 52 -0.1 0.87
Plasma protease C1 inhibitor IPI00291866 55 0.2 0.7
Thyroxine-binding globulin IPI00292946 46 -0.1 0.9
Supplementary Table. Continued from previous page.
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change) p
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Insulin-like growth factor-
binding protein complex acid 
labile subunit
IPI00020996 66 0 0.95
Isoform 1 of Glia-derived nexin IPI00009890 44 -0.3 0.54
Hepatocyte growth  
factor-like protein IPI00292218 80 0 0.99
Vitamin K-dependent protein S IPI00294004 75 0.1 0.89
Complement C1r 
subcomponent IPI00296165 82 0.1 0.81
Isoform 1 of Extracellular 
matrix protein 1 IPI00003351 61 0.1 0.85
Complement component  
C8 gamma chain IPI00011261 22 -0.1 0.94
Carboxypeptidase N subunit 2 IPI00479116 61 0.3 0.65
Hyaluronan-binding protein 2 IPI00746623 63 0 0.86
Tetranectin IPI00009028 23 0.1 0.92
Complement C1s 
subcomponent IPI00017696 77 0.1 0.81
Coagulation factor XIII B chain IPI00007240 76 0.1 0.8
Isoform 1 of  
Carboxypeptidase B2 IPI00329775 48 0 0.98
Coagulation factor X IPI00019576 55 0.1 0.93
Complement factor  
H-related protein 1 IPI00011264 38 -0.4 0.71
Corticosteroid-binding globulin IPI00027482 45 0.1 0.89
Insulin-like growth  
factor-binding protein 3 IPI00018305 32 -0.1 0.82
Isoform 1 of N-acetylmuramoyl-
L-alanine amidase IPI00163207 62 0.1 0.97
Leucine-rich  
alpha-2-glycoprotein IPI00022417 38 -0.3 0.51
Isoform 1 of Phosphatidylinositol-
glycan-specific phospholipase D IPI00299503 92 0.2 0.64
Protein Z-dependent  
protease inhibitor IPI00007199 55 0.1 0.92
Supplementary Table. Continued from previous page.
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Supplementary Table. Continued from previous page.
Name Accession No
MW  
(kDa)
Folic acid 
supplement use 
(log2 fold 
change) p
Isoform 1 of Fibrinogen  
alpha chain IPI00021885 95 -0.1 0.9
Serum amyloid P-component IPI00022391 25 -0.4 0.37
Isoform 1 of Sex hormone-
binding globulin IPI00023019 44 0.3 0.62
Serum paraoxonase/arylesterase 1 IPI00218732 40 0 0.99
Isoform LMW of Kininogen-1 IPI00215894 48 0 0.95
Complement C1r 
subcomponent-like protein IPI00009793 53
Reference 
Missing
Fetuin-B IPI00743766 42 0.1 0.85
Biotinidase IPI00744685 62 0 0.99
Beta-Ala-His dipeptidase IPI00064667 57 0.3 0.64
Isoform V0 of Versican  
core protein IPI00009802 373 -0.1 0.88
Carboxypeptidase N  
catalytic chain IPI00010295 52 0.3 0.78
Plasma serine protease inhibitor IPI00007221 46 -0.3 0.53
Properdin IPI00021364 51 0 0.99
Actin, cytoplasmic 1 IPI00021439 42 0.2 0.91
Monocyte differentiation 
antigen CD14 IPI00029260 40 0 0.94
Zinc-alpha-2-glycoprotein IPI00166729 34 0.3 0.71
Isoform 2 of Prostatic  
acid phosphatase IPI00289983 48 0.3 0.66
Thrombospondin-4 IPI00328550 106 0.3 0.77
Complement factor H-related 5 IPI00006543 67 0.1 0.94
Glutathione S-transferase A1 IPI00657682 26 0.4 0.63
Butyrylcholinesterase, 
isoform CRA_b IPI00025864 73 0.1 0.76
Selectin L precursor IPI00218795 44 -0.1 0.86
Complement C2 (Fragment) IPI00303963 83 -0.1 0.93
Selenoprotein P IPI00029061 43 0.1 0.93
C4b-binding protein alpha chain IPI00021727 67 0.5 0.57
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Metalloproteinase inhibitor 1 IPI00032292 23 0 0.99
Isoform Long of Complement 
factor H-related protein 2 IPI00006154 31 -0.2 0.8
Apolipoprotein E IPI00021842 36 -0.4 0.56
Small proline-rich protein 3 IPI00082931 18 -0.9 0.2
Insulin-like growth  
factor-binding protein 7 IPI00016915 29 0 0.96
Complement C1q 
subcomponent subunit C IPI00022394 26 0.2 0.83
Isoform 1 of Sulfhydryl oxidase 1 IPI00003590 83 0 0.9
Transforming growth factor-
beta-induced protein ig-h3 IPI00018219 75 0.1 0.93
Apolipoprotein C-I IPI00021855 9 1.1 0.016*
Lipoprotein lipase IPI00027847 53 -0.5 0.47
Keratin, type II cytoskeletal 1 IPI00220327 66 -2.2 0.054
Lysozyme C IPI00019038 17 -0.1 0.87
Isoform 1 of Pregnancy  
zone protein IPI00025426 164 -0.4 0.51
Neuronal pentraxin-2 IPI00026946 47 -0.3 0.7
Hepatocyte growth factor 
activator IPI00029193 71 0 0.97
Tumor necrosis factor-inducible 
gene 6 protein IPI00303341 31 -0.1 0.83
Mannosyl-oligosaccharide 
1,2-alpha-mannosidase IA IPI00844511 73 -0.2 0.65
Isoform 1 of C-reactive protein IPI00022389 25 -2 0.0095*
Isoform 12 of CD44 antigen IPI00297160 39 -0.1 0.89
Isoform 2 of Calsyntenin-1 
(Fragment) IPI00007257 109 -0.2 0.73
Glutathione peroxidase 3 IPI00026199 26 0.1 0.93
Complement C1q 
subcomponent subunit B IPI00477992 27 0.2 0.9
Angiogenin IPI00008554 17 0 0.99
Supplementary Table. Continued from previous page.
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Secreted protein, acidic, 
cysteine-rich (Osteonectin), 
isoform CRA_a
IPI00014572 36 -0.1 0.85
Transthyretin IPI00022432 16 0.2 0.81
Plastin-2 IPI00010471 70 0 0.98
Complement factor  
D preproprotein IPI00165972 28 0 0.95
Cysteine-rich secretory  
protein 3 IPI00942117 28
Reference 
Missing
Isoform 1 of EGF-containing 
fibulin-like extracellular  
matrix protein 1
IPI00029658 55 0.3 0.7
Lipopolysaccharide-binding 
protein IPI00032311 53 -0.2 0.78
Lymphatic vessel endothelial 
hyaluronic acid receptor 1 IPI00290856 35 0 0.78
Beta-2-microglobulin IPI00004656 14 -0.2 0.82
Dopamine beta-hydroxylase IPI00171678 69 0.5 0.58
Isoform C of Fibulin-1 IPI00296537 74 0.2 0.83
Isoform 1 of Vitamin 
K-dependent protein Z IPI00027843 45 0.3 0.83
Isoform 1 of Vascular  
cell adhesion protein 1 IPI00018136 81 0 0.99
COL6A3 protein IPI00072917 322 0.1 0.84
Isoform 1 of Cartilage  
acidic protein 1 IPI00451624 71 0.3 0.61
Inhibin beta A chain IPI00028670 47 -0.2 0.67
Gamma-glutamyl hydrolase IPI00023728 36 -0.3 0.79
Retinoic acid receptor  
responder protein 2 IPI00019176 19 0 0.95
Inhibin alpha chain IPI00007080 40 0 0.99
Isoform 1 of Ectonucleotide 
pyrophosphatase/
phosphodiesterase family 
member 2
IPI00156171 99 0 0.96
Supplementary Table. Continued from previous page.
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Isoform 1 of Follistatin IPI00021081 38 -0.2 0.82
Insulin-like growth factor-
binding protein 2 precursor IPI00297284 35 0 0.97
Coagulation factor XIII A chain IPI00297550 83 0.4 0.79
Vitamin K-dependent protein C IPI00021817 52 0 0.95
Isoform 1 of Insulin-like  
growth factor II IPI00001611 20 0 0.98
Cystatin-C IPI00032293 16 0 0.96
Prostaglandin-H2 D-isomerase IPI00013179 21 -0.2 0.76
Phosphatidylcholine-sterol 
acyltransferase IPI00022331 50 0.2 0.75
Putative uncharacterized  
protein ALB IPI00022434 72 0 0.98
Isoform 1 of Peptidase  
inhibitor 16 IPI00301143 49 0.1 0.93
Isoform 1 of Ficolin-3 IPI00293925 33 0 0.93
Apolipoprotein B-100 IPI00022229 516 0.1 0.83
Isoform 1 of Interleukin-1 
receptor accessory protein IPI00031789 65 0.6 0.28
HSPA5 protein IPI00003362 72 0.1 0.97
Signal peptide, CUB  
and EGF-like domain-
containing protein 1
IPI00217435 108 -0.3 0.9
Isoform 5 of Peptidyl-
glycine alpha-amidating 
monooxygenase
IPI00177543 108 0 0.99
Out at first protein homolog IPI00328703 31 0 0.97
Cadherin-5 IPI00012792 88 0 0.97
Isoform alpha-enolase  
of Alpha-enolase IPI00465248 47 0.4 0.36
Follistatin-related protein 1 IPI00029723 35 -0.2 0.81
Amphiregulin IPI00012023 28 0 0.97
Isoform Sap-mu-0 of 
Proactivator polypeptide IPI00012503 58 -0.1 0.89
Supplementary Table. Continued from previous page.
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Muscle type neuropilin 1 IPI00165438 72 0.2 0.73
Intercellular adhesion molecule 2 IPI00009477 31 0 0.95
Isoform 1 of Mast/stem cell 
growth factor receptor IPI00022296 110 0 0.98
Fructose-bisphosphate aldolase A IPI00465439 39 0.3 0.66
von Willebrand factor IPI00023014 309 0 0.97
Insulin-like growth factor-
binding protein 5 IPI00029236 31 -0.1 0.96
Aminopeptidase N IPI00221224 110 0.1 0.93
Di-N-acetylchitobiase IPI00007778 44 0 0.98
Isoform 1 of Metallothionein-1G IPI00008752 6 0.3 0.85
Vasorin IPI00395488 72 0 0.98
Dipeptidyl peptidase 4 IPI00018953 88 0 0.87
Insulin-like growth factor IA IPI00001610 17 0 0.95
Ribonuclease pancreatic IPI00014048 18 -0.1 0.95
Isoform 2 of Neural cell adhesion 
molecule L1-like protein IPI00299059 137 0.3 0.57
Procollagen C-endopeptidase 
enhancer 1 IPI00299738 48 0 1
Isoform 1 of Multiple inositol 
polyphosphate phosphatase 1 IPI00293748 55 0 0.97
Intercellular adhesion molecule 1 IPI00008494 58 0 0.99
Thrombospondin-1 IPI00296099 129 -0.2 0.72
Ribonuclease 4 IPI00029699 17 0 0.98
Metalloproteinase inhibitor 2 IPI00027166 24 0.2 0.49
Lysosome-associated  
membrane glycoprotein 1 IPI00884105 45 0 0.98
Plasminogen activator inhibitor 1 IPI00007118 45 -0.3 0.94
Isoform XB of Tenascin-X IPI00025276 464 0.1 0.87
Galectin-3-binding protein IPI00023673 65 0.2 0.83
Isoform 2 of Apolipoprotein L1 IPI00186903 46 0.3 0.41
L-lactate dehydrogenase B chain IPI00219217 37 0.1 0.92
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Isoform Beta of  
Poliovirus receptor IPI00219425 40 0.3 0.46
Apolipoprotein M IPI00030739 21 0.6 0.44
Apolipoprotein C-III IPI00021857 11 0.7 0.62
Transforming growth factor  
beta receptor type 3 IPI00304865 94 0.1 0.94
FLJ00385 protein (Fragment) IPI00168728 56 0 0.93
Spondin-1 IPI00171473 91 -0.1 0.91
72 kDa type IV collagenase IPI00027780 74 0.1 0.22
Endoplasmin IPI00027230 92 0.1 0.93
Collagen alpha-1(I) chain IPI00297646 139 0 1
Xaa-Pro dipeptidase IPI00257882 55 -0.1 0.91
Fibrinogen beta chain IPI00298497 56 0 0.99
Platelet glycoprotein  
Ib alpha chain IPI00748955 69 0.1 0.96
Low affinity immunoglobulin 
gamma Fc region receptor III-A IPI00218834 29 -0.5 0.83
Neutrophil defensin 1 IPI00005721 10 0 0.99
Keratin, type I cytoskeletal 10 IPI00009865 59 -2.9 0.023*
Apolipoprotein C-II IPI00021856 11 1.3 0.11
Protein S100-A9 IPI00027462 13 0.1 0.98
Isoform 1 of Probable  
serine protease HTRA3 IPI00027862 49 0.3 0.076
Insulin-like growth  
factor-binding protein 6 IPI00029235 25 0 0.93
Profilin-1 IPI00216691 15 0.1 0.83
Collagen alpha-1(VI) chain IPI00291136 109 0.1 0.95
Nucleobindin-1 IPI00295542 54 0.1 0.81
Peroxiredoxin-2 IPI00027350 22 -0.1 0.87
ADP-ribosyl cyclase 2 IPI00026240 36 0 0.96
Isoform 1 of Noelin IPI00017841 55 0 0.61
Exostosin-like 2 IPI00002732 37 0.1 0.8
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Isoform LAMP-2A of 
Lysosome-associated  
membrane glycoprotein 2
IPI00009030 45 0.2 0.64
Isoform A of Decorin IPI00012119 40 0.3 0.73
Isoform 1 of Cell surface 
glycoprotein MUC18 IPI00016334 72 0.1 0.94
Isoform Gamma-B of 
Fibrinogen gamma chain IPI00021891 52 0 0.98
Cartilage oligomeric  
matrix protein IPI00028030 83 0.1 0.94
Cathepsin B IPI00295741 38 -0.2 0.88
Neutrophil gelatinase- 
associated lipocalin IPI00299547 23 -0.3 0.92
Leukocyte immunoglobulin-like 
receptor subfamily A member 3 IPI00329104 47 -0.3 0.8
Farnesyl pyrophosphate synthetase 
like-4 protein (Fragment) IPI00382869 40 0.6 0.87
Cathepsin D IPI00011229 45 -0.2 0.53
Cornifin-A IPI00017987 10 -0.5 0.92
Isoform 1 of Collectin-11 IPI00031490 29 0.1 0.96
Insulin-like growth factor-
binding protein 1 IPI00031086 28 -0.1 0.94
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Preconception folic acid use 
modulates estradiol and follicular 
responses to ovarian stimulation
J.M. Twigt, F. Hammiche, K.D. Sinclair, 
N.G.M. Beckers, J.A. Visser, J. Lindemans, 
F.H. de Jonge, J.S.E. Laven and R.P.M. Steegers-Theunissen
J Clin Endocrinol Metab, 2011 (2): 322-329
AbSTRACT
Background
Folate is a methyl donor. Availability of folate affects DNA methylation 
profiles, and thereby gene expression profiles. Here, we investigate the effects 
of low dose folic acid use (0.4 mg/day) on the ovarian response to mild and 
conventional ovarian stimulation in women.
Methods
In a randomized trial among subfertile women, 24 and 26 women received 
conventional- and mild ovarian stimulation, respectively. Blood samples were 
taken during the early follicular phase of the cycle preceding the treatment 
cycle and on the day of hCG administration for determination of serum 
homocysteine, -AMH, -estradiol and -folate. Folic acid supplement use is 
validated by questionnaire and serum folate levels. Preovulatory follicles were 
visualized, counted and diameters recorded using transvaginal ultrasound. The 
relation between folic acid supplement use and ovarian response is assessed 
using linear regression analysis.
Results
Folic acid supplement use modified the ovarian response to ovarian 
stimulation. The estradiol response was higher in nonfolic acid users receiving 
conventional treatment (βinteraction=0.52, [0.07-0.97]; p=0.03), this effect was 
independent of serum AMH levels and preovulatory follicle count. In the 
conventional treatment the mean follicle number was also greater in non-users 
compared to the users group (14 vs. 9; p=0.03) 
Conclusion
Low dose folic acid supplement use attenuates follicular and endocrine 
responses to conventional stimulation, independent of AMH and follicle 
count. The nature of the observation suggests that the effects of folic acid 
are most prominent during early follicle development, affecting immature 
follicles. Deleterious effects of folate deficiency, like hypomethylation of 
DNA and oxidative stress can help explain the described observations.
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INTRODUCTION
In women undergoing controlled ovarian hyperstimulation (COH) during 
assisted reproductive treatment (ART) there is unpredictable inter- and 
intraindividual variability in the ovarian response to COH.7 Ovarian response 
is defined as ‘the endocrine and follicular reaction of the ovaries to a stimulus’.7 
There is an optimum quantitative ovarian response to COH, where both a low 
and high ovarian response to COH is associated with an unfavourable treatment 
outcome.4 Knowledge of which determinants influence the ovarian response 
to gonadotropins would improve predictions of the response to COH. This 
would reduce the number of treatment cycles required to achieve pregnancy, 
reduce the incidence of treatment complications or offer the possibility to 
tailor the treatment protocol according to patient characteristics. Accurately 
predicting the ovarian response to gonadotropins is currently not possible.
Folate deficient women undergoing COH have a lower oocyte quality, 
lower pregnancy rates and impaired ovarian function.40, 41, 44, 46, 160 The 
underlying mechanism, however, is not known. The natural B-vitamin folate 
is involved in numerous metabolic pathways including cell cycle regulation, 
amino acid biosynthesis and protein processing.130 Folate primarily serves as a 
methylgroup donor for these reactions. In a recent study in ewes fed a methyl 
deficient diet, low methylgroup availability increased mRNA expression of 
genes involved in mediating the ovarian response to gonadotropins.144
Epigenetic mechanisms aim to maintain the gene expression profile of cells 
after mitotic division. Epigenetic mechanisms are essentially post-replication 
modifications superimposed on the genome, regulating gene expression without 
causing changes in DNA sequence. In contrast to the genetic background 
of the individual, the epigenetic composition of the genome is sensitive to 
environmental influences, including nutrition, which effectively modify gene 
expression.161, 162 DNA methylation is an epigenetic mechanism, dependent 
on the availability of methyl groups. In experimental animal and retrospective 
human studies, in utero exposure to low levels of methyl group donors leads to 
an altered DNA methylation profile and phenotype in offspring.62, 163
Due to the nature of complex pathways in which folate is involved, 
especially highly proliferating cells, including those in developing ovarian 
follicles, are affected by folate deficiencies. Therefore, we hypothesized 
that the ovarian response to gonadotropins is affected by the availability 
of methyldonors, like folate. In a randomized clinical trial, comparing 
a mild- and conventional ovarian stimulation protocol, we sought to study 
the effect of low dose folic acid supplement use on specific biomarkers of the 
folate dependent methionine pathway and estradiol concentrations following 
conventional- and mild ovarian stimulation treatment.
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MATERIAlS AND METHODS
Study design
The FOod Lifestyle and Fertility Outcome (FOLFO) study was designed to 
investigate the influence of periconception nutrition and lifestyle factors on 
biochemical, clinical fertility and pregnancy outcome parameters following 
IVF/ICSI treatment. The FOLFO study comprises FOLFO I (an observational 
study) and FOLFO II (a randomized controlled trial). The FOLFO II study 
is designed to compare mild ovarian stimulation treatment with conventional 
ovarian stimulation treatment with regard to maternal biochemical, endocrine 
and clinical parameters. 
Eligible couples visiting the Erasmus MC, University Medical Centre 
in Rotterdam, The Netherlands, with an indication for IVF treatment were 
invited to participate in the FOLFO II study. Exclusion criteria for the 
FOLFO II study were: oocyte donation, endometriosis, hydrosalpinx, a priori 
indication for ICSI treatment, age >37 years old, BMI <18 or >29 kg/m2, 
irregular menstrual cycle, previous IVF treatment without embryo transfer, 
recurrent abortion, abnormal karyotype of man/woman and/or uterus 
anomalies. These criteria served to select only those patients with unexplained 
subfertility in order to be able to assess the role of food and lifestyle factors. 
A higher cancellation rate before oocyte retrieval and fewer embryos were 
expected following mild ovarian stimulation.164 Therefore, randomization 
to one of two treatment groups was performed according to a computer 
generated randomization schedule in a ratio of 2:3 (conventional group : 
mild group), assigned via numbered sealed envelopes. After the patient agreed 
to participate, the treating physician opened the next available numbered 
envelope on entry into the study during the preparatory IVF consultation. Of 
all eligible couples (n=161), 54 participated in the FOLFO II study and 49 
participated in other clinical studies. Fifty-eight couples did not participate in 
any of the studies because the extra effort for participation relative to normal 
treatment was considered too great or they did not see a clear benefit in 
participating. At the end of the inclusion period, 24 couples were randomized 
to the conventional protocol and 30 couples to the mild protocol. After 
randomization 4 women with exclusion criteria appeared to be included into 
the study, they were therefore excluded from the final analysis. 
When the allocated treatments commenced all couples completed 
a questionnaire regarding nutrition, lifestyle, medication and disease history. 
Blood samples were collected for all couples on cycle day (CD) 2, before 
treatment commenced. On the day of hCG administration serum was 
collected from women only. 
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The study protocol was approved by the Central Committee for Human 
Research (CCMO) in The Hague, The Netherlands and the Medical Ethical 
Committee (MEC) and Institutional Review Board of the Erasmus MC, 
University Medical Centre in Rotterdam, The Netherlands. All participants 
gave their written informed consent and all materials and questionnaires were 
anonymously processed.  
IVF procedure
After randomization, patients assigned to conventional ovarian stimulation 
treatment were treated with the GnRH agonist Triptorelin (Decapeptyl®, 
Ferring BV, Hoofddorp, The Netherlands) at 0.1 mg/day s.c., starting on 
CD21 of the menstrual cycle preceding the actual stimulation cycle. After 
two weeks of the GnRH-agonist regimen, co-treatment with rFSH 225 IU/
day s.c. (Puregon®, Schering-Plough, Oss, The Netherlands) was initiated. 
Patients assigned to mild ovarian stimulation treatment were treated with 
a fixed dose of 150 IU/day rFSH s.c. (Puregon®, Schering-Plough, Oss, 
The Netherlands) from CD5 onwards. As soon as the leading follicle reached a 
diameter of 14mm, a GnRH-antagonist (Orgalutran®, Schering-Plough, Oss, 
The Netherlands) was administered at 0.25 mg/day s.c.. To induce final oocyte 
maturation a single s.c. dose of 10,000 IE hCG (Pregnyl®, Schering-Plough, 
Oss, The Netherlands) was administered in both regimens as soon as the 
leading follicle reached a diameter of at least 18 mm and at least one additional 
follicle reached a diameter of 15 mm or more. Oocytes were retrieved 36 hours 
after hCG injection by transvaginal ultrasound-guided aspiration of follicles.
Sample collection and analysis
Isolated oocytes were washed and transferred to a separate droplet of medium 
in order to monitor their quality. The monofollicular fluid samples were 
centrifuged for 10 min at 1,700 rpm to separate red blood cells (RBC), 
leucocytes and granulosa cells. The samples were frozen without preservatives 
and stored at -20°C until assayed.
Venous blood samples were drawn from each woman on CD2, i.e. 
the early follicular phase of the menstrual cycle preceding the treatment cycle and 
on the day of hCG administration. For the determination of folate, cobalamin, 
pyridoxine and hormones, venous blood samples were drawn into dry vacutainer 
tubes and allowed to clot. After centrifugation at 2,000 x g, serum was collected for 
assay. Anti-Müllerian Hormone (AMH) levels were measured using an enzyme-
linked immunosorbent assay (ELISA) (Immunotech-Coulter, Marseille, France). 
Folate and cobalamin were analysed using an immunoelectrochemoluminescence 
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assay (Roche Modular E170, Roche Diagnostics GmbH, Mannheim, 
Germany). Serum concentrations of FSH were measured by luminescence-based 
immunometric assay (Immulite 2000, Siemens Diagnostics, Los Angeles, CA, 
USA). Estradiol was determined using a coated tube radioimmunoassay obtained 
from the same supplier. For the determination of plasma total homocysteine 
(tHcy) and pyridoxine in whole blood, venous blood samples were drawn into 
ethylenediamine tetra-acetate (EDTA) containing vacutainer tubes. The EDTA-
blood samples were placed on ice and within 1 hour, plasma was separated by 
centrifugation. Total homocysteine in EDTA plasma and pyridoxine as pyridoxal-
5-phosphate in whole blood was determined using high-performance liquid 
chromatography with reversed phase separation and fluorescence detection. 
Inter-assay coefficients of variation for folate were 4.5% at 13 nmol/L 
and 5.7% at 23 nmol/L; for cobalamin 3.6% at 258 pmol/L and 2.2% at 
832 pmol/L; for tHcy 4.8% at 14.6 mmol/L and 3.3% at 34.2 mmol/L; for 
AMH this coefficient was <10%; for FSH < 5.8%; and for estradiol, <8.8%. 
The detection limit for folate was 1.36 nmol/L, for cobalamin 22 pmol/L, for 
pyridoxine 5 nmol/L; for tHcy 4 mmol/L, for AMH 0.1 mg/L, for FSH 0.1 
U/L and for estradiol 10 pmol/L. 
Statistical analysis
Prior to statistical analyses, all continuous variables were log-transformed, 
obtaining a near normal distribution of data suitable for parametric statistical 
testing. Normality was assessed using histograms and Q-Q plots. Measures 
of location and spread are depicted as Geometric Mean and Interquartile 
Range (IQR), respectively. When a suitable distribution was not attained 
after transformation, the variable is presented as median (range). 
Comparison of the two treatment groups and subsequent sub-groups was 
done using an unpaired t-test or Mann-Whitney-U test, were appropriate. 
Proportions were compared using a chi-square test. The influence of COH on 
the biochemical levels after COH was determined using paired t-tests. 
To allow for adjustment, linear regression methods were used to investigate 
the relation between baseline biomarkers and endocrine responses after COH. 
Regression parameters are reported with their 95% confidence intervals. 
Collinearity was assessed using the VIF statistic, a VIF of ≥4 was considered 
to indicate collinearity. In the final model the highest observed VIF was 3.4. 
The presented coefficients from the log-log linear regression model should be 
interpreted as follows: β is % change in Y for a 1% change in X.
Serum folate levels were used to confirm folic acid supplement use. 
Patients were considered folic acid supplement users when serum folate level 
was ≥22.5 umol/L.137
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 At the moment of study initiation there was no literature on a possible 
effect size, therefore a sample size estimate was not done. A p-value <0.05 
was considered statistically significant. All statistical analyses were done using 
SPSS 15.0 for Windows software (SPSS Inc., Chicago, IL, USA).
RESUlTS
Study population
At baseline, there were no significant differences with regard to patient 
characteristics between treatment groups (Table I). In the conventional 
group, self-reported folic acid use was 66.7%, in the mild group this was 
80.8%. Self reported use is confirmed in CD2 serum levels in 62.5% and 
76.9%, respectively. 
Table I. Baseline characteristics of women undergoing ovarian stimulation treatment 
(n=50).
Conventional (n=24) Mild (n=26)
Age (years) mean (IQR) 32.7 (31.0-35.7) 34.0 (33.0-36.0)
Body Mass Index (kg/m2) mean (IQR) 21.8 (19.5-23.5) 22.7 (21.0-24.0)
Ethnicity, % (n)
 Dutch 57.1 (12) 66.7 (16)
 Non-Dutch European 9.5 (2) 16.7 (4)
 Non-European 33.3 (7) 16.7 (4)
Education, % (n)
 Low 22.7 (5) 11.5 (3)
 Intermediate 31.8 (7) 38.5 (10)
 High 45.5 (10) 50.0 (13)
Fertilization procedure, % (n)
 IVF 91.7 (22) 87.5 (21)
 ICSI 8.3 (2) 12.5 (3)
Folic acid containing supplement (yes), 
% (n) 66.7 (14) 80.8 (21)
Smoking (yes), % (n) 13.4 (3) 3.8 (1)
Duration of subfertility (months), 
median (range) 41 (16-101) 42 (3-135)
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Biochemical parameters
At baseline, there were no significant differences with regard to biochemical 
parameters between treatment groups (Table II). 
Baseline AMH levels predict the ovarian response to COH (βAMH = 0.43 
[0.14-0.72]; p<0.01). On the day of hCG administration treatment groups 
showed considerable differences with respect to estradiol concentrations, with 
the response in the conventional protocol being the highest (Table II). Also, 
within each treatment group we observed a decline of tHcy levels relative 
to basal concentrations, where the median decline was more profound in 
the conventional stimulation treatment arm than that observed in the mild 
stimulation treatment arm (-1.20 umol/L vs. -0.7 umol/L; p<0.01 and p=0.01, 
respectively). This observation was further analysed using linear regression 
analysis, which showed a differential tHcy decline between the stimulation 
protocols (βprotocol = 0.15 [0.06-0.24]; p<0.01). Furthermore, there was a 
differential decline in AMH levels after stimulation treatment, which was higher 
after conventional stimulation treatment (βprotocol = 0.57 [0.34-0.79]; p<0.001). 
After stratification for folic acid supplement use and stimulation treatment, 
women in the conventional stimulation protocol, who did not use folic 
acid supplements, had an increased ovarian response to COH (Table III). 
To confirm effect modification, this finding was further investigated in 
a linear regression model, which showed an interaction between baseline serum 
folate levels and stimulation protocol with regard to the estradiol response to 
COH (βinteraction =0.52 [0.07-0.97]; p=0.03). The effect of folate was independent 
of preovulatory follicle count and AMH levels and baseline concentrations of 
pyridoxine and cobalamin did not alter the effects of folate on the outcomes.
Clinical outcome parameters after IVF/ICSI treatment
As presented in Tables III and IV, the mean number of preovulatory follicles 
and the median number of retrieved oocytes differed between treatment groups. 
The number of follicles was positively correlated with the estradiol response 
(r=0.78; p<0.001). Furthermore, in the nonusers stratum the conventional 
group had a higher number of preovulatory large antral follicles, an effect 
that was not observed in the low dose users stratum (Table III). Fertilization 
rates were comparable, and the number of transferred embryos did not differ 
(Table IV). The number of ongoing pregnancies was not different (Table IV). 
DISCUSSION
The results of our study suggest that the ovarian response to gonadotropins 
is subject to the availability of the methyl donor folate. After conventional 
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Table II. Biochemical markers of women undergoing ovarian stimulation treatment 
(n=50).
Follicles 
Conventional (n=24) Mild (n=26) p
11 (8-16) 9 (7-9) <0.01
baseline serum
 FSH (U/L) 7.7 (6.5-8.8) 8.0 (6.8-9.7) ns
 Estradiol (pmol/L) 141.6 (103.5-203.6) 160.1 (119.2-199.0) ns
 AMH (ug/L) 4.4 (2.9-6.1) 5.6 (3.3-10.1) ns
 Cobalamin (pmol/L) 351.0 (259.5-480.0) 309.3 (256.8-387.0) ns
 Pyridoxine (nmol/L) 81.5 (66.0-91.0) 83.2 (61.0-108.0) ns
 Folate (nmol/L) 27.3 (17.9-37.4) 37.1 (19.1-72.5) ns
 Homocysteine (umol/L) 9.5 (8.1-11.2) 9.5 (7.7-10.7) ns
hCG-day serum
 Estradiol (pmol/L) 4,293 (2,889-6,646) 2,706 (1,716-3,558) 0.03
 AMH (ug/L) 1.8 (1.4-3.0) 3.5 (2.4-5.3) 0.01
 Cobalamin (pmol/L) 333.4 (262.7-481.5) 300.0 (221.7-381.8) ns
 Pyridoxine (nmol/L) 76.9 (65.0-84.0) 82.1 (56.0-106.0) ns
 Folate (nmol/L) 31.5 (18.2-59.4) 35.7 (19.1-65.4) ns
 Homocysteine (umol/L) 7.9 (6.7-9.8) 8.9 (7.0-10.7) ns
Variables are depicted: Geometric Mean (Interquartile Range)
stimulation treatment, women who did not use a low dose folic acid 
supplement had a higher ovarian response to stimulation treatment than 
those who did use folic acid supplements. This effect is independent of follicle 
count and AMH levels. Kanakkaparambil et al.144 have previously observed 
the interplay between COH and low methyl group availability in ewes fed 
a methyl deficient (MD) diet. They reported a higher ovarian response after 
rFSH administration in MD ewes. Further in vitro analysis of granulosa cells 
revealed higher FSH receptor (FSHR) mRNA expression as homocysteine 
levels increased, reflecting low methyl group availability.
The ovarian response to mild stimulation treatment seems not affected 
by folic acid use. Incidentally, ovarian dynamics differ considerably between 
conventional- and mild ovarian stimulation treatment. After pituitary 
desensitizing using a GnRH-agonist, as is done in the conventional stimulation 
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treatment arm, the proportion of immature, FSH-responsive follicles has 
increased in size.165 In addition to the higher doses of rFSH, this can partially 
underlie the overall higher ovarian response after conventional stimulation 
treatment. The mild stimulation protocol does not interfere with the initial 
follicle recruitment by the natural menstrual cycle, and the lower dose of rFSH 
only stimulates more mature follicles for which the FSH-threshold is higher.166 
Nevertheless, despite a higher oocyte yield, clinical outcome was comparable 
after conventional and mild stimulation treatment.167 This suggests that the 
absolute number of competent oocytes is not different, but only the proportion 
of competent oocytes is higher after mild stimulation treatment. It seems that 
preconception folic acid use attenuates the ovarian response; by affecting only 
less mature follicles that are stimulated after GnRH-agonist treatment. 
Clinical, animal and in vitro studies permit speculation on potential 
mechanisms underlying the observed effect. The intertwined folate-methionine 
cycle is the main route of utilization for folate. In the folate cycle, folate 
primarily serves as a substrate for DNA nucleotide synthesis, where deficiencies 
in folate can result in faulty DNA-repair and nucleotide synthesis.27, 28 In 
the methionine cycle, folate serves as a substrate for the remethylation of 
homocysteine into methionine. Thereafter, methionine-adenosyltransferase 
metabolizes methionine into S-Adenosylmethionine (SAM), which is the 
substrate for virtually all methylation reactions. Deficiencies in folate can 
result in accumulation of homocysteine and S-Adenosylhomocysteine.168 
Deficiencies in cofactors for these reactions, like cobalamin and pyridoxine, 
can also aggravate derailment of the methionine-cycle. In our study, however, 
cobalamin and pyridoxine levels did not affect the results. Homocysteine is a 
reactive metabolite. Homocysteine metabolites can be wrongfully incorporated 
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Table IV. Clinical outcome parameters after ovarian stimulation treatment (n=50).
Conventional (n=24) Mild (n=26) p
Retrieved oocytes (n) median (range) 12 (1-28) 7 (0-17) 0.001
Fertilization rate  56.2 49.0 ns
Positive pregnancy test, % (n) 37.5 (9) 19.2 (5) ns
Ongoing pregnancy, % (n) 30.4 (7) 16.0 (4) ns
Embryo transfer, % (n) ns 
 None 8.3 (2) 24.0 (6)
 Single 83.3 (20) 60.0 (15)
 Double 8.3 (2) 16.0 (4)
in protein instead of methionine, affecting protein function and thereby 
possibly cellular function.29 Also, homocysteine can generate reactive oxygen 
species (ROS).169 Although ROS function as second messengers, an excess of 
ROS results in oxidative stress. Oxidative stress affects female fertility and ART 
success.31 Also, folate availability affects the DNA methylation pattern and 
thereby the gene expression profile of a cell.168 The reduction in SAM levels 
and accumulation of homocysteine due to folate deficiency inhibit the activity 
of DNA-methyltransferases.170 Investigation of the mouse genome indicates 
that the FSHR gene contains CpG repeats, which when methylated inhibit 
FSHR gene transcription.171 In addition, Kanakkaparambil et al.144 showed that 
incubating granulosa cells with homocysteine increases FSHR mRNA levels. 
Similarly, the aromatase enzyme, which converts androgens into estrogens, 
expressed in bovine granulosa cells is regulated by DNA methylation.172 Finally, 
steroidogenesis by the ovarian follicle is augmented by the Insulin-like Growth 
Factor (IGF) family, Insulin-like Growth Factors mainly elicit their effect 
through the type 1 IGF receptor, which is overexpressed in folate deficient 
cells.173, 174 In proliferating tissues, shortages of methyl groups can inhibit the 
full methylation of hemi-methylated DNA strands by DNA methyltransferases, 
eventually leading to hypomethylation of DNA in progeny cells of originally 
methylated gene-loci.161 Such a process of passive demethylation is also seen in 
the early zygote.175 In addition, oxidative DNA products inhibit effective (re)
methylation of DNA or induce loss of methylation.176-178
Folate status is associated with the quality of many parameters in human 
reproduction, from gamete- and embryo quality to the birth prevalence of 
congenital malformations.160 In the current study, folate also attenuates the 
ovarian response to ovarian stimulation treatment. Studies in human show 
that there is an optimal ovarian response with regard to the number of 
retrieved oocytes and attained estradiol levels after stimulation treatment with 
respect to clinical outcome after ovarian stimulation treatment.167, 179 High 
hormone levels affect oocyte competency and endometrial receptivity to the 
embryo.5, 180 Possibly, folate affects ovarian stimulation treatment outcome by 
mediating the ovarian response to gonadotropins through interference with 
FSHR, aromatase availability and an increase in ROS.
We also need to address strengths and limitations of our study. The 
sample size permits for less control for confounding and reduces precision. At 
the moment of study initiation, the effect estimates were unknown and 
therefore a sample size estimate was not possible. Nevertheless, the statistical 
analysis showed no complications common to small numbers and our 
outcome is supported by earlier observations.144 Although, not primarily 
designed as a folic acid intervention study, folic acid supplement use across 
79
C
ha
pt
er
 V
treatment groups was similar. Nevertheless, we cannot exclude selective non-
participation, however, because of the randomized design; confounding factors 
associated with folic acid supplement use will have an equal distribution over 
the two treatment groups.
CONClUSION
Our results show that the ovarian response to ovarian stimulation treatment 
is amongst others subject to the availability of folate. The effect of folate is 
independent of AMH and preovulatory follicle count. The nature of the 
observation suggests that the effect of folate is most prominent during early 
follicle development, affecting less mature follicles. Our finding may offer 
a partial explanation for both the observed inter- and intraindividual variability 
in ovarian response to COH. Possibly, folate affects ovarian stimulation treatment 
outcome by mediating the ovarian response to gonadotropins through interference 
with FSHR and aromatase availability and an increase in ROS. However, folate 
availability might also influence the ovarian response through homocysteine 
metabolites, which might alter protein as well as cellular function.  
Of interest for future studies is to investigate the proteome and DNA 
methylation patterns in human and animal granulosa cells and the deleterious 
effect of ROS on these entities.
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A healthy dietary pattern lowers 
the ovarian response and improves 
the chance of pregnancy after ovarian 
hyperstimulation treatment
J.M. Twigt, M. Vujkovic, J.H. de Vries, J. Lindemans, J.S.E. Laven 
and R.P.M. Steegers-Theunissen
Submitted
AbSTRACT
Background
The ovarian response to controlled ovarian hyperstimulation treatment (COH) 
associates with assisted reproduction treatment outcome and studies show 
that nutrition is of influence on assisted reproduction treatment outcome. In 
this study we investigate the influence of nutrition on the ovarian response to 
COH and reproductive outcomes after IVF/ICSI treatment.
Materials and Methods
In a prospective periconception cohort of 203 women undergoing COH we 
assessed dietary intake using a Food Frequency Questionnaire and performed 
principal component analysis to identify dietary patterns. The pattern of 
interest was stratified into tertiles of adherence. Blood samples taken at cycle 
day 2 preceding the treatment cycle and on the day of ovulation induction 
are used for determination of serum biomarkers. The relation between dietary 
patterns and outcomes of interest was assessed using regression analysis.
Results
A Healthy dietary pattern, characterized by high intake of fruits, whole grains 
and margarine and low intake of refined grains and snacks associates with the 
estradiol response (-0.16; p<0.05). Adjusted for possible confounders, a one-unit 
increase in adherence to the Healthy dietary pattern lowered the estradiol 
response to COH by 14.4%. Similarly, strong adherence to the Healthy dietary 
pattern increased the chance of pregnancy (ORadj: 1.61 [1.07-2.44]; p=0.02)
Conclusion
Strong adherence to the Healthy dietary pattern beneficially lowers the 
estradiol response to COH and increases the chance of ongoing pregnancy 
after IVF/ICSI treatment. This data supports the importance of using 
a preconception healthy diet and confirms the attenuation of the ovarian 
response by folic acid supplement use.
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INTRODUCTION
In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) is a moderately 
successful technique to achieve pregnancy in subfertile couples, with a cumulative 
life birth rate after six IVF/ICSI treatment cycles just over 50%.3 The propensity 
for IVF/ICSI treatment success is in part determined by the ovarian response 
to Controlled Ovarian Hyperstimulation (COH), i.e. the number of growing 
ovarian follicles and the quantity of steroid hormone produced. If one can identify 
modifiable factors, which affect the ovarian response to COH, one can use these 
factors to optimize IVF/ICSI treatment outcomes.
Demographic, ultrasound and endocrine markers predict the ovarian 
response to COH.7 In an effort to decide on the optimal treatment strategy, 
age, BMI, antral follicle count, basal Follicle Stimulating Hormone (FSH) 
and Anti-Müllerian Hormone (AMH) concentrations are used to predict the 
ovarian response to COH.7 Except for overweight status, these factors comprise 
non-modifiable factors with little variability between treatment cycles and are 
therefore not suitable to modify the ovarian response to COH.6, 8 Modifiable 
factors, such as nutrition, can help control and modify the ovarian response 
to COH through improving nutrition.
Improved embryo quality and a more adequate nutritional environment 
for the developing embryo will obviously in part support the beneficial effect 
of nutrition on IVF/ICSI treatment outcomes. Previous studies show that 
B-vitamin status associates with embryo quality and the ovarian response to 
COH, and that the preconception diet associates with the chance of pregnancy 
after IVF/ICSI treatment.44, 134, 181 Nevertheless the mechanism through which 
nutrition supports these IVF/ICSI treatment outcomes remains unqualified. 
Both COH itself and supraphysiologic estradiol levels, such as those seen 
during COH cycles have a detrimental effect on endometrium development.5, 182 
Endometrial development to the ‘receptive’ stage is distorted when subjected 
to high estradiol levels and the composition of endometrial gland secretions, 
which facilitate early embryo development, is altered after a COH cycle.5, 183-185 
Thus, during traditional IVF/ICSI treatment cycles, the embryo is often 
transferred to a relatively unreceptive endometrium. Attaining an appropriate 
ovarian response can thus improve pregnancy chances after IVF/ICSI treatment 
through better synchronization of embryo and endometrium development.5, 186
MATERIAlS AND METHODS
Study Design
The FOod, Lifestyle and Fertility Outcome study was designed to investigate 
the relationship between nutrition, lifestyle and IVF/ICSI treatment outcome. 
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This prospective periconception study has been described in detail before.136 
In short, between September 2004 and January 2007 subfertile couples 
undergoing IVF/ICSI treatment at the Erasmus MC, University Medical 
Centre, Rotterdam, The Netherlands, were invited to participate. 
After inclusion and before treatment commenced participants received a 
self-administered questionnaire addressing age, educational level, medical 
history, BMI, ethnicity, medication use, smoking, and use of folic acid and other 
vitamin supplements. In addition, all participants completed a Food Frequency 
Questionnaire (FFQ) to estimate food intake covering the previous 4 weeks. 
This FFQ was developed by the division of Human Nutrition, Wageningen 
University, The Netherlands and validated for intake of energy, B-vitamins, and 
fatty acids.187, 188 The FFQ was provided on the day of oocyte retrieval or semen 
sample collection and returned on the day of embryo transfer.
The Dutch Central Committee for Human Research and the medical 
ethical and institutional review board of the Erasmus MC University Medical 
Centre in Rotterdam approved the study protocol. Participants provided 
written informed consent and the obtained materials and questionnaires were 
processed anonymously.
IVF/ICSI Procedure
Patients were assigned one of two stimulation treatments, conventional 
and mild. Patients undergoing conventional ovarian stimulation treatment 
were treated with the GnRH agonist Triptorelin (Decapeptyl®, Ferring BV, 
Hoofddorp, The Netherlands) at 0.1 mg/day s.c., starting on Cycle Day (CD) 
21 of the menstrual cycle preceding the actual stimulation cycle. After two 
weeks of the GnRH-agonist regimen, co-treatment with rFSH 225 IU/day s.c. 
(Puregon®, MSD Haarlem, Haarlem, The Netherlands) was initiated. Patients 
receiving mild ovarian stimulation treatment were treated with a fixed dose of 
150 IU/day rFSH s.c. (Puregon®, MSD Haarlem, Haarlem, The Netherlands) 
from CD5 onwards. As soon as the leading follicle reached a diameter of 
14mm, a GnRH-antagonist (Orgalutran®, MSD Haarlem, Haarlem, The 
Netherlands) was administered at 0.25 mg/day s.c. To induce final oocyte 
maturation a single s.c. dose of 10,000 IE hCG (Pregnyl®, MSD Haarlem, 
Haarlem, The Netherlands) was administered in both regimens as soon as the 
leading follicle reached a diameter of at least 18 mm and at least one additional 
follicle reached a diameter of 15 mm or more. Oocytes were retrieved 36 hours 
after hCG injection by transvaginal ultrasound-guided aspiration of follicles.
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Sample collection and analysis
Isolated oocytes were washed and transferred to a separate droplet of medium 
in order to monitor their quality. The monofollicular fluid samples were 
centrifuged for 10 min at 1,700 rpm to separate red blood cells (RBC), 
leucocytes and granulosa cells. The samples were frozen without preservatives 
and stored at -20°C until assayed.
Venous blood samples were drawn from each woman on CD2, i.e. the 
early follicular phase of the menstrual cycle preceding the treatment cycle 
and on the day of hCG administration. For the determination of folate, 
cobalamin, pyridoxine and hormones, venous blood samples were drawn 
into dry vacutainer tubes and allowed to clot. After centrifugation at 2,000 
x g, serum was collected for assay. AMH concentrations were measured 
using an enzyme-linked immunosorbent assay (Immunotech-Coulter, 
Marseille, France). Folate and cobalamin were analysed using an 
immunoelectrochemoluminescence assay (Roche Modular E170, Roche 
Diagnostics GmbH, Mannheim, Germany). Serum concentrations of FSH 
were measured by luminescence-based immunometric assay (Immulite 2000, 
Siemens Diagnostics, Los Angeles, CA, USA). Estradiol was determined 
using a coated tube radioimmunoassay obtained from the same supplier. For 
the determination of plasma total homocysteine (tHcy) and pyridoxine as 
pyridoxal-5-phosphate in whole blood, venous blood samples were drawn 
into ethylenediamine tetra-acetate (EDTA) containing vacutainer tubes. 
The EDTA-blood samples were placed on ice and within 1 hour, plasma 
was separated by centrifugation. Total homocysteine in EDTA plasma, 
pyridoxine in whole blood was determined using high-performance liquid 
chromatography with reversed phase separation and fluorescence detection. 
For the determination of RBC folate, 100ul blood from one EDTA tube was 
hemolyzed with 2 ml freshly prepared ascorbic acid (0.05 g ascorbic acid in 
25 ml aqua dest) directly after blood sampling. Subsequently, the hematocrit 
of the EDTA blood was determined on a Sysmex XE-2100 (Goffin Meyvis, 
Etten-Leur, The Netherlands). The hemolysate was centrifuged for 10 min 
at 2000 x g shortly before the folate measurement. The folate concentration 
in the hemolysate was calculated in RBC folate using the following formula: 
(nmol hemolysate folate X 21) – (nmol/l serum folate X (1 – hematocrit))/
hematocrit = nmol/l RBC folate. Inter-assay coefficients of variation for folate 
were 4.5% at 13 nmol/L and 5.7% at 23 nmol/L; for cobalamin 3.6% at 
258 pmol/L and 2.2% at 832 pmol/L; for tHcy 4.8% at 14.6 mmol/L and 
3.3% at 34.2 mmol/L; for AMH this coefficient was <10%; for FSH < 5.8%; 
and for estradiol, <8.8%. The detection limit for folate was 1.36 nmol/L, 
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for cobalamin 22 pmol/L, for pyridoxine 5 nmol/L; for tHcy 4 mmol/L, for 
AMH 0.1 mg/L, for FSH 0.1 U/L and for estradiol 10 pmol/L. 
Dietary pattern analysis
All 195 food items from the FFQ data of all participants were classified into 
22 food groups and adjusted for total energy intake.189 This was followed by 
Principal Components Analysis (PCA) applied on intake of the energy-adjusted 
food groups of women to construct overall dietary patterns by explaining the 
largest proportion of variation in the food group. Based on the scree plot and the 
proportion explained (eigen-value >1.25), the first three factors were considered 
for dietary pattern analysis (Supplementary Table). Each woman was assigned 
personal scores for the respective factors (i.e. dietary pattern), calculated as the 
product of the food group value and its factor loadings summed across foods. 
According to their personal score the group of women was divided into tertiles 
and classified as low, intermediate, or high adherence to the respective dietary 
pattern. The strength of adherence indicates the resemblance of the woman’s 
diet compared with the respective dietary pattern identified by PCA. 
Prior to analyses, all continuous variables were log-transformed, obtaining 
a near normal distribution of data suitable for parametric statistical testing. 
Normality was assessed using histograms and Q-Q plots. Measures of location 
and spread are depicted as Geometric Mean and Interquartile Range, respectively.
Comparison of the three tertiles of adherence was done using ANOVA. 
Proportions were compared using the Chi-square statistic, correlations using 
Pearson’s correlation. To allow for adjustment for covariates, linear and 
logistic regression methods were used to investigate the relation between 
dietary patterns, patient characteristics and the ovarian response to COH 
and to address the influence hereof on the chance of pregnancy. For the effect 
of dietary patterns on the ovarian response to COH we considered baseline 
AMH, estradiol, FSH and serum and RBC folate concentrations, no. of 
follicles, stimulation protocol and age and BMI of the woman as covariates. 
For the effect of diet on ongoing pregnancy chance we considered number 
of transferred embryo’s, ovarian response, age of the woman, BMI of the 
woman, treatment indication, fertilization rate, woman and partner smoking 
status, ethnicity and education. We applied a backward analysis, with the 
inclusion of higher order variables. During the backward process a variable 
was included into the analysis if its p-value <0.10 and inclusion changed the 
effect estimate of the variable of interest >10%.190 For ease of interpretation, 
linear regression was done using log-transformed dependent variables and 
non-transformed independent variables, i.e. a log-level linear regression. The 
interpretation of the β is thus such that βx100 equals the % change in the 
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dependent variable for a 1 unit change in β. Relevant regression parameters 
are reported with their 95% confidence intervals. Collinearity was assessed 
using the VIF statistic, a VIF of ≥4 was considered to indicate collinearity. 
In the final model the highest observed VIF was 2.0. Statistical analysis was 
performed using SPSS 17.0 for Windows software (SPSS Inc, Chicago, IL).
RESUlTS
Study population and dietary patterns
The three identified dietary patterns (Supplementary Table) were explored 
for associations with the ovarian response. The first two dietary patterns did 
not significantly associate with the outcomes of interest. The third dietary 
pattern, however, associated with the ovarian response and was therefore 
further analysed. This diet is characterized by high intake of fruits, whole 
grains, margarine, and low intake of refined grains and snacks, it explained 
8.9% of variance and is named the Healthy dietary pattern. The Healthy 
dietary pattern associated with the estradiol response after stimulation 
treatment (r=-0.16; p=0.02). In addition, adherence to the Healthy dietary 
pattern associated with baseline RBC and serum folate concentrations (0.27; 
p=0.001 and 0.15; p=0.03), baseline estradiol (-0.15; p=0.03) and BMI of 
the woman (-0.15; p<0.05). To compare women over the range of scores 
of adherence to the Healthy dietary pattern (-2.5-4.6), we divided women 
into three equally sized groups of adherence, i.e. low (-2.5- -0.39), medium 
(-0.38-0.3) and high (0.31-4.58). Table I depicts baseline characteristics of 
women undergoing COH. In the high adherence group, a larger proportion 
of women reported use of a folic acid containing (multi)vitamin supplement, 
excluding women who did not use a vitamin supplement from the 
forthcoming analysis did not alter the results. Other baseline characteristics 
show a comparable distribution over the tertiles of adherence (Table I). 
Biochemical parameters
Table II shows the biochemical markers in blood serum measured prior to COH 
on CD2 and after stimulation treatment on the day of hCG administration. 
First, although not significant, baseline estradiol and AMH concentrations 
are lower in the tertile of highest adherence (Table II). In addition, serum 
concentrations of pyridoxine and RBC folate concentrations are higher in the 
highest tertile (Table II). After COH, the differences are comparable with 
pyridoxine and RBC folate concentrations higher in the highest tertile of 
adherence. In addition, AMH and estradiol concentrations are lowest in the 
highest tertile (Table II). When data were adjusted for stimulation protocol, 
88
C
ha
pt
er
 V
I
age, BMI, number of visualized follicles and baseline AMH concentrations, 
a non-linear association between adherence to the Healthy dietary pattern 
and hCG-day estradiol concentrations (r-model=0.73; βadherence=-0.092 [-0.16 
- -0.023]; p<0.01 and βadherence, squared =-0.052 [-0.088 - -0.016]; p<0.01) could 
be established. In other words, a one-point increase in adherence to the 
Healthy dietary pattern lowers hCG-day estradiol concentrations by 14.4%. 
Table I. Baseline characteristics of women undergoing controlled ovarian hyper-
stimulation, stratified for adherence to the Healthy dietary pattern (n=203).
low  
(n=68)
Medium 
(n=68)
High  
(n=67) p
Age (years) 34.3 (31.0-38.0) 33.9 (31.3-37.0) 35.1 (33.0-38.0) ns
Body Mass Index (kg/m2) 23.7 (21.0-26.3) 22.9 (20.0-25.0) 22.6 (20.0-25.0) ns
Ethnicity, % (n) ns
Dutch 65.6 (42) 72.7 (48) 72.1 (44)
Non-Dutch European 9.4 (6) 10.6 (7) 11.5 (7)
Non-European 25.0 (16) 16.7 (11) 16.4 (11)
Education, % (n) ns
Low 13.4 (9) 20.6 (14) 13.4 (9)
Intermediate 38.8 (26) 41.2 (28) 41.8 (28)
High 47.8 (32) 38.2 (26) 44.8 (30)
Cause of subfertility, % (n) ns
Male 30.9 (21) 35.3 (24) 46.3 (31)
Female 29.4 (20) 22.1 (15) 14.9 (10)
Combined 5.9 (4) 5.9 (4) 3.0 (2)
Unknown 33.8 (23) 36.8 (25) 35.8 (24)
Multivitamin 
supplement use (yes), 
% (n)
80.9 (55) 83.8 (57) 94.0 (63) 0.024
Stimulation protocol, % (n) 0.49
GnRH-agonist 7.4 (5) 13.2 (9) 9.0 (6)
GnRH-antagonist 92.6 (63) 86.8 (59) 91.0 (61)
Smoking (yes), % (n) 7.3 (5) 13.2 (9) 7.6 (5) ns
Duration of subfertility 
(months) 33.1 (24.0-50.0) 36.3 (27.3-51.0) 35.2 (25.3-51.0) ns
Variables are depicted: Geometric Mean (Interquartile Range)
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Clinical outcome parameters after IVF/ICSI treatment
Table III shows the clinical outcome parameters after IVF/ICSI treatment. 
There are no statistically significant differences between the groups. 
Nevertheless, despite a lower fertilization rate in the highest tertile (Table III) 
the proportion of women with a positive pregnancy test and ongoing pregnancy 
was considerably higher in the highest group of adherence (Table III). The 
number of embryos transferred was similar between groups. When adjusted 
for the number of transferred embryo’s, age of the woman, BMI of the woman, 
treatment indication, fertilization rate and woman smoking status we show a 
significant association between adherence to the Healthy dietary pattern and 
the chance of ongoing pregnancy (ORadj: 1.61 [1.07-2.44]; p=0.02).
DISCUSSION
The results of this study shows that strong adherence to a Healthy dietary 
pattern characterized by high intake of fruit, whole grains and margarine 
and low intake of refined grains and snacks is associated with a beneficial 
reduction in the ovarian response to COH and an increase in the chance of 
achieving an ongoing pregnancy after IVF/ICSI treatment. 
The results from this study should be considered within the context of its 
strengths and limitations. The FOLFO study is a prospective periconception 
observational study specifically designed to address the influence of nutrition 
and lifestyle factors on IVF/ICSI treatment outcomes. Generating dietary 
patterns using PCA from FFQ data results in sensible food-item based 
Table III. Clinical outcome parameters after controlled ovarian hyperstimulation, 
stratified for adherence to the Healthy dietary pattern (n=203).
low  
(n=68)
Medium 
(n=68)
High 
(n=67) p
Retrieved oocytes (n), median (IQR) 7 (4-10) 7 (5-12) 6 (4-9) ns
Fertilization rate 65 51 50 ns
Positive pregnancy test, % (n) 23.5 (16) 25.0 (17) 35.8 (24) ns
Ongoing pregnancy, % (n) 17.9 (12) 19.1 (13) 26.9 (18) ns
Embryo transfer, % (n) ns
None 11.9 (8) 9.7 (6) 9.1 (6)
Single 71.6 (48) 79.0 (49) 74.2 (49)
Double 16.4 (11) 11.3 (7) 16.7 (11)
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outcomes that are easily translated into patient care. However, in interpreting 
these components, it is important to consider the tendency of human to over 
represent socially desirable food habits and generally underestimate their 
overall food intake. Also, food habits are culturally determined, sometimes 
requiring an adapted FFQ for different ethnicities.191 In this study excluding 
non-western ethnicities did not alter the result. Even though PCA tends to 
emphasize sample specific factors; the high accordance between the various 
studies in the generated dietary patterns that are considered healthy and 
their associations with treatment outcome is a testament to the external 
validity of this method.181, 192
Controlling the ovarian response to COH using modifiable factors such as 
nutrition can help improve the chance of pregnancy after COH by improving 
endometrial receptivity and reducing the risk of complications. Various 
epidemiological studies investigated the association between post stimulation 
estradiol concentrations and did indeed not always show adverse effects of high 
estradiol on implantation rates or pregnancy after IVF/ICSI treatment.179, 
193-195 Nevertheless, the effect of a high average number of transferred embryos 
(≥3) in these studies is likely to dilute or distort any effects of the ovarian 
response on these clinical outcomes. In vitro studies and studies focussing on 
endometrial gene expression patterns show that high estradiol concentrations 
are associated with endometrial gene expression profiles which are considered 
not beneficial for implantation.5, 183 Furthermore, a more prolonged follow-up 
suggests that a high ovarian response increases the risk for trophoblast 
related pregnancy complications, which suggests an effect of high estradiol 
concentrations on the endometrium.196 Finally, cryopreserving successfully 
fertilized oocytes and delaying embryo transfer until the next menstrual cycle 
doubled the chance of ongoing pregnancy after IVF/ICSI treatment.186
In our study, the chance of pregnancy was highest in women with strong 
adherence to the Healthy dietary pattern. Previous studies by Vujkovic et al. 
shows that nutrition beneficially affects the chance of pregnancy after IVF/
ICSI treatment, the underlying mechanism through which these endpoints 
were reached are unclear.181 The beneficial effects of reduced oxidative stress 
and folic acid supplement use on embryo and placental quality could lead 
to such outcomes, possibly without affecting the ovarian response.44, 65, 75, 197 
This suggestion is supported by the finding that nutrition also affects the 
chance of pregnancy in couples not undergoing IVF/ICSI treatment.192 
Improved pregnancy rates and a lower ovarian response can pose two separate 
effects of nutrition. Further studies need to address whether the association 
between nutrition, the ovarian response and improved pregnancy rates have 
a common causal pathway and if so whether there is a cumulative effect of 
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nutrition on IVF/ICSI treatment outcomes by affecting both embryo quality 
and endometrial receptivity through the ovarian response.
Earlier studies allow for speculation on possible mechanisms through 
which nutrition affects the ovarian response. Previously we showed that 
folic acid supplement use lowered the ovarian response to COH as did a 
diet high in fruit and whole grains in the current study.134 Additionally, 
Kanakkaparambil et al. similarly showed an increased ovarian response in 
methyl-deficient ewes.144 Possibly, the effects of the Healthy dietary pattern are 
even mediated by elevated folate concentrations. The anti-oxidant capability 
of folate and the high anti-oxidant content of fruits propose a mechanism 
through which both nutrition and folate can independently affect the ovarian 
response through a similar mechanism, reducing oxidative stress. In the study 
of Kanakkaparambil et al., increasing homocysteine concentrations, acting as 
an oxidant and used as an indicator of a low methyl group status, associated 
with increasing FSH Receptor (FSHR) expression levels.144 Increased FSHR 
expression will facilitate an increased follicular steroid production and overall 
ovarian response to gonadotropin stimulation. An in vitro study showed that 
anti-oxidant treatment of follicular cells had similar anti-apoptotic properties 
as did FSHR stimulation.49 Indeed, FSHR stimulation mediated a cellular 
response to oxidative stress by stimulating synthesis of the endogenous anti-
oxidant glutathione.47 Possibly, up regulation of FSHR is an attempt to re-
equilibrate the redox balance through production of glutathione. An inherent 
(side-)effect is the increased perceived stimulus for growth and steroid 
production upon FSH stimulation.
CONClUSION
We show that adherence to the Healthy dietary pattern lowers the ovarian 
response to COH, while increasing the chance of ongoing pregnancy after 
IVF/ICSI treatment. These findings support the rational and necessity for the 
use of a healthy preconception diet. It is unclear whether the lower ovarian 
response, improved embryo quality through improved nutrition or both is 
causal for the higher pregnancy rates or poses two separate effects of nutrition. 
The anti-oxidant effects of high fruit consumption may explain the effects on 
both the ovarian response, improved pregnancy rates and is in accordance 
with our previous studies.
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Supplementary Table. Food group loadings for eligible dietary patterns.
First dietary pattern 
(Variance explained: 
10.3%)
Second dietary 
pattern  
(Variance explained: 
9.5%)
Third (Healthy) 
dietary pattern 
(Variance explained: 
8.9%)
Alcohol .039 .009 -.009
Cereals .198 .559 .026
Butter .013 .666 .130
Dairy -.033 -.136 .098
Eggs -.081 .453 .139
Fish .633 -.012 .125
Fruits .357 .044 .622
Legumes .526 .090 .161
Margarine -.089 -.684 .293
Mayonnaise -.021 -.186 -.130
Meat -.517 -.211 -.008
Non-alcohol -.056 -.029 .019
Nuts .078 .079 .148
Refined grains .393 -.092 -.579
Potato -.020 .060 -.111
Sauces .079 -.038 -.075
Snacks -.096 -.231 -.448
Soup .057 -.095 .031
Sugars -.190 .259 -.096
Vegetable oils .138 .208 -.189
Vegetables .683 .073 .096
Whole grains .042 -.235 .705
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The preconception diet is associated 
with the chance of ongoing 
pregnancy in women undergoing 
IVF/ICSI treatment
J.M. Twigt, M.E.C. Bolhuis, E.A.P. Steegers, F. Hammiche, W.G. van Inzen, 
J.S.E. Laven and R.P.M. Steegers-Theunissen
Hum Reprod, 2012 (8): 2526-2531
AbSTRACT
Background
Subfertility and poor nutrition are increasing problems in Western countries. 
Moreover, nutrition affects fertility in both women and men. In this 
study, we investigate the association between adherence to general dietary 
recommendations in couples undergoing IVF/ICSI treatment and the chance 
of ongoing pregnancy.
Methods
Between October 2007 and October 2010, couples planning pregnancy 
visiting the outpatient clinic of the department of Obstetrics and Gynaecology 
of the Erasmus Medical Centre in Rotterdam, the Netherlands, were offered 
preconception counselling. Self-administered questionnaires on general 
characteristics and diet were completed and checked during the visit. Six 
questions, based on dietary recommendations of the Netherlands Nutrition 
Centre, covered the intake of six main food groups (fruits, vegetables, meat, 
fish, whole-wheat products and fats). Using the questionnaire results, we 
calculated the Preconception Dietary Risk score (PDR-score), providing an 
estimate of nutritional habits. Dietary quality increases with an increasing 
PDR-score. We define ongoing pregnancy as an intrauterine pregnancy with 
positive heart action confirmed by ultrasound. For this analysis we selected 
all couples (n=199) who underwent their first IVF/ICSI treatment within 
six months after preconception counselling. We applied adjusted logistic 
regression analysis on the outcomes of interest using SPSS. 
Results
After adjustment for age of the woman, PDR-score of the partner, BMI and 
smoking of the couple, we show an association between the PDR-score of 
the woman and the chance of ongoing pregnancy after IVF/ICSI treatment 
(ORadj: 1.65 [1.08-2.52]; p=0.02). Thus, a one-point increase in the PDR-score 
associates with a 65% increased chance of ongoing pregnancy. 
Conclusions
Our results show that increasing adherence to Dutch dietary recommendations 
in women undergoing IVF/ICSI treatment increases the chance of ongoing 
pregnancy. This data warrants further confirmation in couples achieving a 
spontaneous pregnancy and in randomized controlled trials.
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INTRODUCTION
The preconception diet is often inadequate in women planning pregnancy.198 
Nutrition and lifestyle factors, comprising diet, exercise, stress, alcohol- and 
drug use, smoking, and obesity affect reproductive performance, also after 
assisted reproduction.199 Despite the available knowledge on the relation 
between poor nutrition and lifestyles and the risk of fertility problems, 
congenital malformations and maternal pregnancy complications, there are 
few initiatives that aim to structurally offer preconception counselling on 
these topics in a clinical setting to couples planning pregnancy.84, 181, 200-203 
Screening is the first step in counselling and screening on lifestyle factors, 
such as smoking and obesity, compared to nutritional quality is relatively 
straightforward.191, 204 There are many different questionnaire tools to 
address nutrition, designed to measure diet and nutrient intake as accurate 
as possible. These tools differ in their mode of administration, elaborateness 
and validity.191, 204 However, most of these tools are not suitable for clinical 
practice, because of time and financial constraints. If we can screen nutritional 
behaviours using a simple clinically applicable questionnaire, however, this may 
be a first step in changing poor nutritional behaviours in order to ultimately 
contribute to the improvement of reproductive capacity and performance.
Studies performed on the relation between (micro)nutrients and fertility 
provide evidence that nutrition affects fertility in both men and women.55, 200 
Indeed, the aim of nutrition and nutritional advice is to ensure an adequate 
intake and status of (micro)nutrients. Ensuring that an adequate nutrient 
status is attained through counselling is difficult and troubled by various factors 
such as nutrient interactions, ethnic variation in nutritional habits, day-to-
day variation in intake, misreporting and the method of evaluation.191, 204 In 
addition, there is still much debate on what is the recommended daily intake 
for specific nutrients.204 At present, the Food Frequency Questionnaire is the 
most applied and appropriate tool to quantify and qualify nutritional habits. 
Time and costs are major issues also in the development of preconception 
care. As a result, screening and counselling on nutrition in a clinical setting 
is a trade-off between validity and applicability. The obtained information 
and offered advices should be simple, understandable and applicable for the 
patient-couple, regardless of differences in demographics. 
The Netherlands Nutrition Centre is the official government funded 
institution that undertakes public health initiatives to improve nutrition 
in the Dutch population.205 Based on the general recommendations of the 
Netherlands Nutrition Centre for a healthy diet, which are developed to ensure 
a sufficient nutrient intake, we devised a questionnaire to estimate nutritional 
intake in subfertile patient-couples using six simple questions. In the current 
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clinical study, using this simple questionnaire we addressed the influence of a 
healthy diet on the chance of ongoing pregnancy after IVF/ICSI treatment.
MATERIAlS AND METHODS
Study design
Between October 2007 and October 2010, patient-couples planning 
pregnancy, visiting the outpatient clinic of the department of Obstetrics and 
Gynaecology of the Erasmus MC, University Medical Centre Rotterdam, the 
Netherlands, were offered preconception counselling at the clinic ‘Achieving 
a Healthy Pregnancy’ (AHP). At the first gynaecological visit, couples were 
referred for preconception counselling on nutrition and lifestyle after having 
received a flyer with information and a self-administered questionnaire. The 
questionnaires were filled out at home and included six questions on nutrition. 
We extracted the following additional data from the questionnaires: age, 
ethnicity, educational level, indication for referral, lifestyle factors (smoking, 
alcohol, exercise levels (type of exercise, frequency and duration), stress (yes/
no and cause of stress), and drug use), use of medication (over the counter 
and prescription) and vitamin supplement use. During the preconception 
counselling, the questionnaires were checked by the counsellor and discussed 
in detail with the patient-couple. Height and weight were measured to calculate 
the Body Mass Index (BMI = weight in kilograms divided by squared height 
in meters). Within 3 weeks after counselling, the participating couples and 
the gynaecologist received a letter in which in detail the identified (un)healthy 
lifestyle and nutritional factors and recommendations were reported. Every 
patient-couple was invited for a follow-up visit to evaluate their compliance to 
the recommendations. In our population, 46.2% made use of this opportunity.
The six nutritional questions covered the intakes of the main food groups: 
whole wheat (including cereal consumption), fats, vegetables, fruit, meat 
and fish. This was based on the dietary recommendations of the Netherlands 
Nutrition Centre. These questions provide an overall estimate of the nutrition 
of a person. The current guidelines are at least four slices of whole wheat 
bread daily (or comparable servings of cereals), the use of monounsaturated or 
polyunsaturated oils, ≥200 grams of vegetables daily, ≥2 pieces of fruit daily, 
≥3 servings of meat or meat replacers weekly and ≥1 servings of fish weekly. 
Based on these questions we calculated the Preconception Dietary Risk score 
(PDR-score). When the intake of each food group met the recommendations 
of the Netherlands Nutrition Centre, a score of one point was assigned. Thus, 
the maximum PDR-score was six and represented highly adequate nutrition 
according to recommendations of the Netherlands Nutrition Centre. 
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Patient-couples who received their first IVF/ICSI treatment with embryo 
transfer within six months after their first AHP consultation were selected 
for our analysis. The information on the IVF/ICSI treatment was extracted 
from the database of the Erasmus MC fertility clinic and included treatment 
protocol, no. of retrieved oocytes and transferred embryos and treatment 
outcome. The primary outcome was ongoing pregnancy, defined as a 
pregnancy with positive foetal heart action at around 10 weeks after embryo 
transfer, confirmed by ultrasonography. 
Statistical analysis
Data analysis was carried out using SPSS 17.0 for Windows. We applied 
univariate analysis and statistical comparison between groups is done using 
the non-parametric Mann-Whitney U-test. Variables are reported as Median 
(Interquartile Range). Proportions are compared using the Chi-Square statistic. 
To address the influence of nutrition on the primary outcome, we applied 
multivariable logistic regression with expression of the effect estimate in 
Odds Ratio´s (OR). We considered several confounders: age, BMI, treatment 
indication, smoking status, alcohol use, exercise levels, stress, ethnicity, 
education, no. of transferred embryos, PDR-score and smoking of the man 
and ovarian stimulation protocol. Because couples are offered a second visit to 
the AHP consult, we also considered the change in the PDR-score, with those 
visiting just once receiving a conservative score of ‘0’, reflecting no change. We 
applied a backward analysis, with the inclusion of higher order variables. During 
the backward process a variable was included into the analysis if its p-value <0.10 
and inclusion changed the effect estimate of the variable of interest >10%.190
RESUlTS
Of the 1,270 patient-couples participating in this study up to the date of analysis, 
199 couples received their first IVF/ICSI treatment with embryo transfer within 
6 months after AHP consultation. Women undergoing IVF/ICSI treatment 
were more often of Dutch origin and less often of non-European origin (60.8% 
vs. 53.1%; p=0.04). In addition, treated women were more likely to consume 
alcoholic beverages (62.8% vs. 48.6%; p<0.001), which resulted from the 
different ethnicity distribution between the groups. Women undergoing IVF/ICSI 
treatment were older and the duration of subfertility longer than those who did 
not receive this treatment (33.6 vs. 32.1 years; p<0.001 and 28 vs. 22 months; 
p<0.001, respectively) and had a slightly lower BMI (23.8 vs. 24.8 kg/m2; p<0.01).
Of the 199 couples undergoing their first IVF/ICSI treatment, 35% 
became pregnant, of which 26% was ongoing whereas in 62% no pregnancy 
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could be achieved. For 3%, the outcome of treatment is unknown. Of the 
199 couples, 92 made use of the opportunity to visit the AHP consult a 
second time. In this group, those fallen pregnant were slightly overrepresented 
(56.9% vs. 43.0%; p=0.09). 
Table I shows the characteristics of couples undergoing IVF/ICSI treatment 
stratified for pregnancy status. Women with an ongoing pregnancy tended 
to be younger. In addition, women and men with an ongoing pregnancy 
were more often non-smokers (Table I). The proportion of adherence to the 
recommendations for the main food groups comprised in the PDR-score, i.e. 
what proportion of women scored a point for the PDR-score for each food 
group was comparable between those fallen pregnant and those that did 
not. Without adjusting for any confounders there are no differences in the 
PDR-score between women with and without an ongoing pregnancy (Table I).
However, the logistic regression analysis shows a significant association 
between the PDR-score of the woman and the probability of ongoing 
pregnancy after IVF/ICSI treatment (Table II). A beneficial increase in the 
PDR-score with one point associates with an increase of 65% in the chance of 
ongoing pregnancy after the first IVF/ICSI treatment within 6 months after 
counselling. The OR is adjusted for the confounders: treatment indication, 
age of the woman (squared), BMI and smoking status of the woman and the 
PDR-score and BMI of the partner. Interestingly, an increasing PDR-score of 
the men seemed to reduce the chance of pregnancy after IVF/ICSI treatment. 
After including the interaction between treatment indication and PDR-score 
of the man, the association between the PDR-score of the man and the 
chance of pregnancy was conditional on female factor infertility. Thus, the 
PDR-score of the man did not affect the chance of pregnancy after IVF/ICSI 
treatment. Factors such as alcohol use, exercise and stress levels, ethnicity, 
education level, ovarian stimulation protocol, smoking of the man, the change 
in the PDR-score at the second visit, duration of subfertility and indication 
for treatment did not show effects according to the pre-specified criteria.190
DISCUSSION
In this study, we show that the quality of the preconception diet of patient-
couples undergoing a first IVF/ICSI treatment associates with the chance 
of ongoing pregnancy after IVF/ICSI treatment within 6 months after 
preconception counselling tailored on nutrition and lifestyle. After adjusting 
for several covariates a beneficial one-point increase in the PDR-score reflects 
a 65% increased chance for ongoing pregnancy. 
There are many different tools to measure nutrition.191, 204 The goal of these 
tools is to estimate qualitative and quantitative nutrient intake through the 
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Table I. Baseline characteristics for couples undergoing IVF/ICSI treatment (n=193).
Ongoing pregnancy 
(n=51)
No pregnancy 
(n=142) p
Women
Age (years), median (IQR) 32.5 (30.2-35.3) 33.6 (29.7-38.7) 0.06
Ethnicity, % (n) ns
Dutch 66.7 (34) 58.5 (83)
European 13.7 (7) 10.6 (15)
Non-European 19.6 (10) 31.0 (44)
Education level, % (n) 0.08
High 50.0 (24) 37.6 (50)
Intermediate 39.6 (19) 42.9 (57)
Low 10.4 (5) 19.5 (26)
Subfertility, % (n) ns
Primary 60.8 (31) 59.2 (84)
Secondary 39.2 (20) 40.8 (58)
Reason of subfertility, % (n) ns
E.c.i. 22.5 (32) 27.5 (14)
Male 39.4 (56) 43.1 (22)
Female 27.5 (39) 15.7 (8)
Combined 10.6 (15) 13.7 (7)
Duration of subfertility (months),  
median (IQR) 34 (17-44) 28 (18-45) ns
Smoking (yes), % (n) 9.8 (5) 24.6 (34) 0.03
Alcohol use (yes), % (n) 62.7 (32) 61.3 (87) ns
Body Mass Index (kg/m2),
median (IQR) 24.0 (21.8-29.2) 23.8 (21.8-27.2) ns
PDR-score, median (IQR) 3 (2-4) 3 (2-4) ns
Whole wheat (yes), % (n) 43.1 (22) 38.7 (55) ns
Fats (yes), % (n) 64.7 (33) 62.7 (89) ns
Vegetables (yes), % (n) 23.5 (12) 22.5 (32) ns
Fruits (yes), % (n) 23.5 (12) 15.5 (22) ns
Meats (yes), % (n) 92.2 (47) 90.1 (128) ns
Fish (yes), % (n) 56.9 (29) 47.9 (68) ns
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Men
Smoking (yes), % (n) 20.4 (10) 36.5 (50) 0.04
Body Mass Index (kg/m2), 
median (IQR) 26.1 (24.4-27.8) 26.2 (24.0-28.9) ns
PDR-score, median (IQR) 3 (2-4) 3 (2-4) ns
Whole wheat (yes), % (n) 58.8 (30) 74.6 (106) 0.03
Fats (yes), % (n) 66.7 (34) 64.8 (92) ns
Vegetables (yes), % (n) 19.6 (10) 19.7 (28) ns
Fruits (yes), % (n) 15.7 (8) 15.5 (22) ns
Meats (yes), % (n) 94.1 (48) 93.7 (133) ns
Fish (yes), % (n) 54.9 (28) 47.3 (70) ns
PDR-score (Preconception Dietary Risk score)
Table I. Continued from previous page.
Ongoing pregnancy 
(n=51)
No pregnancy 
(n=142) p
diet mainly in a research setting.204 Our simple clinically applicable tool is 
based on the recommendations of the Netherlands Nutrition Centre, which 
are developed to ensure sufficient nutrient intake.205 This tool does not estimate 
quantitative or qualitative nutrient intake but in a binary fashion it addresses 
whether daily nutrient intake of six main food groups (fruits, vegetables, 
meat, fish, whole-wheat products and fats) is sufficient. Although we were 
able to account for several potential confounders, it is important to realize 
the considerable variability in the reporting of day-to-day nutritional habits 
conditional on obesity, education level, perceived health and ethnicity.191 
Nevertheless, because we discuss the questionnaire in detail with the patient-
couple during the consultation, we were able to address any ambiguity in the 
reporting of nutritional habits and ask for additional information if necessary. 
Previously, Vujkovic et al. have investigated the association between 
adherence to the Mediterranean diet using the FFQ, comprising 195 questions, 
and the chance of biochemical pregnancy after IVF/ICSI treatment.181 This 
diet comprised high intakes of vegetable oils, vegetables, fish, and legumes and 
low intakes of snacks. High adherence to the Mediterranean diet associates 
with a 40% increased chance of biochemical pregnancy on day 15 after 
embryo transfer. Here we show a comparable effect size for the adherence to 
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the recommendations of the Netherlands Nutrition Centre and the chance of 
ongoing pregnancy after IVF/ICSI treatment only using a lower resolution 
and clinically applicable questionnaire.
Studies mostly focus on the relation of (micro)nutrient status, or markers 
thereof, and reproductive outcomes.206 Given that (micro)nutrients are primarily 
derived from the diet, it should be interesting to investigate through which 
specific (micro)nutrients the effect of nutrition is mediated. Here, the effects of 
B-vitamins, such as folate, on reproduction can help provide a mechanism through 
which nutrition mediates its effects on reproduction. Indeed, various studies by 
Vujkovic et al. show that certain dietary patterns are beneficial with regard to 
reproductive outcomes and associate with B-vitamin concentrations.84, 181, 202, 203 
Nevertheless, despite this knowledge, there are few initiatives in reproductive 
medicine to translate these findings into clinical practice. Combined with a 
recent study from our group by Hammiche et al., we show that preconception 
counselling on nutrition seems effective, and now also results in an improved 
chance of ongoing pregnancy after IVF/ICSI treatment.207
Table II. Predictors for ongoing pregnancy after IVF/ICSI treatment (n=193).
β Odds Ratio (95% CI) p
Age2 (woman) -0.022 0.98 (0.96-0.99) <0.01
Body Mass Index (woman) 0.078 1.1 (0.99-1.19) ns
Body Mass Index (man) -0.064 0.94 (0.85-1.04) ns
Smoking (woman) -0.99 0.37 (0.12-1.11) 0.08
PDR-score (woman) 0.50 1.65 (1.08-2.52) 0.02
PDR-score (man) -0.054 0.95 (0.48-1.86) ns
Treatment indication ns
E.c.i REF -
Male -0.49 0.61 (0.23-1.62) ns
Female -1.21 0.30 (0.09-1.01) ns
Combined -0.19 0.83 (0.48-1.86) ns
Treatment indication by PDR-score (man) ns
E.c.i REF -
Male -0.31 0.74 (0.32-1.70) ns
Female -1.14 0.32 (0.11-0.92) ns
Combined -0.42 0.66 (0.22-1.97) ns
PDR-score (Preconception Dietary Risk score)
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During the AHP consult we counsel patient-couples to adopt, if necessary, 
a healthier diet, stop smoking, alcohol and drug use, to increase their exercise 
levels and subsequently lose weight. To review their compliance, patient-couples 
are invited for a follow-up visit. Possibly, not only the baseline difference in 
nutrition affects the chance of ongoing pregnancy after IVF/ICSI treatment but 
also the improvement in nutrition. Of the couples that returned for a second 
AHP consult, there was a significant improvement of the PDR-score, but no 
significant difference in the change of the PDR-score between women getting 
pregnant and those who did not (data not shown). Including this change of the 
PDR-score in the final model did not result in any changes to the effect estimate 
of the PDR-score, suggesting that the effect of nutrition is mediated through 
baseline differences. The study by Hammiche et al. in the ongoing AHP cohort in 
patient-couples, who consulted the AHP twice, shows a beneficial increase in the 
PDR-score.207 This was most notably driven by an improvement in fruit (+15%) 
and fish intake (+13%). Additionally, also self-reported exercise levels (+44%) 
and folic acid containing supplement use (+17%) improved, which are not 
included in the PDR-score. Although not significant in the study of Hammiche 
et al., self-reported use of vegetables, whole wheat products, vegetable oil and 
meat, comprised in the PDR-score, and the distribution of the BMI groups 
improved, with fewer obese people (-3%).207 These findings suggest a significant 
uptake of the counselling. Therefore, it would be interesting to address further in 
depth whether an increase in the PDR-score at a second visit associates with an 
increased chance of ongoing pregnancy after IVF/ICSI treatment.
Paternal dietary and lifestyle factors affect semen quality and thereby could 
influence assisted reproduction treatment success.202, 208 Here, we are not able 
to identify a significant influence of the PDR-score of the man on IVF/ICSI 
treatment outcome. Only in the case of female factor infertility, the PDR-score 
of the man appeared to influence the chance of pregnancy. Nevertheless, 
the unintuitive direction of this association likely reflects the more adequate 
nutritional habits of men of couples that did not fall pregnant and experiencing 
female factor infertility as opposed to those that did fall pregnant (mean +1 
PDR-score point, data not shown). Apparently, and not surprising, the influence 
of female factor infertility is not influenced by nutrition of the man. In addition, 
because our study consisted of IVF/ICSI treatment cycles that resulted in a good 
quality embryo suitable for transfer, this suggests that the effect of maternal 
nutrition on IVF/ICSI treatment outcome is primarily mediated through 
provision of adequate nutrients to the early transferred embryo.
In addition to various nutritional factors that affect the chance of pregnancy 
after IVF/ICSI treatment, lifestyle factors such as smoking and overweight 
status, but also exercise levels and stress could affect the chance of pregnancy 
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after IVF/ICSI treatment.209-212 To our knowledge the only study that specifically 
addresses the influence of physical exercise on IVF/ICSI treatment outcomes is 
by Morris et al.210 This study with a large sample size failed to find an association 
between current exercise levels and IVF/ICSI treatment outcomes, which is how 
this topic is addressed during the AHP consult. Including this measurement of 
physical exercise in the analysis did not affect the influence of the PDR-score 
on the chance of ongoing pregnancy. During the consult we also obtain general 
information on stress, giving a crude estimate of stress. Here we fail to show an 
effect of stress on the chance of pregnancy. Given the evidence in the literature 
for the relation between IVF/ICSI treatment success and physical exercise and 
stress, implementing more detailed measures for both features could help to 
further detail the influence of nutrition on IVF/ICSI treatment. Although 
marginal and not significant, the BMI appears beneficially associated with the 
chance of ongoing pregnancy. This is in contrast with firmly established evidence, 
which shows a decline in IVF/ICSI treatment success with an increasing BMI.209 
As noted, we counsel couples to adopt a healthier lifestyle. Although it is not 
possible to show such an association in the sample for this analysis, possibly 
the largest improvement in dietary and lifestyle factors is noted in overweight/
obese people who require and perceive the greatest necessity for change. Studies 
focussing on weight loss, suggest that it is not necessary to obtain a healthy weight 
but weight reduction of 5-10% is already sufficient to improve fertility and 
endocrine parameters.213, 214 Thus, considering the time-lag between treatment 
and counselling, the discussed results from Hammiche et al.,207 the fact that a 
slight weight reduction is often sufficient to improve the chance of pregnancy 
and the notion that overweight people could perceive the greatest necessity to 
take up counselling; it might me possible that BMI measured prior to treatment 
is a correlate of dietary and lifestyle improvements and thereby explain the 
positive association between BMI and pregnancy chance in this study.
CONClUSION
We show here that adherence to recommendations of the Netherlands Nutrition 
Centre associates with an increased chance of ongoing pregnancy after the first 
IVF/ICSI treatment. We addressed this topic using a low-resolution and clinically 
applicable questionnaire. In line with studies on weight reduction, this study 
provides evidence that programs aimed at beneficially changing preconception 
nutrition and lifestyle factors should be considered a first-choice treatment for 
unexplained subfertility.213, 215 A next step for these investigations would be to 
address whether a beneficial change in nutrition associates with an increase in the 
chance of ongoing pregnancy after IVF/ICSI treatment.
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Introduction & Aim
VIII
I
General Discussion

This thesis reports on the influence of preconception nutrition of a woman 
on her ovarian response to exogenous administered gonadotropins (i.e. 
Controlled Ovarian Hyperstimulation) and the success of achieving pregnancy 
after IVF/ICSI treatment. In the following discussion we elaborate on the 
main findings from this thesis and discuss the implications they might have 
for preconception care and future research. 
PRECONCEPTION NUTRITION, FOlIC ACID 
SUPPlEMENT USE AND THE OVARIAN RESPONSE
The ovarian response is a crude and clinically relevant measure of the numerous 
extrinsic- and intrinsic ovarian factors that are implicated in follicle growth. 
Gaining insight into determinants of the ovarian response to COH improves 
the understanding of mechanisms that regulate ovarian follicle growth and 
those involved in oocyte quality. Additionally, such determinants could be 
used to tailor the COH treatment protocol to a woman’s specific needs and 
requirements; or to optimize a woman’s condition before undergoing COH. 
In this thesis we show that healthy nutrition as well as folic acid supplement 
use are determinants that comparably influence the ovarian response to COH 
(Chapter V and VI). The ensuing recommendations to optimize the maternal 
preconception nutritional status to improve the ovarian response to COH 
are in line with and conducive to current recommendations with regard to 
an uneventful development of, as well as an improved outcome of pregnancy. 
The question remains, however, how these data can be implemented, in 
particular for couples undergoing IVF/ICSI treatment. 
When subjected to COH, the typical ovarian follicle undergoes an 
1800-fold increase in cell count.216 Therefore, based on the results presented in 
this thesis, we propose that an adequate nutritional environment enables the 
ovarian follicle to adequately respond to the gonadotropin stimulus, in contrast 
to a possible negative or inhibitory influence of the nutritional status on the 
ovarian response. Since follicle and oocyte maturation are interdependent, 
the magnitude of the ovarian response could have consequences for oocyte 
quality, subsequent embryo viability and the chance of pregnancy as well. 
Indeed, similarly, the use of an nutritionally insufficient diet to loose weight 
lowers the chance of pregnancy after IVF/ICSI treatment.217 Moreover, under 
the aggravated growth circumstances posed by COH (i.e. stimulating follicles 
to grow that otherwise would have not), it is not unlikely that the presence 
and influence of (genetic, lifestyle, or metabolic) factors on the ovarian 
response, are in part mediated or ameliorated by adequate nutrition.213, 215, 217
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In more detail, previous studies show an optimum in the relation between 
the ovarian response to COH and the chance of pregnancy after IVF/ICSI 
treatment.4 This raises the question: could the reduction in the ovarian response 
to COH due to healthy nutrition and folic acid supplement use also be harmful 
for IVF/ICSI treatment outcomes? Achieving an optimal ovarian response to 
COH is the result of the appropriate balance between determinants of the 
ovarian response and the applied stimulation protocol. Modified by external 
(environmental) factors, a given combination of constitutive factors that 
influence the ovarian response dictate an optimal ovarian response, to which a 
stimulation protocol is adapted. Therefore, a reduction of the ovarian response 
through optimization of extrinsic factors, such as nutrition and overweight status, 
does not necessarily constitute a negative influence on the ovarian response but 
aligns the ovarian response to the anticipated optimal ovarian response.
Adherence to a Healthy dietary pattern characterized by high intake of 
fruit and whole grain lowers the ovarian response to COH (Chapter VI), 
comparable to the effect of folic acid supplement use (Chapter V); nevertheless, 
how do these independent findings from the same cohort compare and agree? 
To compare these findings, the results from chapter V are transformed to 
a log-level model, similar to the type in chapter VI. Second, serum folate 
concentrations from chapter V are binned into seven categories to obtain a 
similar resolution as that of the component of the Healthy dietary pattern 
in chapter VI. Now, a one-unit change of serum folate concentrations 
lowers the ovarian response by 4.9% (-18.2% - 8.4%) compared to 14.4% 
(-24.8% - -0.7%) for a one-unit change of the component for the Healthy 
dietary pattern. Indeed, the larger influence of nutrition on the ovarian 
response suggests that more pathways influencing ovarian follicle metabolism 
are affected through nutrition than by a single nutrient, i.e. folate. 
The food items comprised in the Healthy dietary pattern provide 
antioxidants and various cofactors and substrates for the one-carbon pathway 
but are not the principal sources of folate. Nevertheless, adherence to the 
Healthy dietary pattern associated with serum and RBC folate concentrations, 
and folic acid supplement use had a similar, albeit smaller, influence on 
the ovarian response (Chapter V). Other studies also consistently show 
associations between healthy dietary patterns and biomarkers of the folate 
dependent one-carbon pathway.84, 181, 202, 203 Therefore, we hypothesize that 
the effect of nutrition is in part mediated through the one-carbon pathway. 
Furthermore, this allows for an explanation that a Healthy dietary pattern 
rich in anti-oxidants similarly influences the ovarian response; a deficiency 
of the one-carbon pathway results in oxidative stress.29 The one-carbon 
pathway is the underlying pathway for the synthesis of DNA nucleotides, 
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several amino acids and phospholipids. Moreover, this pathway provides the 
methyl groups that are used for epigenetic processes such as DNA and histone 
methylation and detoxification of various substrates, which are implicated in 
programming of the oocyte and granulosa cell epigenome.11 
It is surprising that ovarian follicles developing in a presumably poor 
nutritional environment show increased metabolic activity as reflected 
by increased steroid synthesis. Especially so since previous studies show 
that folate deficient women are at increased risk of anovulatory infertility, 
which is in turn supported by studies in chimpanzees that have an increased 
proportion of atretic and cystic follicles after folate depletion.37, 218 Possibly, 
this is the phenotype acquired after prolonged folate depletion. Indeed, in 
vitro studies on human, ovine, bovine and rodent granulosa cells show that 
a compromised one-carbon pathway or oxidative stress can indeed establish 
an increased ovarian response to COH. The studies in human described 
in this thesis, but also by Kanakkaparambil et al. in ewes, show that these 
mechanisms also act in vivo.144 First, expression of the FSH-Receptor (FSHR) 
and aromatase is regulated through one-carbon pathway dependent DNA 
methylation.172, 219 Cells with a high mitotic index subjected to a compromised 
one-carbon pathway could lose epigenetic marks, which would result in 
reduced repression of these two proteins that promote the ovarian response.25 
Also, a compromised one-carbon pathway results in oxidative stress, which 
can explain the larger effect of a diet high in anti-oxidants than folic acid 
supplement use alone.29 Indeed elevated homocysteine, as the best-studied 
marker of a compromised one-carbon pathway, and oxidative stress result in 
an up regulation of FSHR, apparently in order to stimulate production of 
the endogenous anti-oxidant glutathione.47, 49, 144 Concomitantly, increased 
FSHR expression will result in an increased perceived stimulus for estradiol 
production through up regulation of aromatase activity in granulosa cells. 
Possibly, increased estradiol production is even the purpose. In vivo, estradiol 
stimulates up regulation of anti-oxidant genes and enzymes.220 Thus, the 
increased ovarian response might be an expression of the cellular response 
to negate the increased oxidative stress due to a compromised one-carbon 
pathway or poor anti-oxidant intake through the diet, through up regulation 
of estradiol dependent anti-oxidant enzymes. A physiologic response to 
oxidative stress that is inadequate in the presence of a supraphysiologic FSH 
stimulus while undergoing COH and a poor nutritional environment. 
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FOlIC ACID SUPPlEMENT USE AND THE 
MICROENVIRONMENT OF THE OOCYTE
The functions of the one-carbon pathway are ubiquitous and it seems 
highly unlikely that changes in the one-carbon pathway result in pathology 
mediated through a single mechanism.130, 135, 221 Therefore, in chapter III and 
IV we aimed to qualify and quantify the effects of folic acid supplement use 
on ovarian follicle metabolism by interrogating the follicle fluid proteome.
The use of follicle fluid and proteomics tools to investigate the effects 
of folate on ovarian follicle metabolism is one of many methodological 
possibilities. Follicle fluid is readily available after COH and its investigation is 
non-invasive with regard to the oocyte and embryo. Follicle fluid is the product 
of follicular cell excretions and an exudate of blood serum; therefore, follicle 
fluid provides insight into the intra-follicular environment resulting from local 
and systemic influences, which are in turn influenced by genetic, metabolic 
and lifestyle factors.108 The contents of follicle fluid are directly linked with 
oocyte quality.44, 112-114, 136 More specific studies into gene expression patterns 
of follicular cells can help disentangle the independent systemic as well as local 
contributions to the follicle fluid. This knowledge can help the direction of 
specific interventions or development of biomarkers to assess oocyte quality 
but also allows more in-depth evaluation through which mechanisms folic acid 
supplement use improves reproductive outcomes. Unfortunately, isolating 
follicular cells from monofollicular fluid and validating the obtained sample 
as follicular cells is at present not feasible without culturing. This precludes 
studies into alternative ‘omes’ because in vivo effects on the epigenome, 
transcriptome and proteome are possibly erased in vitro. 
The proteomic studies of human follicle fluid described in this thesis 
confirm the previously reported complexity of the follicle fluid proteome.109-111 
An important distinction compared to previous studies is that we used 
monofollicular fluids for proteomic analysis instead of multi-follicular fluids. 
Since the ultimate goal is to relate the follicle fluid proteome to oocyte 
and embryo quality, the use of monofollicular fluid is a prerequisite. Of 
interest is that we show an increased abundance of lipoproteins and a lower 
inflammatory state of follicle fluid in folic acid supplement users as compared 
to non-supplement users. This observation is very similar to findings in mice 
where the one-carbon pathway was compromised.222 Also, follicles of users 
appeared more mature as suggested by lower cytokeratin abundance. With 
regard to oocyte development and embryo competence, both high lipoprotein 
concentrations and low CRP concentrations are beneficial for embryo 
quality.153, 223 Although these findings do not provide conclusive evidence as 
to what mechanism would underlie the effects of a healthy diet and folic 
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acid supplement use on the ovarian response, they support the proposal that 
follicle maturation is disrupted due to folate or nutritional deficiencies, as is 
also reflected by cytokeratin concentrations in follicle fluid.155, 224 
In conclusion, the results of the proteomics studies highlight the 
involvement of possible pathways through which folic acid supplement use 
can improve oocyte and embryo quality after IVF/ICSI treatment.
NUTRITION AND PREGNANCY AFTER IVF/ICSI 
TREATMENT
In the studies described in chapter VI and VII we study the influence of 
nutrition on the chance of achieving pregnancy after IVF/ICSI treatment. 
For scientists, nutrition as consumed by humans is a complex exposure. 
Nutrition comprises a wide range of food items with large inter- and intra-item 
nutrient differences. Furthermore, regardless of nutrient content, eventual 
bioavailability of nutrients is affected by amongst others nutrient-nutrient 
interactions, constitutive traits of the consumer, the mode of preparation, 
storage conditions and the age of the food item.225 The problem would only 
be mathematical in case the magnitudes of all involved factors are known. 
Unfortunately this is not the case. Nevertheless, the relevance of nutrition 
studies ultimately resort from the same reason that underlies its difficulties, 
human consumes a constellation of food items, which comprise the diet and 
which provides all substrates for maintenance of homeostasis.
Nutrition and folic acid supplement use influence the chance of pregnancy 
after IVF/ICSI treatment, independent of the ovarian response.181, 226 The 
question is how could the ovarian response contribute to an improved 
chance of pregnancy after IVF/ICSI treatment (Chapter VI)? In addition to 
the previously discussed follicular maturation mechanism, there is also the 
influence of the ovarian response on the endometrium. The endometrium 
in which the embryo implants is very sensitive to steroid hormone 
concentrations and indeed, high estradiol concentrations have a detrimental 
effect on endometrial receptivity.5 The endometrial gene expression pattern 
and endometrial gland secretion composition after COH, is shifted to one 
less favourable for embryo implantation.5, 184, 227 Indeed, a Healthy diet 
and folic acid supplement use may also improve the chance of pregnancy 
after IVF/ICSI treatment, through improved embryo quality regardless of 
endometrial receptivity; which is supported by the findings that folic acid 
supplement use and healthy nutrition associate with the birth prevalence 
of congenital malformations.11 Nevertheless, under the hypothesis that the 
ovarian response to COH is a surrogate for healthy follicle maturation, a 
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lower ovarian response can associate with improved embryo quality. In part 
mediated by the one-carbon pathway, the effects of nutrition on ovarian 
follicle metabolism, embryo quality and endometrial receptivity through 
the ovarian response after COH, could additively cooperate to improve the 
chance of pregnancy after IVF/ICSI treatment as described in chapter VI.
The goal of the studies described in chapters VI and VII is to provide 
points of applications to improve preconception counselling of couples 
undergoing IVF/ICSI treatment. Preconception counselling is best done 
using simple and understandable recommendations. Because of time and 
financial constraints, the tools commonly used to meticulously map nutrition 
in a controlled study environment are often not feasible or available in most 
clinical settings. Indeed, with regard to tailored nutritional counselling, in a 
clinical setting there is clearly a trade-off between applicability and validity. 
To prevent undesirable outcomes, as is the purpose of counselling, it is 
necessary that the screening tool is sufficiently accurate and therefore able to 
identify outcomes of interest. In chapter VII we use a 6-item questionnaire 
based on recommendations of the Netherlands Nutrition Centre to screen 
nutrition in couples.205 The results from the study in chapter VII, and the 
study by Hammiche et al., show that it is possible to screen nutritional habits 
in a clinical setting.207 Also, we observe that an increase in adherence to the 
recommendations of the Netherlands Nutrition Centre associates with an 
improved chance of ongoing pregnancy after IVF/ICSI treatment, with an 
effect-size similar to that described in chapter VI and by Vujkovic et al.181 
Based on these results, it is clearly possible to screen nutritional habits and 
relate these to clinically relevant outcomes.
METHODOlOGICAl CONSIDERATIONS 
The studies described in this thesis are embedded in two observational studies, 
the FOod Lifestyle and Fertility Outcome- and Rotterdam Predict study. 
Indeed, such observational studies are subject to common issues that reflect 
on the validity and generalizability of observational studies. All participants 
in the studies described in this thesis are part of a highly selected population, 
i.e. subfertile couples requiring assisted reproduction to achieve pregnancy. 
In addition, the question remains, does an improvement in nutritional and 
lifestyle behaviour indeed improve the chance of a spontaneous pregnancy? 
It is important to realize the considerable variability in the reporting of 
day-to-day nutritional habits conditional on nutrition and lifestyle factors 
which are perceived to be (un)healthy, but also the possibility of residual 
confounding.191 Nevertheless, despite the day-to-day variation in nutritional 
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habits, the observed effects of nutrition on health are consistent, arguing for 
the validity of dietary pattern based exposure measures. 
In chapters III and IV we applied mass spectrometry based proteomics 
to elucidate the monofollicular fluid proteome. Such high-throughput 
technologies give rise to a large number of protein identifications, with possible 
false positive identifications. Various methods have been developed to tackle 
this issue, which are also enacted on our datasets, resulting in a prudent and 
sensible estimate of the follicle fluid proteome. Unfortunately, given the nature 
of these data and methods it is not possibly to adjust for confounding factors in 
order to specify the influence of folic acid supplement use in more detail. 
Despite such possible shortcomings, the FOLFOstudy is specifically 
designed to address the influence of nutrition and lifestyle factors on IVF/
ICSI treatment outcome, excluding women with known risk factors for 
adverse IVF/ICSI treatment outcome. In addition, the agreement between the 
various studies that have addressed the influence of nutrition on the ovarian 
response and chance of pregnancy is a testament to the validity of these 
findings. Also, the Rotterdam Predict/Achieving a Healthy Pregnancy study 
described in chapter VII is part of the ongoing preconception counselling 
clinic tailored on nutrition and lifestyle in which patient-care and research are 
combined, which allows for a clinically relevant evaluation of the feasibility 
of preconception counselling initiatives and the to be expected change in 
nutritional and lifestyle behaviours.
IMPlICATIONS FOR PRECONCEPTION CARE AND 
RESEARCH
A next step in evaluating the influence of nutrition and addressing the potential 
for preconception counselling on IVF/ICSI treatment is to investigate whether 
improvements in nutrition also result in improved treatment outcomes. 
Moreover, would improving a woman’s nutritional status also increase the 
chance of a spontaneous conception? Finally, should preconception counselling 
be restricted to the woman or should it also address men? 
Nutritional and lifestyle behaviours have great influence on offspring and 
reproductive health; therefore preconception counselling should be available 
to all couples trying to conceive, indeed with great barriers to be overcome 
in case one is trying to address the reproductive population which does not 
require fertility treatment. Given the consistencies in the reported effects and 
the long-term health benefits of a healthier lifestyle, along with the possibility 
that poor nutritional and lifestyle factors are the attributable factor for 
subfertility, preconception counselling should be regarded as a first step in the 
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evaluation of a subfertile couple. Even if poor nutrition is not the attributable 
factor for subfertility, healthy nutrition, as the results in this thesis emphasize, 
improves the chance of pregnancy after IVF/ICSI treatment. This is enforced 
by the notion that the influence of nutrition in both chapter VI and VII 
was independent of the cause of subfertility and that nutritional quality also 
coincides with the chance of unassisted conception.192 
Even though subfertile couples have a strong incentive to change lifestyle and 
nutritional behaviours, it is still difficult to achieve weight-loss, quit smoking 
and improve the nutritional status in a given couple in this population. With 
the notable exception, not only the lack of initiatives to support couples in 
improving nutrition and lifestyle habits but also the perceived solely medical 
origin of the failure to conceive hamper preconception counselling initiatives. 
Successfully implementing preconception counselling is therefore dependent 
on a paradigm shift in medicine itself, more aimed towards primary prevention 
and the perception that nutrition is an important determinant of (reproductive) 
health and longevity. Equally important is the realisation of society that health 
and disease is in large parts the result of ones own behaviour, and that nutrition 
is a factor of considerable importance herein. 
The onset and ongoing attention for the influence of nutrition on fertility 
and the ensuing preconception counselling initiatives will likely subject IVF/
ICSI treatment cohorts to selection bias. Indeed, couples with a healthy diet 
were less likely to visit their physician for difficulty trying to conceive.192 
Based on previous studies on the influence of weight loss and the risk of 
needing IVF/ICSI treatment, healthy nutrition can be considered a competing 
risk with regard to requiring ART, selecting those in who nutrition was not 
the attributable factor for subfertility or those in whom unhealthy lifestyle 
habits are persistent.213 Therefore, with the rise of preconception counselling 
initiatives, failure to prove any influence of nutrition on reproductive success 
after assisted reproduction does not necessarily mean the lack of influence. 
We could advocate that in the reproductive population healthy nutrition 
is a prerequisite for receiving assisted reproduction treatment and should 
be the primary goal to achieve before treatment is initiated. Nonetheless, 
meticulous follow-up of all participants in prospective studies, such as the 
Rotterdam Predict study, that include subfertile couples before treatment and 
preconception counselling or comparable Randomized Controlled Trials will 
show how much benefit is to be gained by improving nutritional habits with 
regard to the need of assisted reproduction. In any case, the beneficial influence 
of healthy nutrition on foetal development has been well established.11 
Furthermore, the fashion in which we address IVF/ICSI treatment 
outcomes need to be readdressed. It remains unclear if there is much room left 
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for improvement of the per treatment cycle success rates after single embryo 
transfer, and thus if odds ratios such as reported in this thesis adequately reflect 
the influence of nutrition on IVF/ICSI treatment outcome. If treatment is 
still required, clinical studies should consider cumulative outcomes for the 
complete assisted reproduction treatment course, starting with preconception 
counselling. Human reproduction seems inefficient, since also in normal fertile 
women or women with tubal factor infertility implantation rates are low.228, 
229 Moreover, there are unknown intra-patient prognostic factors for treatment 
success.9 Studying cumulative outcomes for the entire treatment cycle could 
prove more effective in identifying such prognostic factors and account for the 
apparent inefficiencies in human reproduction. It might well be possibly that 
interventions not necessarily improve the chance of pregnancy after a single 
treatment cycle, but do ameliorate the generally observed decline of success in 
subsequent cycles and thus increase the cumulative chance of success.
CONClUSION
Healthy nutrition lowers the ovarian response to COH and improves the 
chance of pregnancy after IVF/ICSI treatment. The folate mediated one-carbon 
pathway is a likely intermediate through which the effect of nutrition on ovarian 
follicle metabolism and the chance of pregnancy after IVF/ICSI treatment 
are mediated. In-depth studies of follicular cells will provide suggestions for 
underlying pathways that mediate the ovarian response to COH conditional on 
one-carbon metabolism and what the role of the ovarian response to COH is in 
determining the chance of pregnancy after IVF/ICSI treatment.
Finally, the results from this thesis emphasize the necessity to optimize the 
preconception nutritional status of women undergoing COH and IVF/ICSI 
treatment and to change the perceived relation between nutrition, general 
health and reproductive health. Not only to improve the ovarian response to 
COH, but also to improve the chance of pregnancy after IVF/ICSI treatment 
and consequently the chance of an uncomplicated healthy pregnancy. 
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Summary / Samenvatting

ENGlISH SUMMARY
Controlled Ovarian Hyperstimulation treatment (COH) and In Vitro 
Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) are assisted 
reproduction techniques used to achieve pregnancy in subfertile couples. 
Although COH and IVF/ICSI treatment are moderately successful in achieving 
pregnancy, there is room for improvement. There are various approaches to 
improve IVF/ICSI treatment, ranging from the improvement of embryo 
culture conditions to optimizing modifiable patient characteristics. However, 
also the intensity of the ovarian response to COH is thought to influence the 
chance of IVF/ICSI treatment success. In the studies described in this thesis 
we aimed to identify modifiable nutritional factors that associated with the 
one-carbon pathway and influence the ovarian response to COH and the 
chance of ongoing pregnancy after IVF/ICSI treatment. First we elaborate 
on mechanisms through which the effect of nutrition on ovarian follicle 
metabolism can be established and the magnitude of influence of nutrition on 
the ovarian response to COH and IVF/ICSI treatment outcome. Moreover, 
we addressed whether a simple clinically applicable questionnaire to screen 
nutritional habits associated with IVF/ICSI treatment outcome. 
To specify mechanisms through which nutrition and the folate dependent 
one-carbon pathway influence ovarian follicle metabolism we initiated 
proteomics studies of the ovarian follicle fluid. In chapter III we show that 
IEF assisted proteomics is a sensitive method to investigate the follicle fluid 
proteome. Additionally we studied the influence of folic acid supplement 
use on the follicle fluid proteome in chapter IV. In this study we elaborate 
on difficulties associated with the use of follicle fluid as a marker of intra-
follicular processes. Folic acid supplement use associated with higher 
abundance of apolipoproteins that predominantly associate with High 
Density Lipoproteins. These findings show how folic acid supplement use 
can beneficially influence embryo quality after IVF/ICSI treatment. Also 
follicles of folic acid supplement users appeared more mature, as reflected 
by cytokeratin abundance, which can be a reflection of the degree of oocyte 
maturation. Finally, in follicle fluid of supplement users, there was a lower 
abundance of C-reactive protein, suggesting a lower inflammatory status of 
the follicle fluid in folic acid supplement users. 
In chapter VI we studied the diet of 203 women undergoing COH for 
IVF/ICSI treatment using a validated Food Frequency Questionnaire. With 
the use of Principal Component Analysis we identified a dietary pattern that 
associated with the ovarian response to COH. Each woman was assigned a 
personal score, which reflected adherence to this dietary pattern. The Healthy 
dietary pattern consisted of high intake of fruit, whole grain products and 
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margarine and low intake of snacks and refined grain products. In adjusted 
analyses we consequently show a 14.4% reduction in the ovarian response 
for each gained point that reflects adherence to the Healthy dietary pattern. 
Similarly adherence to the Healthy dietary pattern increased the chance of 
ongoing pregnancy after IVF/ICSI by 60%. In chapter V we investigate 
whether the vitamin folate could explain the influence of nutrition on 
the ovarian response. Here we show that folic acid supplement use indeed 
similarly influenced the ovarian response to COH, as did the Healthy dietary 
pattern. However, because the groups were very small, we did not study the 
influence of folic acid supplement use on the chance of pregnancy. 
In chapter VII we describe the clinical implementation of the findings of 
nutritional studies. Using a clinically applicable questionnaire comprised of 
six questions that addresses nutritional adequacy based on guidelines of the 
Netherlands Nutrition Centre, we show an association between the measure 
of nutritional adequacy (the Preconception Dietary Risk score) and the 
chance of pregnancy.
Finally, in chapter VIII we integrate and discuss the findings from 
chapters III-VII and provide tentative future directions for COH and IVF/
ICSI research. We emphasize the necessity for both further experimental and 
observational studies into the influence of nutrition and folic acid supplement 
use on ovarian follicle metabolism but also the required changes in approach 
to clinical IVF/ICSI treatment study design. 
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NEDERlANDS SAMENVATTING
Ovariële hyperstimulatie behandeling (OH) en In Vitro 
Fertilisatie /Intracytoplasmatische Semen Injectie (IVF/ICSI), zijn 
vruchtbaarheidsbehandelingen voor paren met een verminderde 
vruchtbaarheid. Hoewel OH en IVF/ICSI behandeling redelijk succesvol 
zijn in het bewerkstelligen van een zwangerschap, is er nog veel ruimte voor 
verbetering. Er zijn verschillende benaderingen voor verbetering mogelijk, 
variërend van verbetering in de kweekomstandigheden van het embryo 
tot het optimaliseren van eigenschappen van patiënten. Echter, ook de 
ovariële response op OH heeft invloed op de kans van slagen van de IVF/
ICSI behandeling. De studies beschreven in dit proefschrift hadden tot 
doel om, beïnvloedbare voeding- en leefstijl gewoonten te identificeren die 
een rol spelen bij de ovariële response en de kans op zwangerschap na IVF/
ICSI behandeling. Hierbij is ook gekeken naar de invloed van dergelijke 
factoren, onder welke foliumzuur, op het micromilieu van de ontwikkelende 
eicel. Verder hebben we bestudeerd of het mogelijk is om tijdens een 
preconceptioneel consult met korte en simpele vragenlijsten de voeding- en 
leefstijl gewoonten van paren met verminderde vruchtbaarheid te screenen 
en deze te relateren aan het succes van de IVF/ICSI behandeling. 
In hoofdstuk III worden twee methoden om de eiwitsamenstelling van 
follikelvocht te bestuderen beschreven. Hieruit blijkt dat de IEF methode 
een gevoelige methode is om eiwitten in follikelvocht te identificeren. Om de 
invloed van voeding en foliumzuur beter in kaart te brengen hebben wij in 
hoofdstuk IV onderzocht wat de invloed van het gebruik van een foliumzuur 
tablet op de eiwitsamenstelling van follikelvocht is. Uit deze studie blijkt 
dat foliumzuur vele verschillende processen beïnvloed, waaronder die van de 
cholesterol stofwisseling. Er werden hogere gehaltes van apolipoproteinen 
gemeten in het follikelvocht van foliumzuur supplement gebruikers. 
Opmerkelijk was dat foliumzuur gebruikers een lager C-reactief eiwit gehalte 
in het follikelvocht hadden, wat een maat is voor actieve ontstekingsprocessen. 
Ook lijkt het erop dat de follikels van foliumzuur gebruikers beter ontwikkeld 
zijn, blijkend uit de lagere concentraties van cytokeratinen. 
Het doel van de studie beschreven in hoofdstuk VI was om de invloed 
van het dieet van de vrouw op de ovariële response te kwalificeren en 
kwantificeren. Met behulp van Principal Component Analyse identificeren 
wij een dieet dat werd gekenmerkt door veel fruit, volkoren producten en 
margarine. In volgende analyses stellen wij vast dat naarmate dit dieet sterker 
wordt aangehouden, de ovariële response op OH lager wordt. Op dezelfde 
wijze is er een verband tussen het gebruik van dit dieet en een hogere kans op 
een doorgaande zwanger na de IVF/ICSI behandeling. In hoofdstuk V, komt 
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naar voren dat de foliumzuur concentraties in het bloed een vergelijkbaar 
verband vertonen met de ovariële response op OH. Gezien de relatief kleine 
groepen was het niet mogelijk om de invloed van foliumzuur op de kans op 
een doorgaande zwangerschap te kwantificeren. 
In hoofdstuk VII wordt ingegaan op de klinische implementatie van de 
bevindingen uit dit proefschrift aangaande de invloed van voeding op de kans 
op een doorgaande zwangerschap. Hierin laten wij zien dat het mogelijk is 
om voeding- en leefstijl gewoonten te screenen met behulp van een simpele 
klinisch toepasbare vragenlijst en dat de berekende preconceptionele 
voedingsscore samenhangt met de kans op een doorgaande zwangerschap na 
IVF/ICSI behandeling. Hiermee worden de bevindingen in hoofdstuk VI 
bevestigd.
In hoofdstuk VIII wordt ingegaan op de implicaties van de bevindingen 
uit dit proefschrift voor toekomstig onderzoek en preconceptiezorg. Hierbij 
ligt de nadruk op het verder kwantificeren en kwalificeren van de invloed 
van voeding en foliumzuur op de stofwisseling van de ovariële follikel. Ook 
wordt de studie opzet besproken die nodig is om de invloed van voeding- en 
leefstijlfactoren op IVF/ICSI behandeling in kaart te brengen.
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lIST OF AbbREVIATIONS
5-mTHF  5-methyltetrahydrofolate
5,10-mTHF  5,10-methylenetetrahydrofolate
AHCY   S-Adenosylhomocysteine hydrolase
AMH   Anti-Müllerian Hormone
AHP   Achieving a Healthy Pregnancy
ART   Assisted Reproduction Technique
BHMT   Betaine-Homocysteine Methyltransferase
BMI   Body Mass Index
CBS   Cystathione-β-Synthase
CD   Cycle Day
CHD   Congenital Heart Defects
COH   Controlled Ovarian Hyperstimulation
CRP   C-Reactive Protein
CTH   Cystathione-y-lyase
dTMP   Deoxythymidine Monophosphate.
dUMP   Deoxyuridine Monophosphate. 
DS   Down Syndrome
DHF   Dihydrofolate
FFQ   Food Frequency Questionnaire
FOLFO  Food Lifestyle and Fertility Outcome
FSH   Follicle Stimulating Hormone
FSHR   Follicle Stimulating Hormone Receptor
FR   Folate Receptor
GnRH   Gonadotropin Releasing Hormone
GM   Geometric Mean
GNMT   Glycine-N-Methyltransferase
hCG   human Chorionic Gonadotropin
HDL   High Density Lipoprotein
ICSI   Intracytoplasmic Sperm Injection
IEF   Isoelectric Focusing
IGF   Insulin-like Growth Factor
IVF   In Vitro Fertilization
IQR   Interquartile Range
LC-MS/MS  Liquid Chromatography Tandem Mass Spectrometry
MAT   Methionine Adenosyltransferase
MD   Methyl Deficient
MTHFR  5,10-methylenetetrahydrofolate Reductase
MTR   Methionine synthase
MTRR   Methionine synthase reductase
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NTD   Neural Tube Defects
OFC   Orofacial Clefts
PCA   Principal Components Analysis
PDR   Preconception Dietary Risk Score
RBC   Red Blood Cell
ROS   Reactive Oxygen Species
SDS-PAGE   Sodium Dodecyl Sulfate-Polyacrylamide Gel 
Electrophoresis
SAH   S-Adenosylhomocysteine
SAM   S-Adenosylmethionine
SHMT   Serine Hydroxymethyltransferase
tHcy   total Homocysteine
THF   Tetrahydrofolate
TYMS   Thymidylate synthase
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borrels en uitstapjes. 
Mijn lieve ouders. Hoe had ik dit alles zonder jullie onnavolgbare steun 
moeten bereiken? Retrospectief is het haast beangstigend hoe vaak jullie mij 
gestuurd hebben naar de optie die ik niet wilde, maar die de juiste bleek te 
zijn. Jullie steun op werkelijk elk vlak heeft het mogelijk gemaakt dat ik de 
afgelopen jaren heb leren inzien wat echt belangrijk is, en dat ik heb leren 
leven als een god in Frankrijk.
Lieve Annika, zonder jouw onvoorwaardelijke steun had dit alles niet op papier 
gestaan en had ik een stuk minder plezier gehad in alles wat ik doe. Ik hou van je. 
Aan elk feestje komt een einde.
 
Now this is not the end.  
It is not even the beginning of the end.  
But it is, perhaps, the end of the beginning.
Sir Winston Churchill, November 1942
